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SUMMARY
The insulin-like growth factors (IGFs) are important in several areas of animal 
production, for example, IGF-1 mediates the growth-promoting effects of growth 
hormone (GH). GH has effects on a variety of tissues including bone, mammary 
gland and adipose tissue; GH effects on adipose tissue are direct but its effects on 
other tissues are thought to be mediated by IGF production. The aim of this study 
was the investigation of the IGF axis in two areas important to animal performance: 
lactation and the immune system.
In many species the mother has an increased susceptibility to parasitic and 
fungal infections during the pre- and post-partum period with detrimental effects on 
the welfare of both the dam and the neonates dependent on the milk. Although a role 
for the IGFs and growth hormone (GH) have been implicated in the immune system, 
few studies have used farm species. Here I have shown that the immune system of 
the sheep has all the elements of the IGF axis: type 1 IGF receptors, IGF-1, insulin­
like growth factor binding protein (IGFBP), and IGFBP protease. These preliminary 
findings warrant further evaluation of the IGF axis in the sheep immune response 
and in particular its assessment during the periparturient period when 
immunocompetence is compromised.
Although the galactopoietic effects of GH in dairy cows is well established 
the mechanism involved is uncertain. Functional GH receptors have not been shown 
on mammary epithelial cells and the effects of GH have therefore been considered 
to be indirect via either nutrient partitioning or IGF-1 since the mammary gland does 
possess IGF receptors. The IGFs are potent mitogens for mammary cells in vitro, 
however the in vitro culture of mammary tissue is difficult, particularly from
lactating glands. There is limited information on the IGFBPs produced by the 
mammary gland, their regulation and role in mammary gland biology.
The studies in this thesis have used two models of rat lactation in which 
mammary involution has been induced by either litter removal, or by treatment with 
anti-rGH serum to ablate GH and bromocriptine to ablate prolactin (PRL). When 
involution was induced by litter removal the mammary gland expressed IGFBP-2, 
-4 and -5, and high levels of IGFBP-5 were detected in milk. IGF-1 can act as a 
survival factor for several cell types and we hypothesised that IGFBP-5 production 
was increased to abrogate the effects of IGF-1 since serum IGF-1 concentrations 
increased after litter removal. Serum IGF-1 concentrations did not however correlate 
with increased IGFBP expression.
Hormone ablation and litter removal induce different physiological states: 
litter withdrawal induces milk accumulation, whereas after hormone ablation the 
gland is empty of milk because the young continue to suckle. PRL treatment of 
animals whose litters had been removed decreased the levels of IGFBP-5 in milk 
despite milk accumulation. Sealing of half the dams teats showed that IGFBP-5 levels 
increased in sealed mammary glands compared with their unsealed contralateral 
counterparts. Previous studies have shown that after litter removal there is a decrease 
in total mammary DNA and an increase in DNA laddering indicative of apoptosis; 
similarly teat sealing can also induce apoptosis in the sealed gland in the absence of 
endocrine changes. These findings support a role for IGFBP-5 in the induction of 
apoptosis. In contrast, PRL and GH ablation did not induce IGFBP-5 expression 
although previous studies showed increased DNA laddering (although to a lesser 
extent than litter removal).
4GH- and PRL-deficiency decreased serum IGF-1 concentrations but did not 
affect mammary IGFBP-5 expression. GH-deficient lactating rats have decreased 
serum IGF-1 concentrations, but serum IGFBP-3 levels were reduced only when both 
PRL and GH were ablated suggesting dual control of IGFBP-3 during lactation. This 
may have important implications for IGF transport since IGFBP-3 is the main carrier 
of IGF-1 in blood. PRL and GH may thus maintain mammary epithelial cell integrity 
by modulating the IGF-1 survival signal: in this model, during lactation GH induces 
IGF-1 production (possibly produced locally within the mammary gland), and GH 
and PRL stimulate IGFBP-3 concentrations in blood whilst PRL suppresses the 
expression of IGFBP-5. In contrast, during involution the withdrawal of PRL permits 
the production of IGFBP-5 which serves to abrogate the anti-apoptotic effects of 
IGF-1.
We therefore postulate that IGFBP-5 is an initiator of cell death in the 
involuting mammary gland: the direct demonstration of the survival effects of IGF-1, 
and a causal role for IGFBP-5 in involution are required to support this hypothesis.
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CHAPTER 1: INTRODUCTION
1.1 Overview
The insulin-like growth factors (IGFs) were discovered while searching for mediators 
of the growth promoting effects of growth hormone (GH). Although the suppression 
of matrix protein synthesis in hypophysectomised rats can be restored by in vivo GH 
administration, GH could not stimulate sulphate uptake into hypophysectomised rats 
cartilage in vitro. Serum from normal or GH treated hypophysectomised rats, but not 
from hypophysectomised rats had stimulatory activity establishing the presence of an 
intermediatory substance termed ’sulphation factor’ or later ’somatomedin’ (Salmon 
& Daughaday 1958). Two other types of plasma factors were independently 
discovered, an insulin-like activity which was not supressible by antiserum to insulin 
(NSILA), and a potent stimulator of cell growth in culture termed multiplication- 
stimulating activity (MSA). Purification and characterisation identified two 7.5 kDa 
peptides responsible for these biological activities, which were subsequently 
designated IGF-1 and IGF-2. The demonstration of IGF-1 production by several GH 
target tissues challenged the somatomedin hypothesis and established that in addition 
to its endocrine role, IGF-1 may also act as a paracrine growth factor. Local 
administration of GH into cartilage could stimulate growth and this effect could be 
blocked by antibodies to IGF-1 (Schlector et al. 1986), however the growth rate was 
a fraction of that induced by systemic GH administration showing the involvement 
of both endocrine and paracrine IGF-1 in growth. It is now clear that in addition to 
their metabolic role the IGFs are pleiotropic growth factors which affect the 
mitogenesis and differentiation of a wide variety of cell types.
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The majority of IGF in physiological fluids are bound to one of a series of 
binding proteins (IGFBPs) which can modulate IGF action. The IGFBPs are 
synthesised in a wide range of tissues and although their actions are complex it is 
proposed that IGFBPs have several major functions: to prolong the half-lives of the 
IGFs; regulate metabolic clearance of IGFs; to transport IGFs in plasma and control 
their exchange with the tissues; and modulate IGF effects at the local level. The 
IGFBPs have a major impact on IGF action and they form the main subject of this 
thesis.
A large body of literature exists on the IGF-IGFBPs and the following review 
covers IGF-IGFBP biology and discusses in more detail the IGF axis in lactation and 
in the immune system.
1.2 Insulin-like growth factors: genes and proteins
The IGFs are 7.5 kDa proteins which contain four domain structures, called B,C,A, 
and D, based on their homology with insulin. The IGFs from several species have 
been cloned and sequenced and show a high degree of conservation between species 
(Ward & Elliss 1992). Northern blotting demonstrated that the IGF-1 gene gives rise 
to heterogeneous mRNA transcripts, the major mRNA species in the rat being about 
1, 1.7, and 7.5 kb (Daughaday and Rotwein 1989). The rat IGF-1 gene consists of 
6 exons, exons 3 and 4 coding for the mature protein. Exons 1 and 2 code for 
alternative 5’-untranslated regions and N-terminal sequences, and transcription is 
initiated at two different promotors upstream of exons 1 and 2.
IGF-1 is made as a propeptide containing a C-terminal E domain which 
requires proteolytic cleavage to form the mature peptide. There are two precursor
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forms IGF-1 Ea and IGF-1 Eb, which differ in their C-terminal sequence but result 
in identical mature proteins. IGF-1 Ea is derived from exon 4 spliced to exon 6 in 
the rat or splicing of exon 4 to 5 in humans. IGF-1 Eb is derived from exon 4 
spliced to exons 5 and 6 in the rat, or exon 4 spliced to exon 6 in humans. The use 
of alternative polyadenylation signals in exon 6 provide further mRNA heterogeneity 
(Hall et al. 1992). Both precursor forms are represented in all species of mRNA and 
the significance of the transcript heterogeneity remains unclear.
Natural variants of IGF-1 have been described, such as the N-terminal 
truncated des 1-3 IGF-1 which has a restricted distribution and is found only in 
brain, platelet lysates and bovine colostrum (reviewed in Humbel 1990). Site-directed 
mutagenesis studies demonstrated that the N-terminal part of IGF-1 is a recognition 
site for IGFBPs since deletion of residues 1-3 or substitution of residues in this 
region drastically decreases affinity for the IGFBPs (Humbel 1990). Several mutants 
with reduced affinity for IGFBPs but reasonable affinities for type 1 IGF receptors, 
have been useful in the study of receptor binding and the biological effects of IGF 
in the absence of modulation by IGFBPs (Francis et al. 1992).
The rat IGF-2 gene also has 6 exons and is under complex transcriptional 
control. An important feature of IGF-2 expression is parental imprinting such that 
only the paternally derived allele is active (DeChiara et al. 1991). Exons 1-3 
represent alternative 5’-untranslated regions which are transcribed under the control 
of promotors P1-P3, giving rise to the major transcripts which in rats are about 3.8,
4.6 and 3.6 kb (Daughaday & Rotwein 1989). IGF-2 is secreted as a single 
precursor form and the natural variants of IGF-2 are apparently derived from the 
same gene and formed by differential RNA splicing. Large forms of IGF-2 are found 
in human brain, serum, spinal fluid and probably represent partially processed 
precursor forms (reviewed in Humbel 1990).
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1.3 IGF receptors and cell signalling
The type 1 IGF receptor, structurally closely related to the insulin receptor, is a 
disulphide linked heterotetramer consisting of two 130 kDa alpha subunits which 
contain the IGF binding site, and two 95-105 kDa transmembrane beta subunits 
which have intrinsic tyrosine kinase activity (Massague & Czech 1982). The insulin 
receptor binds insulin with high affinity and IGF-1 with much weaker affinity, and 
does not bind IGF-2. In contrast the type 1 IGF receptor binds IGF-1 with high 
affinity, IGF-2 with a slightly lower affinity which sometimes approaches that of 
IGF-1, and binds insulin with much lower affinity. IGF-1 levels are low in foetal life 
and increase in the adult, but type 1 IGF receptors are most abundant in foetal and 
newborn tissues leading to the suggestion that the abundant IGF-2 in the foetus acts 
through the type 1 IGF receptor (Bondy et al. 1990)
A third member of the insulin receptor family is the insulin related receptor 
(IRR) which shares the common structure including the tyrosine kinase domain, but 
does not bind insulin, IGF-1 or IGF-2 (Zhang & Roth 1992) and the ligand is 
unknown.
Hybrid receptors consisting of one type 1 IGF receptor a/S-half-receptor and 
one insulin receptor a/3-half-receptor have been demonstrated in some tissues and 
cell lines. This receptor binds IGF-1 and insulin with affinities similar to those of 
the type 1 IGF receptor, and IGF-1 is more effective in eliciting its 
autophosphorylation (Soos et al. 1990), thus implying that it may behave more like 
a type 1 IGF receptor than an insulin receptor. Human placenta has a high 
percentage of hybrid receptors (Soos & Siddle 1989), however it is unknown whether 
hybrid receptors can mediate responses to IGF-1 or insulin in vivo.
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There have been reports of type 1 IGF receptors with affinities for ligands 
differing from those of the cloned receptor and only some of the data can be 
explained by hybrid receptors or differential splicing of mRNA. IGF stimulation of 
adult and foetal muscle from rat and human demonstrated the presence of two 
species of type 1 IGF receptor with beta subunits of 105 kDa and 95 kDa 
(Alexandrides et al. 1993). The 105 kDa type is preferentially expressed on foetal 
cells and is stimulated in vitro by low concentrations of insulin as well as IGF-1, 
which led to the suggestion that it may have a role in mediating the effects of insulin 
in foetal tissues. Insulin is growth stimulatory in the foetus, whereas in the adult it 
is mainly a metabolic hormone. However insulin receptors are in similar numbers 
in foetal and adult life so receptor distribution cannot account for the developmental 
differences. Antibodies to the alpha subunit (anti-IR-3) are selective for the 105 kDa 
containing receptor suggesting there is a difference in both a and fi subunits of foetal 
and adult receptors. Recently splice variants of the mRNA for the 105 kDa receptor 
have been described which differ at 3 nucleotides (CAG) in the extracellular portion 
of the beta chain. Although these variants have equal affinity for IGF-1, the CAG 
minus version shows an increase in IGF-1 stimulated signalling activity and a 50% 
decrease in receptor internalisation. Thus the receptor variants have distinct 
signalling properties suggesting that the beta subunit may play a role in both 
signalling and internalisation (Condorelli et al. 1994).
The intrinsic tyrosine kinase activity of the type 1 IGF and insulin receptor 
is believed to mediate their actions by the phosphorylation of cellular substrates. 
Several substrates for the type 1 IGF and insulin receptor kinase have been identified
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including the insulin receptor substrate-1 (IRS-1), and the subsequent stimulation of 
PIP3 or Ras activation are common elements (reviewed in Jones & Clemmons 1995). 
How insulin and IGF-1 signalling diverge remains unclear and is the subject of many 
studies. For example chimaeric receptor studies in which the C-terminal domain of 
one receptor was fused to the rest of the heterologous receptor have shown that 
replacement of the insulin receptor C-terminus with the type 1 IGF receptor C- 
terminus markedly affects the responses to insulin, but in contrast replacement of the 
type 1 IGF receptor C-terminus with that of the insulin receptor had little effect on 
IGF-1 responses suggesting the type 1 IGF receptor mitogenic activity is not affected 
by the insulin receptor C-domain (Faria et al. 1994). Receptors with the extracellular 
domain of the insulin receptor and the intracellular IGF-1 domain are more effective 
than the native insulin receptor in delivering a mitogenic signal (Andersen et al. 
1990).
The type 2 IGF/mannose-6-phosphate receptor is a single polypeptide chain 
of 250 kDa comprising a large extracellular domain containing distinct binding sites 
for IGF-2 and mannose-6-phosphate, a single transmembrane domain, and a short 
intracellular domain (MacDonald et al. 1988). A soluble form of the receptor (210 
kDa) has been described in serum which differs from the membrane bound form at 
the cytoplasmic C-terminal portion and it has been proposed that it arises by cleavage 
of the membrane bound form (Clairmont & Czech 1991). Although IGF-2 binds the 
type 2 IGF/mannose-6-phosphate receptor with greater affinity than IGF-1 (insulin 
does not bind) the function of the type 2 IGF/mannose-6-phosphate receptor is the 
targeting of lysosomal enzymes to lysosomes and the mediation of IGF-1 uptake and 
degradation (Neilsen 1992). Most biological responses to IGF-2 are thought to be
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mediated by the type 1 IGF receptor, and the role of the type 2 IGF/mannose-6- 
phosphate receptor in mediating IGF-1 or IGF-2 signalling remains to be elucidated.
1.4 IGF actions in vitro
1.4.1 Metabolic and mitogenic effects
The IGFs exert acute metabolic effects on protein and carbohydrate metabolism on 
most cell types via the widely expressed Type 1 IGF receptors. IGF-1 stimulates 
amino acid transport, glucose utilisation, lipid formation and protein synthesis though 
its effects vary depending on cell type. In skeletal muscle the major in vitro effect 
of IGF-1 is in the stimulation of glucose uptake, glycogen synthesis and glycolysis 
(Dimitriadis et al. 1992).
The ability of IGFs to stimulate DNA synthesis has been widely studied. 
Competence factors, such as PDGF and FGF induce quiescent cells to enter Gj and 
IGF-1 functions as a progression factor in the cell cycle late in G1} allowing the cell 
cycle to continue resulting in DNA synthesis and proliferation (Pardee 1989). Since 
PDGF increases the numbers of type 1 IGF receptors in fibroblasts (Clemmons & 
Shaw 1983) and receptor over- expression bypasses the need for PGDF, the function 
of PDGF as a competence factor may be to increase type 1 IGF receptor levels 
(Baserga & Rubin 1993). Likewise haemopoietic IL-3 dependent cells overexpressing 
type 1 IGF receptors become IL-3 independent in the presence of excess IGF-1 and 
the high frequency of IL-3 independence suggested that no other mutation was 
necessary (McCubrey et al. 1991). As might be expected from its role in cell cycle 
progression IGF induces mitogenesis in a wide variety of cell types (see Lowe 1991 
for review).
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Analogous with IGF effects on cell proliferation is its capacity to act as a 
survival or anti-apoptotic factor (Raff 1992). It has been suggested that apoptosis has 
an important role in blood cell production (Williams et al. 1990). IGF-1 abrogated 
apoptosis of cytokine (CSF) dependent cells deprived of cytokine (Rodriguez- 
Tarduchy et al. 1992), supporting a role for IGF-1 in inhibiting apoptosis and in 
controlling the regulation of blood cell formation.
1.4.2 Effects on differentiation and cell function
IGF-1 and IGF-2 can induce differentiation of several cell types including 
osteoblasts, osteoclasts, chondrocytes, neural cells and adipocytes (Sara & Hall 1990 
(review)). IGFs also affect a wide range of cell functions for example: regulation of 
hormone secretion in several cell types such as ovarian cells where they act 
synergistically with FSH and oestrogen (Adashi et al. 1994); the stimulation of 
extracellular matrix component synthesis by endothelial cells (Lowe 1991); increased 
chemotactic migration in several types of epithelial and endothelial cells (reviewed 
in Jones & Clemmons 1995).
Thus the IGFs regulate the growth, differentiation and function of a wide 
range of cell types. IGF-1 can elict a motility response, a mitogenic response, or a 
metabolic response (which may be part of a mitogenic response), but it is unclear 
whether the intracellular signalling pathways are the same for the different responses. 
Intracellular events including some of the cell signalling, are likely to be shared by 
different signalling molecules so that the overall "signal" and subsequent response 
depends on the context of the IGF-1 signal. The integration of all the signals from 
the microenvironment such as hormones, growth factors, extracellular matrix
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components, and also the cells’ receptivity e.g. the distribution and abundance of 
receptor subtypes and the differentiation state of the cell, determine the outcome.
1.5 In vivo effects of IGF-1
The anabolic effects of GH are well established and IGF-1 can mediate both the 
growth promoting and anabolic effects of GH. Anabolic effects of IGF-1 on protein 
synthesis and nitrogen balance have been demonstrated using a variety of stimulated 
catabolic states including rats treated with dexamethasone (Tomas et al. 1992) and 
in dietary protein restriction (Thissen et al. 1991). In protein restricted animals 
carcass weight was not increased but the weights of gut, kidneys and spleen 
increased (Tomas et al. 1992; Thissen et al. 1991). However IGF-1 infusion in well 
fed rats does stimulate carcass weight suggesting there is IGF-1 resistance in protein 
restricted rats (Thissen et al. 1991).
Infusion of IGF-1 into GH-deficient mature rats stimulated body weight gain 
and longitudinal bone growth, but not as potently as GH (Lowe 1991). Whereas GH 
administration causes proportional organ growth, IGF-1 treatment results in greater 
increases in kidney, spleen and thymus weights in neonatally hypophysectomised rats 
(Glasscock et al. 1992). There is also some evidence that GH and IGF-1 effects may 
differ depending upon the route of administration since a growth response was seen 
when IGF-1 was infused but not when it was injected (Skottner et al. 1987).
IGF-1 infusion in hypophysectomised and protein restricted rats restores the 
depressed IGFBP-3 level to normal (Clemmons et al. 1989). Therefore the difference 
in the effects of GH and IGF-1 may be related to tissue delivery of IGF-1 since 
although IGF-1 may modulate IGFBP-3, GH is required for ALS production
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(Gargosky et al. 1994) thus affecting ternary complex formation; alternatively GH 
may have IGF-1-independent effects on tissues. In contrast to the wealth of evidence 
comfirming IGF-1 as a mediator of GH action, GH administration to GH deficient 
rats in the presence of antisera to IGF-1 failed to influence the response to GH in 
terms of growth rate (Spencer et al. 1991).
IGF-1 administration to humans has comparable effects to those seen in rats. 
In normal subjects GH and IGF-1 have comparable anabolic and growth effects but 
opposite effects on glucose and fatty acid metabolism. The ability of IGF-1 to restore 
the nitrogen balance in calorie restricted subjects was comparable to that of GH but 
there was a hypoglycaemia at doses well tolerated by fed subjects (Clemmons et al. 
1992a). However in calorie restricted subjects combined IGF-1\GH treatment was 
more potent than individual treatment in restoring nitrogen balance and IGFBP-3 
levels (Kupfer et al. 1993). This is probably due to an increased proportion of IGF-1 
in ternary complexes (because GH regulates ALS) which will increase its half life 
thus increasing its anabolic effects and protecting from hypoglycaemia. Combined 
IGF/GH therapy may therefore have clinical uses in critically ill patients with 
hypercatabolism (Bentham et al. 1993).
1.6 IGFBP Structure
Six structurally distinct IGFBPs have been purified, cloned and sequenced and the 
strong sequence homology suggests the genes are closely related, probably arising 
from successive gene duplication (Shimasaki & Ling 1991). The human and rat 
genes have 4 exons and IGFBP-3 has a fifth exon which codes for 3’-untranslated 
sequences. The promotor regions of some IGFBPs have been reported; human
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IGFBP-1 and -3 genes contain TATA boxes recognised by the RNA polymerase II 
initiation complex, rat IGFBP-4 and -5 also have a TATA box but the initiation site 
is not defined, and IGFBP-2 and -6 have no TATA box.
A single IGFBP mRNA species has been described for most tissues, with a 
few exceptions such as larger hepatic forms of IGFBP-1 mRNA. The IGFBPs are 
synthesised as prepeptides and form mature protein of approximately 200-300 amino 
acids. The amino and carboxyl termini of the six IGFBPs have 60-70% homology 
and contain 18 cysteines whose alignment is conserved, IGFBP-6 being the exception 
as it lacks 2 of the homologous cysteines in the rat and 4 homologous cysteines in 
the human. The central region of the molecule is most divergent with only 30% 
homology, this region lacks cysteines with the exception of IGFBP-4 which has 2 
additional cysteines in this region.
There are several differences between IGFBPs in their structure and post- 
translational modifications which are summarised in Table 1.1. The C-terminal end 
of IGFBP-1 and -2 contain an RGD sequence which could bind to integrin receptors. 
IGFBPs contain putative glycosaminoglycan (GAG)-binding consenus sequences 
(XBBXBX and XBBBXXBX where B is any basic amino acid and X is undefined) 
which may interact with the extracellular matrix. All IGFBPs in rat and human 
contained at least one GAG-binding sequence, with the exception of rat and human 
IGFBP-4 and human IGFBP-6; both rat and human IGFBP-5 contain three such 
sequences (Hodgkinson et al. 1994).
27
IGFBP
1 2 3 4 5 6
RGD sequence + + — — — —
GAG binding + + + — + +
phosphorylation + — + — + —
glycosylation — — N N 0 O
preference for IGF-1 
or IGF-2
IGF-2 IGF-2 IGF-2
Table 1.1 Structural features of the IGFBPs. N is N-linked glycosylation; O is 
O-linked glycosylation.
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IGFBP-3 and to a lesser extent IGFBP-4, are N-glycosylated (Martin & 
Baxter 1986; Ceda et al. 1991). IGFBP-1, -3, -5 and -6 have potential O-linked 
glycosylation sites but this type of glycosylation has been demonstrated for IGFBP-5 
and -6 only (Martin et al. 1990). There is little information regarding the role of 
carbohydrates in IGFBP function. Although recombinant glycosylated and non­
glycosylated IGFBP-3 have the same affinity for IGF-1 (Keifer et al. 1992), the 
carbohydrate moiety could be important for other properties such as their half life, 
stability or targeting. Serine phosphorylation have been demonstrated for IGFBP-1, 
-3, and -5 (Jones et al. 1993a; Mukku & Chu 1990; Jones et al. 1992) although 
IGFBP-1 phosphorylation is best studied. IGFBP-1 from decidual cells and amniotic 
fluid is mainly phosphorylated, but as pregnancy progresses the ratio of 
phophorylatedrnon-phosphorylated forms in amniotic fluid increases (Koistenen et 
al. 1993); phosphorylation of IGFBP-1 increases its affinity for IGF-1. Human 
IGFBP-1 is phosphorylated solely on serines and although phosphorylation occurs 
at 3 sites the phosphorylation of only one of these sites is associated with alterations 
of the affinity for IGF-1 (Jones et al. 1993a). IGFBP-1 appears to be phosphorylated 
only at the intracellular level since functional ectokinases on the surface of tranfected 
CHO cells do not phosphorylate secreted or exogenous IGFBP-1 (Jones et al. 1991). 
Unlike IGFBP-1, dephosphorylation of IGFBP-3 does not alter its affinity for IGF-1, 
though it did increase the formation of the ternary complex (Mukku et al. 1991). 
Thus IGFBPs derived from different sources may vary in their post translational 
modifications, but the functional significance of these differences is unclear.
The affinities of IGFBPs for IGF-1 and IGF-2 have been determined using 
IGFBPs from a variety of sources. In general IGF-1 and IGF-2 bound with roughly
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similar affinities to all IGFBPs with the exception of IGFBP-6 which consistently 
shows markedly greater affinity for IGF-2 (Martin et al. 1990); slightly higher 
affinity for IGF-2 has also been shown for IGFBP-2 and -5 (Clemmons et al. 
1992b).
The homology of the cysteine rich regions between the different IGFBPs 
suggested that the IGF binding site resides here, furthermore reducing agents abolish 
IGF binding suggesting that the 3-D structure is important. The IGF-binding capacity 
of IGFBP fragments and mutants has been used to determine the binding site. 
Truncation of IGFBP-2 at the N-terminus (Wang et al. 1988) or C-terminus (Zapf 
et al. 1988) reduced but did not abolish IGF-binding suggesting both termini can 
bind IGF. Likewise an N-terminal truncated IGFBP-1 bound IGF (Huhtala et al. 
1986). However mutation at the C-terminus of IGFBP-1 destroyed IGF binding and 
showed 226Cys is essential for IGF binding (Brinkman et al. 1991). A study using 
several structural analogues of IGF-1 indicate that recombinant IGFBP-1 and -2 have 
very similar affinities for the analogues, but IGFBP-3, -4 and -5 have some 
similarities but significant differences. For example, mutations in the A or B chain 
of IGF-1 decreased its affinity for IGFBP-1 or -2. In contrast, although A chain 
mutations had little effect on IGFBP-3 binding, B chain mutations reduced affinity 
by 50% (Clemmons et al. 1992b). These studies provide further support for 
differences between IGFBPs in their structural requirements for IGF binding.
1.7 IGFBP action at the cellular level
1.7.1 Introduction
The IGFBPs were originally identified as serum proteins which inhibited the
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potentially hypoglycaemic effects of serum IGF concentrations and it was therefore 
assumed that they had an inhibitory function. In simple binding assays IGFBPs 
appeared to inhibit IGF action by blocking IGF binding to receptors, however the 
use of whole cell systems challenged this view. It is now apparent that IGFBPs may 
also enhance IGF action, and in addition IGFBPs can have direct cellular effects 
which are IGF independent. The biological actions of IGFBPs are complex and may 
depend on their posttranslational modifications, ability to bind cell surfaces, or the 
presence of proteases which may alter their affinity for growth factors; these 
parameters vary between IGFBPs therefore the biological actions of each IGFBP will 
be considered separately.
1.7.2 IGFBP-1
IGFBP-1 in molar excess of IGF concentrations has a predominantly inhibitory 
action on [3H]thymidine uptake in many cell types such as FRTL-5 thyroid cells 
(Frauman et al. 1989). In general, studies where inhibition has been seen have used 
serum free conditions, whereas there are several reports of enhancing effects in the 
presence of serum or plasma.
IGFBP-1 can enhance IGF-1 stimulated DNA synthesis in porcine aortic 
smooth muscle cells, but only in the presence of a low concentration of platelet poor 
plasma (Elgin et al. 1987). Furthermore, the potentiating capacity of IGFBP-1 was 
reduced when IGF-1 mutants with low binding to either IGFBP-1 or the type 1 IGF 
receptor-1 were used suggesting that binding to both IGF-1 and its receptor are 
necessary for potentiation (Clemmons et al. 1990a).
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IGFBP-1 exists in differentially phosphorylated forms, which differ in their 
biological effects. Only the cell-adherent form of IGFBP-1 isolated from amniotic 
fluid could potentiate IGF-1 action on smooth muscle cells (Busby et al. 1988). The 
authors subsequently demonstrated that the adherent form was non-phosphorylated 
and this had a lower affinity for IGF-1 (Jones et al. 1991). However conflicting 
evidence comes from a separate study in which IGF-1 mediated [3H]thymidine uptake 
into fibroblasts was potentiated by IGFBP-1 irrespective of the phosphorylation state 
of IGFBP-1 (Koistenen et al. 1993).
The presence of an RGD sequence in IGFBP-1 suggested that it may adhere 
to cells through integrin receptors, and it has been recently demonstrated that 
IGFBP-1 binds the a5|(31-integrin receptor (Jones et al. 1993b). The functional 
significance of this was shown using CHO cells expressing abundant a5/31 -integrin 
receptors. CHO cells expressing IGFBP-1 show enhanced migration which is 
abrogated by mutation of IGFBP-1 at the RGD sequence. This effect of IGFBP-1 
was IGF-1 and IGF-2 independent but this does not preclude the involvement of 
IGFBP-1 cell adherance to integrin receptors in the potentiation of IGF action in 
other cell types.
1.7.3 IGFBP-2
Purified IGFBP-2 inhibited [3H]thymidine uptake in rat astroglial cells (Knauer & 
Smith 1980) and foetal rat calvaria (Feyen et al. 1991). IGFBP-2 inhibits IGF 
binding to MDBK cells but des-(l-3)IGF stimulates DNA synthesis in these cells 
more potently than native IGF-2 suggesting that at least under the conditions used 
in the system, IGFBP is exerting its inhibitory action via IGF binding (Ross et al.
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1989).
Although in most cases IGFBP-2 appears to inhibit IGF action, IGFBP-2 can 
be a weak potentiator of IGF action. In the presence of platelet poor plasma, IGFBP- 
2 potentiated the response of porcine smooth muscle cells to IGF-1 although less 
potently than IGFBP-1. In contrast, in serum free medium IGFBP-2 was a potent 
inhibitor of IGF-1 stimulated DNA synthesis (Boumer et al. 1992).
1.7.4 IGFBP-3
IGFBP-3 can inhibit IGF-1 action in several cell types. IGFBP-3 inhibits DNA 
synthesis in human skin fibroblasts when co-incubated with IGF-1 in a molar excess 
(DeMellow & Baxter 1988). Studies using transfected cell lines have suggested 
endogenously produced IGFBP-3 is inhibitory to cell growth and may have IGF- 
independent effects (Cohen et al. 1993). Hs578T breast cancer cell monolayer 
growth is inhibited by IGFBP-3 in the absence of IGF-1 administration (Oh et al.
1993). Although IGFs alone have no effect on monolayer growth, they can block 
IGFBP-3 growth inhibition. Subsequently membrane proteins of about 20, 26 and 50 
kDa which specifically bind IGFBP-3 were demonstrated on these cells but the 
nature of these proteins is unknown (Oh et al. 1993).
Many studies have established the ability of IGFBP-3 to enhance IGF action. 
DeMellow & Baxter (1988) found that pre-incubation of IGFBP-3 with dermal 
fibroblasts followed by its removal, could potentiate IGF-1 action on DNA synthesis. 
Similarly IGFBP-3 only enhanced IGF action on bovine fibroblasts if previously 
incubated with cells (Conover et al. 1992). During incubation IGFBP-3 becomes 
associated with the cell surface and undergoes processing to lower molecular weight
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forms; these surface bound forms had 10-fold lower affinity for IGF-1 compared with 
the intact IGFBP-3 in the solution phase. There is no evidence that treatment with 
IGFBP-3 increases the number of type 1 receptors or their affinity for IGF-1. 
However, the use of IGF analogues with low affinity for IGFBPs but which still bind 
type 1 IGF receptors, demonstrate that the ability of IGFBP-3 to enhance IGF-1 
action may also depend upon altered reactivity of type 1 IGF-1 receptors.
These studies indicate that cell surface association is required for potentiation 
of IGF action but the mode of binding is unknown. The C-terminal end of IGFBP-3 
has abundant basic amino acids which may interact with glycosaminoglycans on the 
cell surface or in the extracellular matrix. Heparin disrupts such non covalant 
interactions and increased the amount of IGFBP-3 in the medium of cultured 
fibroblasts (Martin & Baxter 1993).
1.7.5 IGFBP-4
In contrast with other IGFBPs, in most studies IGFBP-4 appears to inhibit rather than 
enhance IGF-1 action. For example IGFBP-4 isolated from osteosarcoma cells 
showed a dose dependent inhibition of IGF action on cartilage (Mohan et al. 1989). 
IGF-2 treatment of bone cell cultures increased IGFBP-4 proteolytic activity in the 
conditioned medium (Kanzaki et al. 1994). This effect did not require the presence 
of cells and because analogues with low affinity for IGFBPs were ineffective in 
enhancing IGFBP-4 proteolysis, IGF binding to IGFBP is important rather than 
binding to receptors. IGFBP-4 proteolysis is enhanced by IGF-1 in decidual cells, a 
process which is IGF-1 receptor independent (Myers et al. 1993). Similar effects are 
seen with fibroblasts, furthermore only intact IGFBP-4 could inhibit IGF-1 stimulated
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[3H]aminoisobutyric acid uptake in fibroblasts whereas proteolysed IGFBP-4 had no 
effect (Conover et al 1993). Since proteolytic cleavage of IGFBP-4 virtually 
abolishes its binding capacity for IGF, proteolysis may be a mechanism for releasing 
cells from this inhibition.
1.7.6 IGFBP-5
A molar excess of recombinant IGFBP-5 inhibited IGF-1-stimulated DNA and 
glycogen synthesis in human osteosarcoma cells (Keifer et al. 1992). An inhibitory 
function of IGFBP-5 is further suggested by its ability to inhibit steroidogenesis in 
granulosa cells stimulated with IGF-1 (Ling et al. 1993).
A characteristic of IGFBP-5 is its ability to avidly bind fibroblast ECM (Jones 
et al. 1993a). When incubated with the ECM IGFBP-5 potentiated IGF-1 action 
whereas IGFBP-5 added to the culture medium was proteolytically cleaved to a 21 
kDa fragment which did not potentiate IGF-1 action. When attached to the ECM the 
affinity of IGFBP-5 for IGF-1 was lowered 7-fold suggesting that IGF-1 would be 
more available to receptors. This lowering of affinity and protection from proteolytic 
cleavage may be important in the potentiating capacity of ECM bound IGFBP-5.
A 23 kDa truncated form of IGFBP-5 derived from osteosarcoma cells, 
enhanced the mitogenic effect of IGF-1 on osteoblasts (Andress & Birmbaum 1992). 
This fragment bound the cell surface and had a greatly reduced affinity for IGF-1 
compared with intact IGFBP-5, suggesting that proteolysis is associated with its 
enhancing action. In addition this fragment had some mitogenic capacity which was 
IGF-independent (Andress et al. 1993). Thus the lowering of IGF binding affinity, 
cell surface association, and proteolytic cleavage may be important in regulating the
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potentiating action of IGFBP-5. IGF-2 treatment of bone cell cultures decreased 
IGFBP-5 proteolytic activity in the conditioned medium by a process requiring the 
presence of cells (Kanzaki et al. 1994).
1.7.7 IGFBP-6
There are very few reports of the in vitro effects of IGFBP-6 although a recent paper 
suggests it may have an antigonadotropin effect in the ovary (Rohan et al. 1993).
1.7.8 Summary
The functions of the IGFBPs at the local level are to enable site directed (tissue, cell 
type) localisation of IGF and modulation of IGF action. The molecular mechanisms 
of these IGFBP action are complex. Enhancing effects on IGF action have been 
demonstrated for IGFBP-1, -2, -3 and -5, although the mechanism involved differs 
between IGFBPs. IGFBPs possess GAG binding sequences which could interact with 
glycosaminoglycans on the cell surface or in the extracellular matrix (Hodgkinson 
et al. 1994). Thus the effects of IGFBPs involve complex interactions which are 
incompletely understood and caution is therefore required in interpreting changes in 
IGFBP levels in cell culture since these may result from alterations in synthesis rate, 
in post translational modifications of IGFBP (e.g. phosphorylation) altering 
functional status, or in the distribution between the cell surface and fluid phase. 
There are few in vivo studies using exogenously administered IGFBPs and it is 
unclear whether their overall effects in vivo are to inhibit or enhance IGF-1 action.
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1.8 IGFBP regulation of IGF bioavailability in vivo
Although the relative role of endocrine and locally produced IGFs are unclear, 
circulating IGF provides a pool of IGF which can be exchanged with the tissues and 
IGFBPs can regulate this exchange. Most of the IGF in serum is bound to IGFBP-3 
which along with an 88 kDa acid labile subunit (ALS) forms a ternary complex of 
150 kDa (Baxter et al. 1989). Lesser amounts of IGF are bound in a 40 kDa 
complex with IGFBP-1, -2, -4, and -6 which contain most of the unsaturated IGF 
sites (Guler et al. 1989). IGFBP-5 and -6 are in very low amounts in serum and 
IGFBP-5 has not been detected in these complexes.
IGFBP increases the t1/2 of IGF from 10 minutes for free IGF, to 30 minutes 
when in the 40 kDa complex, and about 15 hours when in a ternary complex; the 
IGF-1 analogue des(l-3)IGF-l, which has a low affinity for IGFBPs, is rapidly 
cleared from the circulation (Ballard et al. 1991). The acid labile subunit is in molar 
excess over the other components of the ternary complex and although in normal 
serum it does not alter the association constant of IGFBP-3 for IGF, it stabilises the 
IGF into a complex too large to cross the endothelial barrier (Martin & Baxter
1992). The ability of exogenous human IGFBP-3 to form ternary complexes in rats 
has been used to assess the amount of bioavailable IGF. Human IGFBP-3 rapidly 
formed a ternary complex which persisted in the circulation for hours, suggesting 
that there is a larger pool of free IGF than previously thought from the steady state 
free levels (Lewitt et al. 1993). In another study where human recombinant 
nonglycosylated IGFBP-3 was administered to rats, IGFBP-3 was initially cleared 
rapidly, but a portion which formed ternary complexes was stable for a few hours. 
IGFBP-3 which left the circulation was distributed to the tissues suggesting that
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IGFBP-3 not associated with acid labile subunit rapidly leaves the vasculature (Arany 
et al. 1993). The initial high clearance rate contrasts with the studies of Lewitt et al. 
(1993) where complexes were formed rapidly, but the two studies used glycosylated 
or non-glycosylated IGFBP-3 respectively and, as suggested previously, glycosylated 
IGFBP-3 may equilbrate more rapidly in rat blood than non-glycosylated protein 
(Sommer et al. 1993).
Using a rat heart perfusion model IGFBPs -1 to -4 and IGF-1 were shown to 
cross the capillary boundary. IGFBP-1, -2, -3, and IGF-1 localised to muscle, but 
both glycosylated and non-glycosylated IGFBP-4 localised to connective tissue (Boes 
et al. 1992). When IGFBP-4 was administered with IGF-1 it localised to muscle like 
free IGF-1, suggesting that IGF-1 determines the distribution (Bar et al. 1990a). 
Administration of insulin along with the IGFBPs, did not change the pattern of 
localisation of the IGFBPs, but did have differential effects on transcapillary efflux 
of IGFBPs. Movement of IGFBP-4 was decreased, IGFBP-1 efflux increased and 
that of IGFBP-2 was unchanged (Bar et al. 1990b). The in vivo administration of 
[125I]-IGFBP-1 and -2 to rats showed IGFBP t1/2 was greater than that of free IGF-1 
but less than that of ternary complex, suggesting these IGFBPs rapidly equilibrate 
with the extravascular compartment although a portion is stable with a t1/2 of 2 hours 
(Young et al. 1992).
The mechanism of transport of IGFs and IGFBPs out of the vasculature is not 
clear. Bovine vascular endothelial cells possess IGF-1 receptors (Bar & Boes 1994) 
and there is evidence that endothelium itself may directly uptake and release intact 
IGF-1 (Bar et al. 1986). Circulating IGFBPs may attach to endothelial cells via their 
RGD sequences (IGFBP-1 and -2), or their GAG-binding regions (Hodgkinson et al.
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1994), but the mode of translocation is unclear. Likewise the mechanistic basis for 
the selectivity of localisation or insulin effects on IGFBP translocation in the studies 
of Bar et al. 1990b has not been explained. This may involve the differential 
expression of extracellular matrix components between tissues (perhaps altered by 
insulin), and the differences in ECM binding between IGFBPs.
Thus the functions of circulating IGFBPs are: to prolong IGFs half-lives; 
regulate IGFs metabolic clearance; to transport IGFs in plasma and control their 
exchange with the tissues. During several pathophysiological conditions such as 
protein restriction (Clemmons et al. 1989) the amount of IGF bound in temary:low 
molecular weight complexes decreases, however how this would alter IGF biological 
activity has not been determined.
1.9 Proteolysis of IGFBPs
IGFBP-3 was substantially reduced in the serum of pregnant women (Hossenlop et 
al. 1990, Giudice et al. 1990, rats (Davenport et al. 1990), and mice (Fielder et al. 
1990) when analysed by Western ligand blotting (WLB). However since other studies 
(Baxter & Martin 1986) showed elevated levels of IGFBP-3 by radioimmunoassay 
it was postulated that IGFBP-3 protease activity in pregnancy serum altered IGFBP-3 
affinity for IGFs rendering the IGFBP-3 undetectable by WLB (Hossenlopp et al. 
1990; Giudice et al. 1990). This protease activity was demonstrated by the ability 
of serum from pregnant dams to degrade radiolabelled IGFBP-3 (Lamson et al 1991) 
or IGFBP-3 in normal serum. This phenomenon was subsequently shown in other 
catabolic states, such as after elective surgery (Davenport et al. 1992a), severe 
illness (Davies et al. 1991), and diabetes (Bang et al. 1994).
39
It has been postulated that the proteolytic cleavage of IGFBP-3 in pregnancy 
results in decreased affinity for IGF-1 and the increased dissociation kinetics 
(Lassarre & Binoux 1994) makes IGF more available. However the physiological 
significance of proteolysis is difficult to demonstrate although serum from pregnant 
women had an enhanced ability to stimulate DNA synthesis in chick fibroblasts cells 
suggesting increased IGF availability in pregnancy serum (Blat et al 1994).
IGFBP-3 from pregnant woman shows little impairment in ternary complex 
formation (Baxter et al. 1993) and IGFBP-3 still circulates in an 140 kDa complex 
(Suikkari & Baxter 1992) although there is an additional complex of around 110 
kDa. IGFBP-3 from human pregnancy serum has a normal molecular weight of 
about 50 kDa after acid gel chromatography but several other alterations are 
apparent. Under the harsher in vitro conditions of SDS-PAGE, proteolysed IGFBP-3 
has an apparent molecular weight of about 30 kDa which contrasts with 40-45 kDa 
shown for intact IGFBP-3 (Baxter et al. 1993). In addition reverse phase 
chromatography inactivated IGFBP-3 from pregnant women but not that of the non­
pregnant state (Baxter et al. 1993). IGFBP-3 from pregnancy serum shows impaired 
solution phase binding to radioiodinated IGF (Hossenlopp et al. 1990; Suikkari & 
Baxter 1990). Proteolysed IGFBP-3 could not form ternary complexes in the 
presence of [Tyr60]IGF-l or and IGF-1 analogue altered in the A domain, though it 
could form complexes with native IGF-1 (Baxter et al 1993). How pregnancy 
IGFBP-3 can form 140 kDa complexes when IGF binding is apparently impaired is 
an anomaly since ALS only binds IGFBP-3 (at least in vitro) when the IGF binding 
site is occupied (Baxter et al 1989). The use of monoiodinated tracers has further 
clarified the nature of the IGFBP-3 alteration during pregnancy. Using recombinant
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IGF-1 analogues it was shown that the amino acid substitution at Tyr60 and Tyr24, but 
not Tyr31, resulted in poor binding of binary complex to ALS (Baxter et al. 1993). 
Proteolysed IGFBP-3 has about a 10-fold lower affinity for Ser24 and Leu60 IGF-1 
than for normal IGF-1 or Ala31IGF-l. Thus the specificity of IGFBP-3 for IGF-1 is 
altered around the Tyr60 or Tyr24 of IGF-1, and the affinity of IGF/IGFBP-3 
interaction is increased by acid labile subunit binding thus enabling the formation of 
ternary complexes with normal affinity (Baxter & Skriver 1993).
There is evidence for limited proteolysis of IGFBP-3 occurring in the normal 
state outside the bloodstream. Non-pregnant serum has low levels of proteolysis 
(Gargosky et al 1992) and Lalou & Binoux (1993) showed that proteolysis is higher 
in the lymph than serum suggesting that the site of proteolysis is the tissues, perhaps 
occurring at the cell surface or interstitium rather than in transit across capillaries. 
Normal rat serum contains IGFBP-3 proteolytic activity which is absent in the 
hypophysectomised rat. Proteolysis could be restored by the administration of GH 
but not IGF-1, suggesting that GH can modulate IGF action indirectly by altering 
IGFBP-3 (Rutishauser et al. 1993). Although proteolysis of IGFBP-3 is the best 
studied, early WLB studies of pregnancy serum detected a reduction in the intensity 
of IGFBP-4, and more recently IGFBP-4 and -5 protease activity has been 
demonstrated in human pregnancy serum (Claussen et al. 1994). IGFBP-2 can be 
proteolytically cleaved in the plasma of newborn animals (McCusker et al. 1991).
Proteolysis of IGFBPs has also been demonstrated in cell culture medium. 
Conditioned medium from bone cultures contains a protease of between 67 and 169 
kDa by gel filtration, which degrades IGFBP-4 and -5 (Kanzaki et al. 1994). A 
calcium-dependent protease which degraded IGFBP-5 but did not affect IGFBP-1 to
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-4, has been purified from human fibroblast conditioned medium (Nam et al. 1993). 
Fibroblast conditioned medium may contain proteases for IGFBP-4 and -5 (Conover 
et al 1993; Fowlkes & Freemark 1992). Proteolytic cleavage of IGFBP-2 and -4 
usually results in the abolition of its IGF binding capacity; this contrasts with 
proteolysis of IGFBP-3 and -5 where proteolytic fragments tend to retain some IGF 
binding capacity (reviewed in Jones & Clemmons 1995). The physiological 
importance of the proteolytic activity in conditioned medium is unclear but their 
presence may alter the biological activity of the IGFBP in the assay system used.
Proteolysis plays an important role in regulating many physiological processes 
such as the activation of growth factors and zymogens. Physiological fluids therefore 
contain many extracellular proteases, many of which can cleave IGFBPs in vitro. 
Most proteolytic modifications of IGFBPs are due to metal dependent serine 
proteases, however comparison of the proteolytic activity of proteases from different 
sources established that serum IGFBP-3 proteolytic activity is similar during 
pregnancy and critical illness but differs from that of common proteases like plasmin 
(Frost et al 1993).
It is difficult to identify the protease responsible for the effects seen since 
many extracellular proteases like plasmin can proteolyse IGFBP-3 in vitro but in vivo 
they would be in an inactive form or blocked by the presence of inhibitors. Little is 
known about the regulation of the IGFBP-protease activities and the physiological 
role of proteolytic cleavage of IGFBPs in vivo remains to be demonstrated.
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1.10 Regulation of IGF and IGFBP synthesis
1.10.1 Developmental regulation
IGF-1 and IGF-2 are present in almost all foetal tissue although their abundance 
varies between tissues (Han et al. 1988). In the rat, IGF-1 mRNA levels are lower 
than those of IGF-2 in foetal liver, kidney and heart, and these rise postnatally, 
whereas expression of IGF-1 in foetal lung, heart and stomach is higher than those 
found postnatally (Adamo et al. 1989). The abundant IGF-2 levels in the foetal rat 
decrease postnatally (except in the brain), however in other species such as man and 
ruminants there are significant IGF-2 levels in the adult. The high IGF-2 levels in 
the foetal and embryonic tissues suggest a role for IGF-2 in foetal growth. Studies 
of IGF-1 and -2 gene knockout mice show that while deletion of either gene reduced 
birth weight to 60%, postnatal growth of IGF-2 knockout mice was normal but IGF- 
1 knockouts had a reduced growth rate, extreme muscle hypoplasia and most died 
before adulthood. The growth retardation effect of IGF-2 deletion is associated only 
with failure of early embryonic growth, whereas IGF-1 deletion causes progressive 
growth failure, suggesting that growth effects of IGF-2 are dominant in the embryo, 
but IGF-1 is dominant in late gestation and in the perinatal period (Baker et al.
1993).
IGF-1 levels in the foetus are largely independent of GH but are under 
nutritional control. Maternal starvation leads to a rapid fall in foetal plasma IGF-1 
in sheep (Bassett et al. 1990) and in rats (Bernstein et al. 1991). In contrast only 
extreme placental failure or undemutrition alters IGF-2 levels in foetal sheep, 
suggesting that IGF-2 may have a constitutive role in foetal growth but IGF-1 is 
acutely modulated by nutrition (Bassett et al. 1990).
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The IGFBP profile also differs with developmental stage. Foetal serum 
IGFBP-3 levels are comparatively low and IGFBP-1 and-2 levels comparatively high. 
However species differences exist as there is little IGFBP-3 in foetal rat serum but 
it is easily detectable in foetal sheep serum (Osborn et al. 1992) although less 
abundantly than postnatally. IGFBP-1 and -2 are both expressed in a variety of foetal 
tissues; the expression of both is high in the liver but IGFBP-2 mRNA is abundant 
in foetal brain, kidney and stomach (Ooi et al. 1990). Serum and hepatic mRNA 
levels of IGFBP-1 and -2 decrease postnatally in rat, although IGFBP-2 is the major 
IGFBP in neonatal rat serum. IGFBP-2 levels progressively decrease and IGFBP-3 
levels gradually increase, becoming detectable at about day 10 (Glasscock et al.
1990).
1.10.2 Hormonal regulation
It is well established that GH has major effects on IGF-1 levels (Daughaday & 
Rotwein 1989). In neonatal rats growth is under partial pituitary control and becomes 
pituitary dependent after a few weeks when IGF-1 and IGFBP-3 levels rise and 
IGFBP-2 decreases (Cooke & Nicoll 1983; Yang et al. 1989). In neonatally 
hypophysectomised rats IGF-1 and IGF-2 serum levels decrease, IGFBP-2 increased 
after an initial drop, and IGFBP-3 became detectable at day 20 at only 10% of 
normal levels (Glasscock et al. 1990). This reciprocal relationship of IGFBP-2 and 
-3 was thought to be coordinately regulated by GH, however when neonatal rats 
were treated with anti-GH serum in the first few weeks of life, their subsequent 
IGFBP-3 levels were much reduced compared with controls but immunoreactive 
IGFBP-2 levels still declined as usual (Pallmer et al. 1994).
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GH is the major hormonal influence on serum IGF-1, IGFBP-3 and ALS in 
adults. Administration of GH or IGF-1 to GH-deficient rats demonstrated that while 
GH directly regulates serum ALS and IGF-1, IGFBP-3 is primarily regulated by 
IGF-1 (Gargosky etal. 1994). Although IGF-1 and IGFBP-3 mRNA are coexpressed 
in a large number of tissues, mRNA levels are not always coordinately regulated 
(Albiston & Herington 1992).
Serum IGFBP-1 levels are inversely proportional to insulin levels (Brismar 
& Hall 1993), and insulin is thought to be a major regulator of serum IGFBP-1, 
though there may also be a role for intracellular glucose (Lewitt & Baxter 1991a). 
Insulin treatment of streptozotocin diabetic rats could restore normal hepatic IGF-1 
and IGFBP-1 gene transcription (Pao et al. 1992). Insulin also increases IGF-1 
mRNA in hepatocytes in culture suggesting its effects on transcription are direct 
(Johnson et al. 1989).
In contrast IGFBP-1 is increased in insulin-induced hypoglycaemia and it is 
now apparent that the glucose counter regulatory hormones regulate IGFBP-1 (Lewitt 
& Baxter 1992). Glucocorticoids and glucagon increase IGFBP-1 mRNA in cultured 
rat hepatocytes (Kachra et al. 1994). Although insulin suppresses IGFBP-1 
expression in rat H4IIE hepatoma cells and glucocorticoids increase it, insulin effects 
are dominant (Unterman et al. 1991). Dexamethasone administration to rats does not 
affect serum IGF-1 levels but reduces weight gain while increasing IGFBP-1 in 
serum and mRNA in the liver (Luo et al. 1990). Glucocorticoids have however a 
suppressive effect on the expression of other IGFBPs. For example in vitro 
glucocorticoid treatment of human osteoblast like cells increased IGFBP-1 mRNA 
but decreased mRNA for IGFBP-3, -4, -5 and -6 (Okazaki et al. 1994). Likewise
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dexamethasone decreased IGFBP-3 and -5 in foetal fibroblasts (Camacho-Hubner et 
a l 1992).
Serum IGFBP-2 levels are inversely related to GH status, decreasing in 
diabetes and acromegaly, and increasing in GH deficiency (Clemmons et a l  1991). 
However serum IGFBP-2 also increases in states of IGF excess, for example IGF-1 
infusion (Zapf et a l 1990); thus serum IGFBP-2 levels increase when IGFBP-3 levels 
are insufficient to bind the available IGF (Baxter 1993). Insulin does not seem to be 
a major regulator of IGFBP-2, and it has been suggested that IGF-2 could be the 
major regulator of circulating IGFBP-2 in vivo (Blum et a l 1993).
Less is known about hormonal regulation of IGFBP-4 and -5. FSH decreases 
IGFBP-4 and -5 mRNA in rat granulosa cell culture (Liu et a l 1993). In human bone 
cells IGFBP-4 levels are increased by calcium mobilising hormones PTH and vitamin 
D but decreased by bone morphogenic protein-7, IGF-1 and progesterone. In 
contrast, IGFBP-5 levels in human bone cells are increased by IGF-1 and 
progesterone (reviewed by Mohan (1993)). IGFBP-4 in conditioned medium was 
increased by IGF-1 in muscle cells (McCusker et a l 1989). In contrast IGF-1 
treatment decreased IGFBP-4 and -5 in foetal fibroblasts culture, although there was 
no decrease in mRNA (Camacho-Hubner et a l 1992).
1.10.3 Nutritional regulation
The IGFs are important regulators of tissue growth, and nutrition is a major regulator 
of the IGFs. In most species GH is elevated by fasting, but IGF-1 levels fall in 
undernourished children and animals, showing the dominance of nutritional control 
of IGF-1 over that of GH. Fasting decreases GH receptors which may partly account
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for this apparent GH resistance (Straus & Takemoto 1990a). In contrast there is little 
change in GH receptor expression in protein restriction (Straus & Takemoto 1990b) 
suggesting a post receptor mechanism of GH resistance. IGF-1 and GH receptor 
mRNA are decreased in the liver and in other tissues of fasted rats though they are 
not coordinately regulated in all tissues (Lowe et al. 1989) but the physiological 
relevance of this is not determined. IGF-1 infusion does not normalise growth in 
protein restricted rats but spleen and kidney growth is enhanced (Thissen et al.
1991). Dietary energy or protein restriction decreased IGF-1 message but only 
protein restriction affects serum albumin production demonstrating that serum IGF 
decreases are not merely reflecting a general decrease in serum proteins.
The effects of nutrition on IGF-2 levels have been less well studied than those 
of IGF-1. IGF-2 appears less affected by acute fasting than IGF-1 but is significantly 
decreased by chronic dietary restriction (see Straus 1994 for review).
Changes in nutritional status markedly alter the expression of both IGFBP-1 
and -2; in general the modulation of IGFBPs-1 and -2 by nutrition follows a pattern 
inversely related to IGF-1 expression. IGFBP-1 mRNA is increased in fasting 
animals in both protein and energy restriction due to increased transcription (Straus 
et al. 1993). Hepatic IGFBP-2 mRNA increases in rats by fasting (Tseng et al.
1992), protein restriction (Straus & Takemoto 1990b), or energy restriction (Straus 
& Takemoto 1991). In contrast IGFBP-3 levels are decreased by fasting or protein 
deprivation in growing rats (Clemmons et al. 1989).
Normally IGFBP-2 and -3 levels are constant throughout the day, however 
IGFBP-1 levels show marked diurnal variation. Insulin and carbohydrate which are 
major inhibitory regulators of IGFBP-1 (Cotterill et al. 1988) and a role for IGFBP-
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1 in glucose homeostasis has been suggested (Lewitt & Baxter 1991b). Possible 
alternative roles for IGFBP-1 have also been suggested such as an IGF shuttle or 
regulator of mitogens (Holly 1991).
Nutrition is not only a major regulator of IGF-1 but also alters the expression 
of IGFBPs although the physiological consequences of changes in IGFBPs are 
unclear. IGF-1 clearance from the serum into tissues is increased in protein deprived 
rats, and this increased clearance may be due to an increase in the amount of IGF-1 
complexed to IGFBP-1 and -2 (Thissen et al. 1992).
1.11 The GH/IGF axis and the immune response
1.11.1 Introduction
It is now established that the endocrine and immune systems interact and there is 
growing evidence that polypeptide hormones play a supporting role in 
immunoregulation. The growth stimulatory effects of GH on lymphoid tissue was 
first suggested in 1930 when Smith reported thymic atrophy in hypophysectomised 
rats (Smith 1930). In subsequent studies GH or PRL restored thymus and spleen 
growth in hypophysectomised rats (Berczi & Nagy 1987). Similarly, in 
immunodeficient dwarf dogs GH treatment improved clinical condition and increased 
thymic size and cellularity (Roth et al. 1984). These studies described the role of GH 
only in gross anatomical terms but many subsequent studies demonstrated a specific 
role for GH in the development and function of immune tissues. For example, 
administration of a specific antiserum to GH resulted in defects in lymphatic tissue 
and humoral immunity in neonatal rats (Crilly et al. 1994).
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Many studies have suggested that GH actions are mediated via the endocrine 
or paracrine synthesis of insulin-like growth factor-I (IGF-1) and since cells of the 
immune system can produce and respond to GH and IGF-1, some of GH’s effect 
may thus be mediated by IGF-1. For example, recombinant human IGF-1 treatment 
restored thymus and spleen weights to normal in hypophysectomised rats (Guler et 
al. 1988). Similarly, in diabetic rats, IGF-1 treatment restored thymus weight and 
increased thymocyte proliferation (Binz et al. 1990). In some studies administration 
of IGF-1 but not GH increased the weight of spleen and thymus disproportionally to 
overall body size (Guler et al. 1988, Skottner et al. 1989, Binz et al. 1990). These 
in vivo studies described the effects of IGF-1 in gross anatomical terms, but more 
recent in vivo studies have investigated the effects of IGF-1 administration on the 
immune functionality as well as cell numbers and changes in cell size (Clark et al.
1993). There are an increasing number of studies of IGF effects on immune cells in 
vitro, initally these concentrated on T-lymphocytes but recently the effect on 
immunoglobulin synthesis and B-cell lymphopoiesis have received more attention.
1.11.2 Production of IGFs by cells of the immune system 
GH stimulates IGF-1 production from rat spleen cells (Baxter et al. 1991) in culture 
and stimulates the growth of T-lymphoblasts lines via local IGF-1 production 
(Geffner et al. 1992). IGF-1 production also has been demonstrated by transformed, 
but not freshly isolated, human B-lymphocytes (Merimee et al. 1989) however the 
amount of IGF-1 released was low though IGFBPs did not seem to be interfering 
with IGF-1 measurement.
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An IGF-like molecule is released from cultured alveolar macrophages (Rom 
et al. 1988) and IGF-1 mRNA is expressed by wound macrophages (Rappolee et al. 
1988). Arkins et al. (1993) detected IGF-1 expression in differentiated mouse 
macrophages (but not pre-myeloid cells) using Northern blotting or PCR 
amplification; since IGF-1 mRNA was negligible in lymphoid cell lines and 
lymphoid tissues this suggests that in haemopoietic cells it is the myeloid rather than 
lymphoid cells which express IGF-1.
IGF-2 appears to be the major IGF within the thymus of the young rat and 
human (Geenan et al. 1993). IGF-2 was localised by immunohistochemistry to 
stromal cells in the subcapsular cortex and medulla of human thymus, and to stromal 
cells dispersed throughout the parenchyma of rat thymus. In contrast IGF-1 was 
localised to non epithelial-like cells in the interlobular septa; this confirms Han’s 
earlier study of IGF-1 mRNA distribution in the human foetus, which showed IGF-1 
mRNA exclusively in the capsule and interlobular septa (Han et al. 1987).
1.11.3 Production of IGFBPs by cells of the immune system 
Few studies have investigated the production of IGFBPs in the immune system. 
Although there are satisfactory serum-free culture media for lymphoid cells, the use 
of serum is routine and since serum contains IGFBPs this interferes with the 
detection of endogenously produced IGFBPs. IGFBP production has been 
demonstrated from human leukaemic blasts (Neely et al. 1991) and human peripheral 
blood cells express mRNA for several IGFBPs only some of which are demonstrable 
by WLB (Nyman & Pekonen 1993). Spleen tissue from adult rats expresses mRNA 
for IGF-1, IGFBP-2, and IGFBP-4 (Domeneerfl/. 1994). Hypophysectomy reduced
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splenic mRNA for IGF-1 and IGFBP-2 but increased IGFBP-4 mRNA, and GH 
treatment can partially prevent these effects. Hypophysectomy of juvenile rats has 
similar effects (Yakar et al. 1994).
1.11.4 Expression of IGF receptors
Type 1 IGF receptors have been demonstrated on a variety of myeloid and lymphoid 
cells: human peripheral blood T-lymphocytes (Tapson et al. 1988, Johnson et al.
1992), B-lymphocytes, monocytes and Natural killer cells (Kooijman et al. 1992a), 
platelets (Hartmann et al. 1989); human malignant myeloid (Sinclair et al. 1988), 
B-cell (Freund et al. 1994) and T cell lines (Lee et al. 1986); rat thymus and 
thymoma cells (Verland & Gammeltoft 1989); bovine peripheral blood mononuclear 
cells, neutrophils and to a lesser extent, erythrocytes (Zhao et al. 1992).
1.11.5 Effects of IGFs on immune cell function
IGF-1 enhances H20 2 production by bovine neutrophils (Zhao et al. 1993) and 
enhances human neutrophil phagocytosis (Jin et al. 1993). IGF-1 and GH can prime 
human and porcine neutrophils for 0 2 production (Fu et al. 1991) although GH 
effects are not mediated by IGF-1. In contrast GH or IGF-1 stimulate human thymic 
epithelial cell proliferation and enhance thymic hormone production; both the IGF-1 
and growth hormone effects could be abrogated by an antibody to IGF-1 suggesting 
that the GH effect may be mediated by IGF-1 secretion (Timsit et al. 1992).
The use of serum in culture medium has complicated the interpretation of 
some studies of IGF effects since serum contains IGF and insulin, and IGFBPs 
which could modify IGF responses. IGF-1 augments [3H]thymidine incorporation
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into human peripheral blood mononuclear cells (PBMC) (Kooijman et al. 1992b), 
lymphoblastoid cell lines and human tonsillar B-lymphocytes (Kimata & Yoshida
1994), bovine PBMC (Zhao et al. 1993), rat thymocytes (Yamada et al. 1994), and 
stimulates normal and transformed T-lymphocyte growth (Geffner et al. 1992). 
However other studies failed to show stimulatory effects of IGFs e.g. on 
[3H]thymidine incorporation into rat thymocytes (Verland & Gammeltoft 1989). Some 
studies using human peripheral blood cells showed little enhancement in the presence 
of serum but significant enhancement in the presence of serum treated with reducing 
agent to inactivate growth factors (Kooijmann et al. 1992b). The enhancement was 
greater when purified T-cells depleted of monocytes were used, though 
supplementation with IL-1 showed the IGF effects were independent of monocytes 
or IL-1 production. The authors suggest the absence of monocytes enhanced IGF-1 
effects because monocytes secrete IGFs or IGFBPs which may inhibit IGF-1 action 
on mitogen stimulation. This is plausible since Arkins et al. (1993) showed IGF-1 
expression by myeloid rather than lymphoid cells, and although IGFBP production 
has not been demonstrated by macrophages, exogenous IGFBP-1 could block the 
polyclonal activation of human peripheral blood cells (Kooijman et al. 1992b). The 
direct effect of IGF-1 on lymphoid cells was demonstrated when antisense 
oligonucleotide strategy showed that IGF-1 receptor expression was necessary for 
mitogenic stimulation of mononuclear cells (Reiss et al. 1992). Recently IGF-1 has 
been shown to enhance PHA stimulated [3H]thymidine uptake in human lymphocytes 
by reducing Gj phase length thus enhancing clone expansion rather than altering cell 
numbers (Schillaci et al. 1994). IGF-2 alters surface determinants on neutrophils and 
lymphocytes and may thus affect their reactivity (Vetvicka & Fusek 1994).
52
Human platelets show enhanced aggregation in response to stimulants in the 
presence of IGF-1; since the platelet is anucleate this demonstrates a metabolic 
response to IGF-1 in the absence of its mitogenic effect (Motani et al. 1992).
IGF-1 has effects on haematopoiesis of myeloid and lymphoid cells. IGF-1 
augments human granulopoiesis in vitro (Merchav et al. 1988) and in vivo 
administration of IGF-1 increases bone marrow B-lineage cells (Jardieu et al. 1994). 
IGF-1 increases proliferation of intrathymic pre-T lymphocytes in vitro (Gjerset et 
al. 1990) and stimulates the differentiation of pro-B cells in response to IL-7 
(Landreth et al. 1992). Mature B-lymphocyte function can also be modulated by 
IGF-1 and GH. GH and IGF-1 can enhance immunoglobulin synthesis by tonsillar 
B-lymphocytes as well as human B-lymphocyte lines in vitro (Kimata & Yoshida
1994). There is evidence that in human peripheral B-cells, IGF-1 can induce IgE and 
IgG4 production by class switching through an IL4- and IL3-independent mechanism. 
GH had a similar effect which was direct i.e. not mediated by IGF-1 (Kimata & 
Fujimoto 1994). Infusion of IGF-1 into mice increased lymphocyte numbers in 
peripheral lymphoid tissues, and enhanced Ig production in response to in vivo 
challenge. In addition IGF-1 alone could stimulate Ig production by antigen primed 
splenocytes in vitro (Robbins et al. 1994).
1.11.6 Role of IGFs in the immune response
There is clearly evidence for a role of IGFs in the immune response, in ontogeny 
and in the mature differentiated function of both specific and non-specific arms of 
the immune response. IGF-1 may mediate some of the effects of GH but not all, for
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example GH has direct effects on mature neutrophils (Fu et al. 1991) but its effect 
on granulocyte maturation is mediated by IGF-1 (Merchav et al. 1988).
Immune responses require complex interactions between different cell types 
and the ECM within the micro-environment. Although IGF-1 production by 
lymphoid cells is low, IGF-1 produced by stromal cells including macrophages, may 
act by a paracrine mechanism. Murine bone marrow stromal cells produce IGF-1 and 
IGFBPs (Abboud et al. 1991) and thymic epithelial cells produce IGF-1, in response 
to GH (Timsit et al. 1992). In addition to its mitogenic effect IGF-1 is chemotactic 
for human T-lymphocytes (Tapson et al. 1988). Some cytokines bind ECM 
components, where they not only form a reservoir of cytokine, but are often better 
motility agents than free cytokine. IGFBPs attached to the ECM via their GAG 
binding regions could likewise sequester IGFs in the microenvironment thus 
enhancing the chemotactic properties of IGFs.
The endocrine role of the IGFs is not fully elucidated, but they are thought 
to play a role in carbohydrate, lipid, and whole body protein metabolism. Evidence 
suggests that changes in IGF-1 and GH are permissive to protein catabolism. GH and 
IGFBP-1 levels are raised but IGF-1 and IGFBP-3 are low (IGFBP-3 protease 
activity is increased) in some catabolic states such as critical illness, cancer, and 
septicaemia (Bentham et al. 1993). Hypercatabolic states such as injury and severe 
illness, are associated with immunosuppression and since IGFs appear to be 
important in the maintenance of the immune response, the alterations in IGFs may 
be contributing to the observed immunosuppression.
The acute phase response (APR) consisting of fever, reduced food intake, 
weight loss, hypercatabolism etc. is the first phase in the inflammatory response to
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injury or infection. The APR normally lasts for a few days and may be detrimental 
if it continues e.g. in rheumatoid arthritis. Cortisol initiates the hepatic response but 
is also inhibitory to the production of secondary cytokines, thus forming a loop 
limiting the response. Insulin can modulate the APR by attenuating the response of 
the liver to IL-1 and IL-6 (Campos & Bauman 1991). Recent evidence suggests IGF- 
1 may be a component of the APR. Endotoxin administration to rats immediately 
reduced plasma GH and IGF-1 but IGFBP-3 was unaltered, showing the dissociation 
of serum IGF/GH and IGFBP-3 (Fan et al. 1994). Because nutrition is a major 
regulator of IGF-1, the endotoxin-related changes in the IGF axis are confounded by 
the effect of reduced food intake induced by endotoxaemia. In ruminants short term 
reduction in food intake has little effect on circulating IGF-1 levels making them a 
good model in which to study the effects of endotoxin. Similar to its effects in rats, 
endotoxin administration to cattle reduced serum IGF-1 but IGFBP-3 was unaffected 
(Elsasser et al. 1995). In contrast yeast administration to lambs increased circulating 
IGF-1 concentration (Moore et al. 1994). Although circulating IGF-1 and IGFBP-3 
levels decrease in many catabolic states, serum IGF-1 is unaltered in sepsis (Dahn 
et al. 1988) and serum IGFBP-3 was unaltered in infected pigs (Prickett et al. 1992). 
IGF-1 levels tend to rise after moderate injury and fall in severe trauma; the 
catabolic response may vary with the severity of the insult.
IGF-1 and GH have been used in preliminary clinical trials to restore the 
nitrogen balance in catabolic states, but the effect of treatment on the immune 
responses was rarely determined in spite of the clinical problem of post-trauma 
immunosuppression. Aggressive nutrition eliminated the depressed CD4+/CD8+ T- 
cell ratio seen in patients with head injuries; IGF-1 administration in addition to
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nutrition increased the CD4+/CD8+ ratio while IGF-1 levels were elevated (Kudsk 
et a l  1994).
IGF-1 and IGF-2 are found high amounts in wounds and poor wound healing 
is associated with IGF-1 deficiency states. Wound IGF-1 is likely to be derived not 
only from the circulation, but by local production by wound macrophages and 
fibroblasts, and from the lysis of platelets which contain IGF-1 and IGFBP-3. IGF- 
1: IGFBP-3 complexes are effective in promoting wound healing in animal models 
(Sommer et al. 1991). IGF-1 and GH have potential clinical uses in restoring 
immune function in immunosuppressed states such as the regeneration of bone 
marrow after irradiation. Alternatively, ablation of IGF-1 or GH may be of use in 
leukaemias (Hooghe et al. 1993). IGF-1 and GH clearly modulate the immune 
response and the clinical and agricultural importance of the interactions between the 
immune and endocrine systems is beginning to be recognised.
1.12 The IGF axis during pregnancy
During pregnancy the maternal metabolism adapts under hormonal control to meet 
the increased energy requirements imposed by the foetus and placenta, and maternal 
glucose utilisation is reduced to spare glucose for the foetus. In rats maternal muscle 
is degraded to help meet this energy demand and because IGF-1 inhibits the 
breakdown of protein it is possible that the decrease in IGF-1 in late pregnancy is 
involved in the regulation of glucose and protein metabolism during pregnancy 
(Chiang & Nicoll 1990).
Serum IGF-1 levels abruptly decrease in the second half of pregnancy in rats 
(Travers et al. 1993, Davenport et al. 1990), pigs (Lee et al. 1992), and the baboon
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(Putney et al. 1990). The decreased serum IGF-1 levels in rats during late pregnancy 
are believed to be caused by decreased transcription in the liver as IGF-1 mRNA 
decreases per unit of RNA. However since total hepatic IGF-1 mRNA is higher if 
the total RNA content (because of increased liver size during pregnancy) is taken 
into account, decreased transcription alone cannot explain the decrease in serum IGF- 
1 and other mechanisms are likely such as increased clearance from the circulation 
(Travers et al. 1993). In contrast, in human pregnancy there is a steady rise in serum 
IGF-1, although IGF-2 was either unchanged (Hall et al. 1984) or raised (Gargosky 
et al. 1990). Serum IGF-1 and IGF-2 are unchanged in pregnancy in sheep 
(Gluckman et al. 1979) and in mice (Fielder et al. 1990). Rats support a 
comparatively greater weight of foetal tissue than humans in late pregnancy. It has 
been suggested that this higher metabolic burden induces a maternal catabolic state 
which accounts for the decrease in serum IGF-1 in the rat but not in humans 
(Gargosky et al. 1990).
In man, mice and rats IGFBP-3 protease activity is greatly increased in late 
pregnancy rendering IGFBP-3 undetectable by WLB. The appearance of protease 
activity in rat serum coincides with the switch of maternal metabolism to a catabolic 
state and since IGFBP-3 protease activity occurs in other catabolic states it has been 
suggested that the function of the protease is to reduce IGFBP-3 affinity for IGF and 
therefore increase its availablity. However ewes are often in a negative energy 
balance in late pregnancy but both serum IGF and IGFBP-3 concentrations are 
normal and there is no evidence of increased IGFBP-3 protease activity by WLB. 
Neither pigs nor humans are in a negative energy balance in late pregnancy, but 
whilst pig serum IGF-1 decreases in the absence of marked IGFBP-3 protease
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activity (Lee et al. 1992), IGF-1 levels remain high in human pregnancy serum in 
spite of increased protease activity. Therefore increased IGFBP-3 protease and low 
serum IGF-1 do not necessarily correlate with catabolism and the physiological 
function of this IGFBP-3 protease in pregnancy remains unclear.
The Baboon, Pig and Rhesus monkey, which exhibit little or no IGFBP-3 
protease activity in late pregnancy, have superficial placentas, however species like 
rats and humans which do exhibit increased IGFBP-3 protease activity have an 
invasive trophoblast. Decidualisation is associated with increased production of 
proteases which enable trophoblast invasion. The source of IGFBP-3 protease may 
be the decidua since human decidual cell explants (Deal & Lamson 1991) and rat 
uterine decidua (Davenport et al. 1992b) produce IGFBP-3 protease in culture. 
Therefore the sparse endometrial decidualisation in some species may explain the 
absence of IGFBP-3 protease expression in late pregnancy (Giudice et al. 1993).
IGFBP-3 from human term placental trophoblasts (Deal et al. 1991) and from 
pregnant baboon serum (Giudice et al. 1993) is about 2 kDa higher than that in 
normal serum, and deglycosylation studies suggest they may be differentially 
glycosylated or differ in primary structure, though the functional significance of this 
alteration is unknown.
IGFBP-3 is not the only serum IGFBP which shows alterations during 
pregnancy. Human pregnancy serum shows decreased IGFBP-2 and -4 by WLB after 
about week 10 (Giudice et al. 1990). IGFBP-1 serum levels measured by RIA 
increase in human(Rutanen et al. 1982). IGFBP-1 is also present in human amniotic 
fluid (Rutanen et al. 1982) and is abundantly produced by decidual cells in culture 
(Clemmons et al. 1990b). Amniotic levels of IGFBP-1 increase throughout human
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pregnancy and the proportion of phosphorylated IGFBP-1 increases (Koistenen et al. 
1993).
In contrast, serum IGFBP-4 in pregnant rats appears resistant to proteolysis 
(Davenport et al. 1990) and hepatic mRNA for IGFBP-1 and -4 is increased although 
hepatic IGFBP-2 mRNA was barely detectable (Donovan et al. 1991). IGFBP-2 was 
the major binding protein in rat decidua, placenta, and uterus by day 15 (Davenport 
et al. 1992b). IGFBP-1 protein is expressed by rat uterus but only in the non- 
decidualised endometrium (Sadek et al. 1994).
Although IGFBP-3 is apparently reduced in pregnancy when detected by 
WLB, human serum IGFBP-3 levels are actually raised and rat hepatic IGFBP-3 
mRNA is normal (Donovan et al. 1991a). Since rats are GH resistant in late 
pregnancy this shows the dissociation of IGFBP-3 and GH levels, and implies that 
IGFBP-3 expression is not under such strict GH control during pregnancy. The effect 
of GH administration on foetal growth has been investigated in several studies using 
ad lib. fed rats, but conflicting results were obtained; foetal growth was unaffected, 
increased, or the effect varied with maternal size. The marked GH resistance during 
late pregnancy in the rat can only be overcome with high doses of GH (Chiang et 
al. 1990), but lower GH doses administered to pregnant rats on a low food intake 
could reduce foetal and placental growth, and high doses led to advanced resorption 
of the foetuses (Chiang & Nicoll 1991). Ablation of GH in pregnant rats by 
administration of anti-rGH serum decreased maternal muscle mass and increased 
foetal weights (Palmer et al. 1996). These studies suggest that maternal GH 
resistance is an important adaptation in diverting nutrients from dam to foetus.
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There is increasing evidence that maternal IGF-1 is a key determinant of 
maternal-foetal nutrient partitioning. For example Gluckman et al. (1992) showed 
that the administration of IGF-1 (but not GH) overcomes maternal constraint, 
abolishing the negative correlation between foetal weight and litter size, but does not 
affect foetal and placental weights. Similarly Gargosky et al. (1991) showed 
administration of IGF-1, but not GH, to ad lib. fed rats increased serum IGF-1 
levels and maternal weight but did not affect the foetal placental unit. IGF-1 does not 
cross the placenta and probably exerts its effects by altering placental function in 
favour of nutrient transfer to the foetus.
The type of placentation and the consequent relationship of maternal-foetal 
circulations differs between species and their different IGF-IGFBP profiles may 
reflect this. However the role of the IGFBPs and their regulation in mother and 
foetus during pregnancy are poorly understood.
1.13 The IGF axis and the mammary gland
1.13.1 Introduction
The mammary gland cycle of growth, development and involution comprises distinct 
physiological states: mammogenesis, the development of mammary tissue during 
puberty and pregnancy; lactogenesis, the initiation of milk secretion at parturition; 
galactopoiesis, the maintenance of established lactation; and involution, when milk 
secretion ceases and the gland regresses to a resting state. The regulation of these 
events involves the complex coordination of a range of hormonal stimuli, growth 
factors and cell-cell interactions. The hormonal control of each stage is largely 
independent and marked species differences exist.
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1.13.2 Mammary differentiation and development
1.13.2.1 In vivo
Mammary development is dependent on a variety of lactogenic and mammogenic 
factors. The presence of a lactogen, PRL or Placental lactogen (PL) has been 
considered essential, but there is increasing evidence of the importance of GH 
although the relative role of the different hormones and the mechanisms involved are 
unclear. The effect of GH was originally attributed to its similarities with PRL but 
Kleinberg and coworkers have in a series of studies provided evidence for a role of 
GH in mammary development using the castrated, estradiol-treated male rat as a 
model. rGH which is non-lactogenic, was more potent than rPRL in directly 
stimulating mammary gland growth and differentiation when implanted in rat 
mammary gland (Kleinberg et al. 1990). Feldman et al. (1993) subsequently 
compared the ability of implanted GH, PRL and PL to induce mammary 
development; only hormones which could bind to GH receptors induced mammary 
development, regardless of their lactogenic activity. This supports a role for GH by 
a mechanism independent of lactogenic receptors.
A direct mode of action for GH within the mammary gland seemed unlikely 
because GH receptors have not been convincingly demonstrated on mammary cells. 
For example GH receptors could not be found on mammary glands of the pregnant 
non-lactating ewe using conventional binding assays (Akers 1985). GH receptor 
mRNA has been detected during late gestation and early lactation in mammary acini 
tissue of rabbit (Jammes et al. 1991) and cow (Hauser et al. 1990) though adipocyte 
GH receptors may account for some data. However in pregnant and early lactating 
rats, immunocytochemistry showed GH receptor protein localised to ductal epithelial
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cells, alveolar cells and myoepithelial cells as well as adipocytes (Lincoln et al. 
1990).
Several lines of evidence support a role for IGF-1 in mammary development. 
IGF-1 can substitute for the pituitary in mammary development (Ruan et al. 1992). 
The mammary gland expresses IGF-1 mRNA (Murphy et al. 1987) and expression 
was stimulated by systemic GH administration (Kleinberg etal. 1990) suggesting that 
GH may exert its effects on mammary development through IGF-1. IGF-1 expression 
in mammary glands of pregnant rats decreases during pregnancy; IGF-1 was 
immunolocalised to myoepithelial cells (Marcotty et al. 1994) suggesting a paracrine 
role for IGF-1 in mammary development. Consistent with this hypothesis, mammary 
type 1 IGF receptors have been demonstrated in several species. In rats type 1 IGF 
receptors increase in pregnancy compared with virgin animals (Collier et al. 1989). 
In the ewe also, type 1 IGF receptors are higher in gestation than lactation, and IGF- 
2 receptors are higher prepartum than during lactation (Disenhaus et al. 1988). In 
contrast, type 1 IGF receptors on lactating cow mammary gland declined during the 
prepartum period, although IGF-2 receptors, which are more abundant than type 1 
IGF receptors, were unchanged (Hadsell et al. 1990; Dehoff et al. 1988). In the pig 
also, type 1- and -2 IGF receptor mRNA expression in pregnant mammary tissue 
were greater during early growth than later stages (Lee et al. 1993) suggesting that 
IGF-1 is more important in early mammary development.
1.13.2.2 In vitro
IGF-1 is mitogenic for mammary cells in culture, for example IGF-1 stimulated 
[3H]thymidine uptake in undifferentiated bovine mammary epithelial cells (Gertler
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et al. 1983). Mammary tissue in culture produces IGF-1 and IGFBPs, the production 
of which can be modulated by IGF-1. Mammary explants from pregnant cows 
synthesise IGF-1 and IGFBPs but acini synthesise only IGFBPs; GH, PRL, insulin 
or cortisol had no effect on IGFBP production (Campbell et al. 1991). However 
IGF-1, des-IGF-1, and to a lesser extent IGF-2, enhanced the production of both 
IGFBP-2 and -3 in conditioned medium of mammary cells from pregnant heifers 
(McGrath et al. 1991).
In vitro culture of mammary tissue has generally used tissue from pregnant 
animals induced into lactogenesis by combination treatment with insulin, cortisol and 
PRL. The effects of GH, PRL and IGF-1 on mammary growth have been studied in 
vitro using mammary glands from young mice implanted with oestogen and 
progesterone (Plaut et al. 1993). Explants cultured in insulin, hydrocortisone, 
aldosterone and EGF with either PRL or GH showed lobular-alveolar development, 
but higher doses of GH than PRL are required. Similarly PRL is more potent than 
GH in stimulating /3-casein expression. These findings contrast with those of 
Kleinberg’s in vivo studies in which GH was more potent. Plaut et al. suggest the 
conflicting results may reflect differences in the models used or the use of 
homologous GH in Kleinberg’s study, which is not available for the mouse studies. 
IGF-1 did not substitute for GH, PRL or insulin in tissue maintenance of mouse 
explants, perhaps due to the absence of appropriate IGFBPs in culture or 
alternatively, GH action may not be mediated by IGF-1 but may work through a GH 
receptor-independent mechanism (Plaut et al. 1993). IGF-1 can however stimulate 
the proliferation of mammary cells from mice (Imagawa et al. 1986), rats (Deeks et 
al. 1988), non-pregnant (Peri et al. 1992) and pregnant cows (McGrath et al. 1991).
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In addition IGF-1 stimulated /Lcasein expression and the transport of glucose and 
alpha-lactalbumin in mammary explants (Prosser et al. 1987).
The effects of IGFs, GH and placental lactogens have been investigated in 
vitro using floating collagen gel culture of mouse mammary epithelial cells from 
pregnant mice. Cells were cultured in floating collagen gels, treated with mouse 
PRL, PL-1, PL-2, GH, IGF-1 and IGF-2. Cells in basal conditions produced 
IGFBPs at 40-45 kDa and at 29 kDa though at a lower level. Treatment with PRL 
and PLs increased the 29 kDa IGFBP, but the 40-45 kDa IGFBP was not as lactogen 
dependent. GH was a less potent stimulator of 29 kDa IGFBP but IGFs increased 
this IGFBP as potently as lactogens; IGF effects were additive with one of the 
lactogens. These IGF-1 effects did not seem to be type 1 IGF receptor mediated. 
IGFs however had no effect on alpha-lactalbumin production nor did they enhance 
the lactogenic effects of PL-1. The 40-45 kDa IGFBP was thought to be IGFBP-3, 
the 29 kDa IGFBP however did not react with antibody to IGFBP-1 or -2 and could 
not be identified (Fielder et al. 1992).
A mouse mammary epithelial line (Comma-D/MME) produced predominantly 
IGFBP-2 and -3 when cultured in serum free medium and their production was 
regulated by several hormones and growth factors. The mammogenic growth factors 
IGF-1 and EGF both stimulated DNA synthesis, but IGFBP-2 and -3 secretion was 
stimulated by IGF-1 and inhibited by EGF. Combinations of lactogenic hormones 
were also tested: insulin stimulated DNA synthesis and IGFBP-3 secretion but not 
IGFBP-2 secretion; cortisol inhibited IGFBP-3 secretion and DNA synthesis but 
increased IGFBP-2; whereas PRL had no effect on production of either IGF or 
IGFBPs (Skaar & Baumrucker 1993).
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Thus mammary tissue produces and responds to IGFs and there is strong 
evidence for a role of IGFs in the development of the mammary gland, probably 
acting in a paracrine manner mediating mesenchymal-parenchymal interactions.
1.13.3 Galactopoiesis
1.13.3.1 In vivo
GH is well established as the major galactopoietic hormone in ruminants although 
the mechanism of action is not clear (Breier et al. 1991). GH also increases milk 
volume in lactating women (Milsom et al. 1992). In contrast, PRL is the major 
galactopoietic hormone in rodents although GH plays a lesser but significant role, 
especially when PRL is low (Madon et al. 1986).
There are several possible mechanisms of action of GH: nutrient partitioning, 
direct action on the mammary gland, or indirect effects via IGF-1. GH does not 
seem to increase milk yield by acting directly on the ruminant mammary gland 
because local infusion of GH could not show a unilateral stimulation of milk yield 
in sheep (McDowell et al. 1987). Consistent with this was failure to detect GH 
receptors on mammary epithelial cells (Akers 1985). However GH receptor mRNA 
has been detected in lactating mammary gland of the cow (Hauser et al. 1990) and 
rabbit (Jammes et al. 1991). Some of this mRNA could be derived from other cell 
types such as adipocytes, but in the rabbit during the phase of epithelial cell 
proliferation in late gestation the proportion of adipocytes and connective tissue is 
decreasing as the GH-receptor mRNA increases. Furthermore, during lactation 
mRNA is still detectable even though milk protein expression is high suggesting GH- 
receptor mRNA expression is by epithelial cells. Systemic administration of GH
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increased immunoreactive IGF-1 in the cytoplasm of bovine secretory cells which 
may reflect intemalistion of IGF or local production (Glimm et al. 1988). Glimm et 
al. (1990) subsequently used in situ hybridisation to show that GH receptor mRNA 
was expressed in alveolar epithelial cells and GH treatment decreased mRNA levels. 
One study did demonstrate GH receptor protein in lactating rat mammary epithelial 
cells (Lincoln et al. 1990). Receptor protein decreased at the onset of lactation and 
was only weakly detectable by day 18, suggesting that while GH may act directly in 
mammary development in the rat, this may not be the case in the maintenance of 
lactation. Another implication of this finding is that the contribution of GH, as a 
stimulant of locally produced IGF-1, is a minor contribution in galactopoiesis in the 
rat.
Consistent with a role for IGF-1, IGF receptors have been detected on 
lactating mammary tissue in several species. In the lactating cow both type 1- and 
-2 IGF receptors are expressed on mammary microsomes with type 2 receptor in 10- 
fold abundance. Binding to type 1 IGF receptors increased by 75 % at the onset of 
lactation but declined throughout the postpartum period (Hadsell et al. 1990). Bovine 
mammary gland membranes expressed both 135 kDa and 127 kDa species of type 
1 IGF receptor, but non-lactating have only the 135 kDa type suggesting that 
lactation is associated with structural changes in receptors as well as the level of 
expression (Dehoff et al. 1988). In contrast, rat type 1 IGF receptors levels decrease 
in lactation compared with pregnancy, although IGF-2 receptors were unchanged 
(Collier et al. 1989). In the ewe type 2 IGF receptors are lower during lactation than 
during the prepartum period (Disenhaus et al. 1988).
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A role for circulating IGF-1 in galactopoiesis is supported by the ability of 
GH administration to increase serum IGF-1 and mammary blood flow thus increasing 
the supply of IGF-1 to the gland (Prosser et al. 1989). However systemic IGF-1 
administration elevated circulating IGF-1 levels two-fold but milk yield was 
unaffected (Davis et al. 1989). Although GH consistently increased serum IGF-1, 
the galactopoietic response correlated with the amount of IGF-1 in milk and 
mammary tissue suggesting that the availability of circulating IGF-1 to the mammary 
gland is important in the response to GH (Prosser et al. 1991a). Local infusion of 
IGF-1 into mammary gland of goats apparently stimulated milk production (Prosser 
et al. 1990) but subsequently Prosser et al. (1992) showed that although intra­
mammary infusion of IGF-1 increased mammary blood flow and milk yield, more 
frequent milk removal on the day before intra-mammary infusion attenuated both 
milk yield and mammary blood flow effects whilst not attenuating the response to 
GH. The role of IGF-1 in mediating GH effects within the gland was therefore 
questionable. The effects of GH and IGF-1 administration differ in several ways 
including their nutrient partitioning effects (Prosser & Mepham 1989) and depression 
of insulin and IGF-2 by IGF-1 infusion (Prosser & Davis 1992). IGF-1 and GH 
administration elicit different IGFBP profiles (Davis et al. 1989) with consequent 
affects on IGF availability; it is feasible that IGF-1 does mediate GH action within 
the gland but the delivery to the gland or local availability of exogenously 
administered IGF does not mimic that obtained with GH administration.
Although IGF-1 concentrations in milk and mammary tissue correlated with 
galactopoiesis in goats a role of IGF-1 has not been demonstrated. Mammary tissue
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can express IGFs and IGFBPs but whether those found in milk are derived from the 
mammary tissue or enter by the paracellular route is unclear. The milk of all species 
studied contains IGFs and several of the IGFBPs are present in milk depending on 
the species. The presence of IGFs in the milk follows the pattern of other growth 
factors and immunoglobulin: higher in colostrum than in mature milk. Because type 
1 IGF receptors are found in the rat gastrointestinal tract (Laburthe et al. 1988) and 
colostrum stimulates intestinal growth in suckling rats, a role for IGF-1 in the 
development of the gastrointestinal tract has been postulated (Berseth et al. 1983). 
A truncated IGF-1 which has reduced affinity for IGFBPs accounts for 50% of the 
IGF-1 in bovine colostrum but 3% of milk IGF-1 (Francis et al. 1986). It is unknown 
if this exists in the milk of other species, however this variant IGF-1 is particularly 
potent in promoting growth of the rat gastrointestinal tract (Read et al. 1992).
Serum IGF-2 concentrations in the adult rat are low and IGF-1 is the major 
IGF in both serum and rat milk. The concentration of IGF-1 decreased in both milk 
and serum during lactation although serum IGF-1 concentrations were still higher 
than those of milk. In contrast serum and milk IGF-2 concentrations were low and 
did not change during lactation (Donovan et al. 1991b). IGF-1 and -2 mRNA was 
low or absent in day 11 lactating rat mammary gland (Murphy et al. 1987) although 
IGF-2 mRNA was detectable in lactating rat mammary gland in another study (Manni 
et al. 1992). Marcotty et al. 1994 confirmed that IGF-1 mRNA is low at day 5 and 
10 of lactation although IGF-1 could still be immunolocalised to myoepithelial cells. 
The low levels of expression suggested that serum may be the source of milk IGF-1 
in the rat. Rat milk contains IGFBP-3, IGFBP-2, and a 24 kDa IGFBP identified by
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WLB. IGFBP-2 was undetectable by WLB in maternal serum but lactating mammary 
gland expressed IGFBP-2 mRNA suggesting that IGFBP-2 is synthesised in the gland 
(Donovan et al. 1991b). However mammary gland IGFBP-3 mRNA is decreased at 
parturition and remains low in lactation suggesting that in rats, IGFBP-3 in milk is 
serum derived (Marcotty et al. 1994).
IGF-2 is usually the major milk IGF in species where it is the major serum 
IGF such as ruminants and man. Bovine colostrum has high IGF-1 levels although 
serum IGF-1 is low (Vega et al. 1991). Both IGF-1 and IGF-2 are transported into 
milk in goats, however IGF-1 is specifically transported and IGF-2 is non- 
specifically transported (Prosser et al. 1991b; Prosser & Fleet 1992). Bovine 
colostrum contains IGFBP-3 and -2, and IGFBPs at 30 kDa and 25 kDa (Skaar et 
al. 1991). Bovine serum IGFBP-2 is high in early lactation and lower in the dry 
period (Vicini et al. 1991) and may be the source of the IGFBP-2 in bovine milk. 
GH treatment of lactating cows decreased serum IGFBP-2 concentrations whilst 
increasing milk yield but whether IGFBP-2 is involved in galactopoiesis is unknown 
(Vicini et al. 1991). Similarly, GH administration lowered hepatic IGFBP-2 mRNA 
and plasma IGFBP-2 in lactating ewes (Klempt et al. 1993). Hepatic IGFBP-2 
mRNA expression was much higher than that of mammary gland suggesting that in 
sheep, milk IGFBP-2 is serum derived.
IGF-1 is the predominant IGF in human colostrum but concentrations 
decreased in the first 2 days of lactation whereas IGF-2 concentrations increased at 
day 6 (Eriksson et al. 1993). During this period IGF-1 and -2 in serum decreased 
although IGF levels were still much higher than those of milk. Whereas several 
IGFBPs are detectable in bovine or rat milk, IGFBP-2 is the major IGFBP in human
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milk. However on day 1 postpartum IGFBP-3 was detectable in colostrum although 
maternal serum IGFBP-3 was poorly detectable. IGFBP-2 concentrations were 10- 
fold higher in milk than maternal serum suggesting that milk IGFBP-2 is made in the 
mammary gland (Eriksson et al. 1993). GH administration to lactating women 
increased IGF-1 in both serum and milk but IGF-2 or IGFBP-1 levels were 
unaffected (Breier et al. 1993). Similar to its effect in ruminants GH treatment 
reduced IGFBP-2 in serum of lactating women, although milk levels were 
unaffected. Although GH did not alter milk IGFBP-3 levels, plasma levels (100 fold 
higher than milk levels) showed a delayed rise compared with IGF-1 and correlated 
with milk yield (Breier et al. 1993). Thus GH may cause a coordinated rise in 
plasma IGFBP-3 and mammary gland IGFBP-2, and decrease in plasma IGFBP-2 to 
facilitate the partitioning of serum IGF-1 to the gland.
1.13.3.2 In vitro
In vitro studies of mammary gland tissue generally utilise tissue from pregnant 
animals induced into lactogenesis in vitro by lactogenic hormones (insulin, PRL and 
cortisol); few studies use fully lactating tissue because milk stasis rapidly leads to 
cell death. Although GH is the major galactopoietic hormone in the ruminant, 
administration of GH in vitro had no galactopoietic effect on cultured lactating 
bovine mammary gland (Gertler et al. 1983). Nor could IGF-1 affect fatty acid 
synthesis and alpha-lactalbumin secretion by cultured lactating bovine mammary 
tissue (Shamay et al. 1988). Similarly des-IGF-1 or IGF-2 were not galactopoietic 
for lactating bovine mammary gland in culture using lactogen responsive fat 
synthesis as a test, nor did they affect the galactopoietic effects of PRL (Peri et al.
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1992). However IGF-1 has been shown to increase [3H]thymidine uptake in bovine 
lactating mammary explants (Baumrucker 1986). Lactating bovine mammary tissue 
explants synthesise IGFs and a variety of IGFBPs (28-46 kDa), but cultured acini 
synthesise IGFBP although they release IGF into the medium (Campbell et al. 1991); 
this is similar to findings with tissue from non-lactating pregnant cows.
1.13.4 Breast cancer
1.13.4.1 In vivo
Human and animal breast cancer cells have receptors for both steroid and peptide 
hormones and tumour growth has been shown to be hormone dependent. Clinical 
studies indicate that patients with tumours expressing high levels of oestogen 
receptors have a better prognosis than those with receptor negative tumours. 
However not all receptor positive tumours respond to endocrine treatment suggesting 
a role for other hormones and growth factors; therefore the interactions of the steroid 
hormones and growth factors is obviously an area of importance.
The IGFs are among the variety of growth factors involved in the growth of 
breast cancer cells. IGF-1 is a potent mitogen for these cells and may also elicit a 
motile response in some breast cancer cell lines (Kohn et al. 1990). The majority of 
studies of the IGF axis in breast cancer tissue have utilised cell lines; primary tissue 
culture or in vivo studies are less well characterised. In clinical studies IGF-2 mRNA 
is commonly expressed in both tumour and stromal tissue (Yee et al. 1988), but 
IGF-1 mRNA is only expressed by stromal cells (Yee et al. 1989). Furthermore 
fibroblasts from mammary carcinomas preferentially express IGF-2 mRNA rather
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than IGF-1 whereas fibroblasts from benign tumours preferentially express IGF-1, 
suggesting IGF-2 was assoociated with neoplasia (Cullen et al. 1991).
Type -1 and -2 IGF receptor mRNA is ubiquitous in tumour homogenates 
(Cullen et al. 1990), although type 1 IGF receptors were localised to the neoplastic 
tissue rather than the stroma (Pollack & Tremblay 1989). These studies suggest the 
IGF-1 and IGF-2 from the stroma, and IGF-2 from the tumour cells themselves may 
act by an autocrine or paracrine mechanism, and since human breast tumour tissue 
expresses mRNA for IGFBP-2, -3, -4 and -5 (none expressed IGFBP-1), local 
IGFBP production may modulate IGF action (Yee et al. 1991).
IGF and IGFBP expression has been studied in animal models of hormone 
responsive mammary tumours. In the well characterised nitrosomethylurea-induced 
rat mammary tumour, IGFs have been identified as having a major role in mediating 
hormonally stimulated growth in vitro. Tumour tissue in vivo synthesised mRNA for 
IGF-2 and IGFBP-2, -3 and -4, whereas normal lactating rat mammary tissue 
synthesised IGF-2 and IGFBP-2; neither tissue expressed IGFBP-1 (Manni et al. 
1992). In agreement with the findings in human breast cancer cells, IGF-1 mRNA 
was not detected in either tumour or normal tissue in this rat model. In situ 
hybridisation studies localised mRNA for IGF-2, IGFBP-5 and -6 to the stromal cells 
but IGFBP-2 mRNA was expressed by epithelial cells (Manni et al. 1994). 
Ovariectomy caused regression of the tumour and was associated with a marked 
increase in IGFBP-6 and a smaller increase in IGFBP-2, and these changes were 
reversible with hormone repletion.
Similar compartmentalised IGFBP expression was demonstrated in the rat 
insulin-responsive R3230AC adenocarcinoma model. Type 1 and 2 IGF receptors are
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expressed by these cells although neither IGF-1 or -2 was mitogenic in vitro, 
however IGF-1 enhanced cell adherance to plastic suggesting a role for IGF-1 in 
tumour growth. Tumours from normoglycaemic animals expressed IGFBP-2, -5 and 
lesser amounts of IGFBP-3, -4 and -6. In situ hybridisation analysis identified 
IGFBP-3 mRNA mainly on vascular endothelial cells, IGFBP-4 mRNA mainly on 
tumour stromal cells, and IGFBP-5 mainly on epithelial cells. This pattern of 
expression contrasts with that of the nitrosomomethyl-induced tumour described 
above in which IGFBP-5 mRNA was localised to the stromal cells. R3230AC 
tumours from diabetic rats showed increased IGFBP-2 mRNA which could be 
normalised by insulin treatment, although the other IGFBPs were unaffected. Insulin 
treatment however increased tumour IGFBP-4 and -5 mRNA to higher levels than 
those of normoglycaemic or diabetic animal. IGFBP-5 expression was decreased in 
long-term cultured cells but insulin addition to cultures or implantation in vivo could 
increase its expression suggesting a role for insulin as a modulator of IGFBP-5 
expression in this mammary tumour (Korc-Grodzicki et al. 1993). These data show 
the differential regulation of IGFBPs by hormones and stresses the importance of 
stromal-epithelial interactions in controlling IGF action on tumour cells.
1.13.4.2 In vitro
A range of human breast cancer cell lines (HBCC) are widely used as model systems 
in breast cancer research and many studies have investigated the role of IGFs. In 
general the findings of these studies have agreed with those in human tissues. IGF-2 
mRNA is expressed by some HBCC although using an RNAse protection assay 
recent studies found that none expressed IGF-1 mRNA (Yee et al. 1989).
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Type 1 and 2 IGF receptors are expressed on both ER-positive and ER- 
negative lines (De Leon et al. 1988) and the potent mitogenic effect of IGF-1 on 
HBCC probably acts through the type 1 receptor as this effect of can be blocked by 
anti receptor antibody (Arteaga & Osborne 1989). Anti-IGF-1 antibody treatment in 
vivo inhibited MDA231 cell growth in athymic mice, though MCF-7 cell growth was 
not inhibited (Arteaga 1992). Interestingly the type 1 IGF receptors in several breast 
cancer cell lines abundantly express the 105 kDa /3-subunit found on foetal cells but 
not the 95 kDa /3-subunit found on adult cells (Alexandrides et al. 1993).
Several recent studies have investigated the production of IGFBPs by HBCC, 
and in general IGFBP production has correlated with oestrogen receptor (ER) status. 
ER positive lines express IGFBP-2, -4 and -5. ER negative lines express IGFBP-3 
and -4, with IGFBP-1 as a minor component, and at least one line expresses IGFBP- 
5. Expression of IGFBP-6, although less well studied, has been demonstrated in 
three ER negative lines and also on the ER positive line MCF-7 (Figueroa & Yee 
1992; Clemmons et al. 1990c; Sheikh et al. 1992). IGFBP expression is modulated 
by IGF-1 treatment of both ER-positive and ER-negative cells. IGF-1 increased 
IGFBP-2 levels and stimulated cell proliferation in MCF-7 cells (Adamo et al. 
1992), but in MDA-MB231 cells (ER negative) IGF-1 decreased IGFBP-1 and-2 
levels, and increased IGFBP-3 (Camacho-Hubner et al. 1991).
Oestrogens modulate IGFs and IGFBPs although its effects depend on ER 
status. Oestrogen stimulates IGF-2 mRNA expression in ER-positive T47D cells 
(Yee et al. 1988) but not in ER-negative MDA-MB-231 cells (Brunner et al. 1989). 
Anti-oestrogens are believed to antagonise oestrogen effects and to modulate the 
actions of growth factors such as IGF-1 (Winston et al. 1994). Oestradiol is
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synergistic with IGF-1 in stimulating growth of MCF-7 cells and combined treatment 
increases IGFBP-4 and -5 expression (Sheikh et al. 1992), whereas anti-oestrogen 
treatment reduced IGFBP-4 and -5 in ER-positive T47D cells (Coutts et al. 1993). 
Anti-oestrogen treatment reduced type 1 IGF receptors in both ER-positive lines 
(MCF-7, T47D), but not ER-negative BT20 cells (Freiss et al. 1990), suggesting that 
although anti-oestrogens reduce circulating IGF-1 levels this would mainly affect ER- 
positive cells.
The retinoids have a wide range of effects which include antagonising the 
oestrogen stimulation of breast cancer cells. Retinoic acid inhibits IGF-1 stimulation 
of MCF-7 cell proliferation and greatly increased the levels of IGFBP-3 in 
conditioned medium. Treatment with retinoic acid alone increased IGFBP-3 mRNA 
and this was not further increased by combination treatment with IGF-1 suggesting 
that retinoic acid increases IGFBP-3 transcription whilst the effects of combination 
treatment on IGFBP-3 are postranscriptional (Fontana et al. 1991; Adamo et al. 
1992).
Several studies have investigated the effects of IGFBPs on cell growth. Chen 
et al. (1994) showed that recombinant IGFBP-3 and -2, but not -4 and -5, enhanced 
IGF-1 stimulation of MCF-7 cells. In contrast IGFBP-3 treatment had an inhibitory 
effect on Hs578T cell growth, and the specific binding of IGFBP-3 to cell surface 
proteins suggest the presence of IGFBP-3 receptors which mediate this inhibitory 
effect on monolayer growth (Oh et al. 1993a; Oh et al. 1993b). IGFs can regulate 
IGFBP-3 in conditioned medium of this cell line (Hs578T) by non-receptor mediated 
dissociation of cell surface binding and protection from proteolytic activity (Oh et 
al. 1993c). IGFBP-3 proteolytic activity has been detected in the sera of women with
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breast cancer (Frost et al. 1993) and this may result in IGFBP-3-mediated 
enhancement of IGF-1 action.
The mitogenic potency of the IGFs make them a potential target for clinical 
intervention. Cancer cells which are IGF-responsive may respond to endocrine or 
paracrine IGF expression, and the modulation of IGFBPs descibed above in in vitro 
systems may contribute to the modulation of IGFs effects. However these studies in 
vitro are an over-simplication of the in vivo situation which is undoubtedly more 
complex, therefore a greater understanding of the IGF axis in breast cancer is 
required before therapeutic agents can be designed.
1.14 Aims of study
The IGFs are of importance to several areas of animal production such as the 
mediation of the growth-promoting effects of GH. GH exerts effects on a variety of 
tissues including bone, mammary gland and adipose tissue; GH effects on adipose 
tissue are direct but its effects on other tissues are thought to be mediated by IGF 
production.
The galactopoietic effects of GH in dairy cows is well established but the 
mechanisms involved remain uncertain. It has been suggested that GH may exert its 
effects through the the IGFs and indeed IGFs are potent mitogens for mammary 
cells. The mammary gland is responsive to IGFs but their importance may vary with 
the stage in the mammary gland cycle. There is strong evidence of IGF-1 
involvement in mammary gland development during pregnancy; type 1 and type 2 
IGF receptors are high, and IGF-1 is mitogenic in vitro.
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In contrast, although mammary epithelial cells lack functional GH receptors 
but possess type 1 and 2 IGF receptors, no clear galactopoietic effect of IGF-1 can 
be shown in vitro or in vivo. However the increase in milk and mammary gland IGF- 
1 in goats is correlated with increased milk yield thus supporting a role for IGF-1. 
IGFBPs have a major role in modulating IGF action, therefore it is plausible that the 
absence of appropriate IGFBPs (in vivo and in vitro) accounts for the failure of IGF- 
1 to mimic GH action. Mammary tissue synthesises IGFBPs and hormonal control 
has been demonstrated in in vitro studies. However the in vitro culture of mammary 
tissue is difficult (particularly from lactating glands) and many studies have used 
transformed cells. Therefore there is limited information on the IGFBPs produced 
in the mammary gland, their regulation, and their role in mammary gland biology.
The role of GH during lactation has previously been investigated using 
hormonally manipulated rats given an antiserum to GH to ablate GH, and 
bromocriptine to ablate prolactin (PRL) (Madon et al. 1986). Although PRL is the 
major galactopoietic hormone in rats, GH is important, especially when PRL is low 
and furthermore the importance of GH increases as lactation progresses. The use of 
a rodent model was necessary to enable in vivo hormone replacement studies which 
would be impossible in larger animals. This model has subsequently been used to 
investigate if the galactopoietic effect of GH are mediated by IGFs, and to study the 
hormonal control of IGFBPs during lactation; work contained in this thesis forms 
part of these studies (Flint et al. 1992; Flint et al. 1994). The major aim of this 
thesis was to investigate the IGF axis in the rat during lactation and involution with 
emphasis on the role of the IGFBPs.
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In many species the mother has an increased susceptibility to parasitic and 
fungal infections during the pre- and post-partum period with detrimental effects on 
the welfare of both the dam and the neonates dependent on the milk. A role for GH 
and the IGFs has been implicated in the immune response, however few studies have 
used farm species although altered immunity would be of importance to animal 
welfare and hence production. It is feasible that modulation of the IGFs and their 
binding proteins may be involved in the immunosuppression of pregnancy and 
lactation. Therefore this study aimed to establish a role for IGFs and their binding 
proteins in the immune system of sheep which would then provide a basis for 
investigating the IGF axis in the immune system during pregnancy and lactation.
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials
2.1.1 General laboratory chemicals and reagents
General reagents were obtained from BDH (Thomliebank, Glasgow, UK) or Fisons 
(Loughborough, UK), and most other chemicals were from Sigma (Poole, Dorset, 
UK) unless stated otherwise. Molecular biology reagents were from Promega 
(Southhampton, UK) or Boehringer (Lewes, UK). Tissue culture media and 
supplements were from Gibco (Paisley, UK) or ICN Biomedicals (High Wycombe 
UK). Plasticware was from Greiner Labortechnik Ltd (Glos, UK) Water was double 
distilled tap water.
2.1.2 Animals
Wistars rats were allowed free access to food (Labsure irradiated CRM diet, 
Labsure, Poole, Dorset, UK) and water. Sheep were Finn-Dorset cross given free 
access to hay plus 400g/day cereal mix for at least four weeks prior to slaughter. 
Dutch breed rabbits were housed in groups and allowed free access to food 
(RG1 diet, BS & S, Edinburgh, UK) and water.
2.1.3 Radionuclides
Iodinations were carried out using the iodogen method (Fraker et al. 1986). IGF-1 
or IGFBP-3 (2.5 jxg) was added to 0.5 mCi 125I in an 20 ^1 volume to an Iodogen 
(Pierce) coated tube (1 mg/30 fx\ chloroform) for 20 min before adding 100 (A KI 
(200 mg/ml) and 100 /ri of phosphate buffer containing 0.5% BSA. The mixture was 
then removed and passed down a Sephadex G10 column to separate labelled protein
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from free iodine. Specific activities were 100-280 /-tCi/jtg for IGFs, and about 100 
/*Ci//xg for IGFBP-3. Gamma counting used a Cobra auto-gamma counter (Canberra 
Packard, Pangboume, UK)
2.1.4 Cell lines
Clone 9 hepatocyte cell line derived from normal rat liver (ATCC code CRL 1439) 
was obtained frozen from the European Collection of Animal Cell Cultures 
(ECACC, PHLS, Porton Down, UK).
2.1.5 IGF and IGFBP peptides
Recombinant human IGF-1 was purchased from Bachem (UK), Saffron Walden, 
Essex, UK and Peninsula Laboratories Europe, St Helens, Merseyside, UK. 
Recombinant human IGF-2 was a gift from Monsanto Europe, Brussels, Belgium. 
Recombinant human IGFBP-3 (Escherichia coli expressed) was a gift from Celltrix 
Pharmaceuticals, Santa Clara, CA, USA. IGF-1 analogues, Long IGF-1, R3IGF-1, 
and Long R3-IGF-1, were a gift from Dr J Ballard, Cooperative Centre for Tissue 
Growth and Repair, Adelaide, Australia.
2.1.6 Anti-IGF-1 and IGFBP antisera
Polyclonal rabbit antisera raised against purified bovine IGFBP-2 was purchased 
from TCS Biologicals (Bucks, UK). Antisera to a synthetic peptide sequence of rat 
IGFBP-2 was a gift from Dr N. Ling (The Whittier Institute, Dept of Molecular 
Endocrinology, La Jolla, CA). Polyclonal guinea-pig antisera raised against human 
IGFBP-5 was a gift from Dr D.R. Clemmons, Dept Medicine, University of North
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Carolina, North Carolina). Polyclonal rabbit anti-rhIGF-1 was a gift from NIDDK 
(Bethesda Maryland, USA).
2.1.7 IGF-1 and IGFBP nucleic acid probes
IGF-1 mRNA was detected using either a 32P-labelled DNA probe derived from a rat 
cDNA cloned into pBluescript (Davenport et al. 1990) or a 32P-labelled RNA probe 
generated from this using T7 RNA polymerase (Zinn et al. 1983). Dr S. Shimasaki 
(The Whittier Institute, Dept of Molecular Endocrinology, La Jolla, CA) kindly 
provided constructs of IGFBP fragments subcloned into pBluescript: IGFBP-1, 407 
bp; IGFBP-2, 397 bp; IGFBP-3, 699 bp; IGFBP-4, 444 bp; IGFBP-5, 300 bp; 
IGFBP-6, 245 bp. Sense and antisense IGFBP riboprobes were generated from these 
using T7 or T3 polymerase depending on the orientation of the clone.
2.2 Methods
2.2.1 Cell line culture
Conditioned medium containing IGFBP-2 was prepared from Clone 9 cells. Cells at 
passage 21 or 22, were grown in Hams-F12 supplemented with 10% foetal calf 
serum (FCS), 100 U/ml penicillin, 100 /zg/ml streptomycin at 37 °C in 5 % C 02/95 % 
air. When cells were confluent conditioned medium was prepared by washing the 
monolayer in Hanks balanced salt solution (HBBS), and incubating in basal Hams 
F-12 supplemented with antibiotics (in some cultures with 0.5% BSA) for 48 h. 
Medium was then harvested and centrifuged at 13,000 x g for 10 min, then frozen 
in liquid nitrogen and stored at -20 °C.
2.2.2 DNA measurement
DNA was measured using the method of Labarca & Paigen (1980). Tissue was 
homogenised on ice in 4 volumes of extraction buffer (2 M NaCl, 50 mM NaH2P04, 
pH 7.4) using an ultraturax homogeniser. The homogenate was then diluted 1/100 
in buffer, and a 500 /xl sample of this was mixed with Bisbenzamidine (Fluka 
H33258) at a final concentration of 1 /xg/ml for 1 h before reading in a fluorimeter 
set at 355 nm exitation, 445 nm emission.
2.2.3 Protein assay
Protein estimates were made using Biorad Protein Assay reagent, a commassie 
brilliant blue G-250 dye-binding assay. Samples were incubated for 10 min in a 50 
/xl volume with 240 /xl Biorad reagent diluted 1:4 in distilled water, and absorbances 
at 600 nm were read in a Titertek Twinreader (Flow labs). Protein content was 
determined using a standard curve of 1-5 /xg BSA or casein for milk samples.
2.2.4 IGF-1 Radioimmunoassay (RIA)
IGF-1 concentrations were determined by a non-equilibrium RIA using a modified 
double antibody technique. IGFBPs were extracted by adding 200 /xl of extraction 
medium consisting of 2 N HC1:95% ethanol (1:7 v/v), to 50 /xl of sample, mixing 
and incubating at room temperature for 30 min. After centrifuging at 1700g for 5 
min, 100 /xl of neutralisation buffer (330 mM Tris) was added. When serum samples 
were used 20 /xl neutralised sample was diluted 10-fold in dilution buffer (4 ml 
extraction buffer:5 ml neutralisation buffer in 100 ml RIA buffer). RIA buffer 
consisted of 60 mM NaPo4 pH 7.4, 0.9% w/v NaCl, 0.5% w/v BSA, 0.1% w/v
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NaN3 or 0.1% w/v thiomersal. Diluted sample (100 /xl) was mixed with 100 /xl of a 
1/2000 dilution of polyclonal rabbit anti-rhIGF-1 and pre-incubated for 24 h at room 
temperature before adding 100 /xl [125I]IGF-1 (20,000 cpm/tube in RIA buffer) for a 
further 24 h. Complexed IGF-1-antibody was precipitated by adding 300 /xl of donkey 
anti-rabbit IgG precipitating serum (Scottish Antibody Production Unit, Carluke, 
Strathclyde, UK) diluted in RIA buffer: 16% polyethylene glycol:antibody (15:15:1), 
containing 10 mM EDTA. After incubating at room temperature for 4 h, tubes were 
centrifuged at 1700 x g for 30 min, the supernatant was decanted and the radioactivity 
in the pellets counted. The assay was validated for use in rat serum by demonstrating 
parallelism of displacement by sample and standard after acid-ethanol extraction.
2.2.5 Solution phase assay for IGFBP activity
IGFBP activity was measured as previously described by Conover et al. (1989). 
Samples in a 200 /xl volume were mixed with 100 /xl of [125I]IGF-1 (20-30,000 cpm) 
in 50 mM Tris HC1 pH 7.4 containing 0.5% BSA and incubated overnight at 4°C. 
Bound and unbound radiolabel were separated by adding 300 /xl 1 % activated charcoal 
containing 0.2 mg/ml protamine sulphate, incubating at 4°C for 10 min, then 
centrifuging at 1700 x g for 10 min at 4°C. The supernatants were then decanted and 
the pellets counted. Non-specific binding was defined as the amount bound to buffer 
or unconditioned medium, and this was subtracted from the total bound radioactivity 
to the samples to determine specific binding activity.
2.2.6 IGFBP-3 proteolytic activity
Proteolysis was assayed as previously described by Lamson et a l (1991). Samples 
were incubated with 30,000 cpm [125I]IGFBP-3 at 37 0 C for 5 h in a water bath,
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then electrophoresed on a 12.5 % SDS-PAGE, the gel was then dried and exposed 
to film for 6-18 h.
2.2.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was carried out according to the method of Laemmli (1970). Samples 
were prepared by boiling for 3 min in sample buffer composed of 62.5 mM Tris-HCl 
(pH 6.8), 0.1% SDS, 10% glycerol, and 0.05% bromophenyl blue. Where reducing 
conditions were required 5 % 2-mercaptoethanol was included in the sample buffer.
Separating gels consisted of 10% or 12.5% total acrylamide (2.7% Bis- 
acrylamide crosslinker), 375 mM Tris-HCl (pH 8.8), 0.1 % SDS (w/v). Stacking gels 
consisted of 4% acrylamide, 125 mM Tris-HCl (6.8), 0.1% SDS. Polymerisation 
was initiated by adding ammonium persulphate (Biorad) and TEMED. Samples were 
electrophoresed at 100-150 V on a Biorad mini protean II, using running buffer 
consisting of 25 mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1% SDS.
2.2.8 Western blotting
Western blotting was carried out as in Towbin et al. (1979). Following 
electrophoresis gels were equilibrated for 15 min in transfer buffer consisting of 25 
mM Tris, 192 mM glycine, 20% methanol at 4 °C. Blotting medium was 
nitrocellulose, either 0.2 /xm pore size (Biorad transblot transfer membrane) or 0.45 
^m (Biotrace, Gelman). The nitrocellulose filter was pre-wetted in transfer buffer, 
the gel sandwich assembled and transfer was carried out using a Biorad mini 
transblot cell at 100 V for 1 h. After transfer the molecular weight markers (Sigma 
SDS-7) were visualised by staining with 0.02% Ponceau S (0.3% TCA/0.3%
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sulphosalicylic acid), and their position recorded in pencil before eluting the Ponceau 
S by incubating in Tris buffered saline (TBS). Blots were then air dried and stored 
at 4 °C until used. The efficiency of transfer was assessed by staining the gels in 
Coomassie Brilliant Blue R in 40% methanol, 10% acetic acid, and destained in 40% 
methanol, 10% acetic acid.
2.2.9 Western ligand blotting
Western ligand blotting was carried out essentially as in Hossenlopp et a l  (1986). 
After SDS-PAGE and Western blotting, blots were wetted in 50 mM Tris-HCl (pH 
7.4), 150 mM NaCl (TBS), blocked in 3% Nonidet P-40 in TBS for 30 min, 1% 
BSA in TBS for 2 h, then 0.1% Tween 20 in TBS for 10 min, all at 4 °C. Blots 
were then incubated overnight at 4 °C in a sealed plastic bag with [125I]IGF-1 (2 x 
106 cpm/ml in TBS with 1% BSA, 0.1% Tween 20. After incubation the blot was 
washed twice in TBS/0.1% Tween and three times in TBS (15 min each wash) then 
air dried and exposed to film at -80 °C or a Phospholmager screen at room 
temperature.
2.2.10 Western immunoblotting
Western blots for IGFBP-2 detection were blocked for 30 min in 2% dried milk 
powder (Marvel) in TBS pH 7.4, then incubated with 1/1000 dilution anti-IGFBP-2 
serum in TBS/0.2 % Marvel at room temperature for 1-2 h. The blots were then 
washed for 10 min using 4 changes of TBS and incubated at room temperature for 
45 min with affinity purified alkaline phosphatase conjugated anti-rabbit IgG 
antiserum diluted in TBS/0.2 % Marvel. The blot was washed as above and rinsed
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in alkaline phosphatase substrate buffer consisting of 100 mM Tris/HCl pH 9.5, 5 
mM MgCl2, 5 mM ZnCl2. Substrate consisting of 0.4 mM nitro blue 
tetrazolium/0.38 mM BCIP (5 bromo-4-chloro-3-indolyl phosphate) in substrate 
buffer was added and incubated at room temperature for 20 min or until colour 
developed.
Western blots for IGFBP-5 detection were blocked in 3% Nonidet P-40 in 
TBS for 30 min, 1 % BSA in TBS for 2 h, 0.1 % Tween 20 in TBS for 10 min, all 
at 4 °C. Blots were then incubated overnight at 4 °C in a sealed plastic bag with 
1/1000 dilution of anti-IGFBP-5 serum in TBS with 1 % BSA, 0.1 % Tween 20. The 
blots were then washed for 10 min using 4 changes of TBS/0.1% Tween and 
incubated at room temperature for 45 min with affinity purified peroxidase 
conjugated anti-guinea-pig IgG antiserum diluted in TBS/1% BSA/0.1% Tween 20. 
The blot was washed as above and incubated for 1 min with Enhanced 
Chemiluminesence (Amersham) reagent, then exposed to Reflection film (Du Pont) 
at room temperature.
2.2.11 RNA isolation
RNA was isolated from tissues using guanidinium isothiocyanate homogenisation and 
caesium chloride centrifugation (Chirwin et al. 1979). Tissues were collected and 
immediately frozen in liquid nitrogen. Tissue was ground to a fine powder in liquid 
nitrogen and added to an appropriate amount of denaturing solution (1 M 
guanidinium isothiocyanate, 50 mM Tris-HCl, 10 mM EDTA, 2% sodium lauryl 
sarkosine, 0.1% 2-mercaptoethanol) while frozen, the mixture was then passed 
through an 19g and then a 23g needle to disperse the tissue and shear the DNA.
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Solid caesium chloride was dissolved in the homogenate (to a final 40% w/v) which 
was then overlaid on a cushion of 5.7 M caesium chloride/100 mM EDTA pH 7.5 
and centrifuged at 35,000 rpm (150,000 x g) for 18 h. The RNA pellet was 
resuspended in water and an equal volume of chloroform/butanol (4:1) added, then 
mixed and centrifuged at 4000 x rpm for 5 min at 4° C. This extraction was 
repeated, the aqueous layers were collected and added to 0.1 volume of 3 M sodium 
acetate pH 5.3 and 2.5 volumes of absolute alcohol and precipitated at -20 °C 
overnight. RNA was recovered by centrifugation at 12,000 x g for 20 min at 4 °C, 
freeze dried and resuspended in water. RNA concentrations were determined by 
measuring absorbance at 260 nm.
2.2.12 Northern blotting
RNA (usually 20-40 f i g )  was resolved on a 1.2% agarose gel (20 mM MOPS pH 
7.0, 5 mM sodium acetate, 1 mM EDTA, 2.2 M formaldehyde, 0.5 f i g / ml ethidium 
bromide), for 1-2 h. Samples were heated at 65 °C for 5 min in a 10 fil volume with 
denaturing buffer (6.6 M formaldehyde, 50% formamide, 20 mM MOPS pH 7.0, 
5 mM NaCl, 1 mM EDTA), then cooled and loading buffer added (final 0.08% 
bromophenol blue, 5% Ficoll 400). The gel was run in 20 mM MOPS pH 7.0, 5 
mM sodium acetate, 1 mM EDTA at 70 V for 1-2 h. Gels were photographed and 
rinsed in 10 x standard saline citrate (SSC) for 20 min (1 times SCC is 150 mM 
NaCl, 15 mM sodium citrate, pH 7.0) before diffusion blotting overnight onto 
Hybond N nylon filters (Amersham). RNA was bound to the filter using a 
Spectrolinker XL-1000 UV crosslinker (Spectronics Corporation, New York, USA).
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2.2.13 Probe preparation for Northern analysis
A labelled IGF-1 cDNA probe was prepared by incubating 25 ng denatured insert 
DNA with 1 U of Klenow fragment E. coli DNA polymerase (BRL 8012), 25 /xCi 
32P dCPT, 2.7 OD units/ml random oligonucleotide primers, 10 /xM 
dATP/dTTP/dGTP, 200 /xg/ml BSA, 0.04% 2-mercaptoethanol, 25 mM Tris HC1 
pH 8.0, 2.5 mM MgCl2, 100 mM HEPES pH 6.0 in a final volume of 50 /xl at room 
temperature for 2.5 h. The reaction mixture was then diluted to 100 /xl with 50 mM 
NaCl, 1 mM EDTA pH 7.5 and the labelled probe was separated from incorporated 
label using a Sephadex G-50 column.
Labelled IGF-1 and IGFBP riboprobes were prepared by incubating 1 ng 
linearised plasmid DNA template with 10 U RNA polymerase, 20 /xCi 32P CTP, 12 
/xM CTP, 0.5 mM GTP/ATP/UTP, 20 U ribonuclease inhibitor, 10 mM 
dithiothreitol (DTT), 2 mM spermidine, 20 /xg/ml BSA, 10 mM NaCl, 6 mM MgCl2 
and 40 mM Tris HC1 pH 7.5 in a final reaction volume of 10 /xl for 90 min at 37 
°C. The reaction was stopped by adding 90 /xl 50 mM NaCl, 1 mM EDTA pH 7.5 
and the labelled probe was separated from incorporated label using a Sephadex G-50 
column.
2.2.14 Hybridisation to Northern blots
Northern blots were prehybridised for 4 h at 55 °C in a solution containing 50% 
formamide, 900 mM NaCl, NaP04 50 mM pH 7.0, 5 mM EDTA, 2 mg/ml Ficoll 
400, 2 mg/ml BSA, 2 mg/ml polyvinylpyrrolidone, 0.1 % SDS, 200 /xg/ml denatured 
salmon sperm DNA and in addition, 0.1 mg/ml tRNA was used with RNA probes. 
Blots were hybridised overnight with 1 x 106 cpm/ml 32P-labelled probe in the above
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solution at 42 °C for the DNA probe and 55 °C for riboprobes. The DNA probe was 
heat denatured before hybridisation.
After hybridisation blots were washed three times in 2 x SSC for 15 min at 
room temperature, incubated in 2 x SSC containing 1 /xg/ml RNAse A for 30 min 
at room temperature before a final wash at 55-65 °C in 0.2 x SSC/0.1 % (w/v) SDS 
for 30 min. Blots were then exposed to film at -80 °C.
2.2.15 Autoradiography and densitometry
Western ligand blots and Northern blots were wrapped in Saranwrap and exposed to 
Hyperfilm MP (Amersham) film at -80 °C using enhancing screens. Film was then 
developed for 3 min in developer and fixed for 3 min (Kodak). Autoradiographs 
were analysed by densitometry using either a Biorad 620 Video Densitometer and 
1-D Analysis software (Herts, UK) or a Molecular Dynamics Personal Densitometer 
SI with Image-Quant software (Molecular Dynamics Ltd, Kensing, UK). The area 
under the peaks was measured, and expressed as arbitrary OD units normalised for 
control samples run on each gel.
Some Western ligand blots were exposed to a Molecular Dynamics 
Phospholmager screen at room temperature and the image detected by a 
Phospholmager 445SI and analysed by Image-Quant software. Quantification by 
densitometry or the Phospholmager used bands within the linear range; the 
Phospholmager screen has the advantage of a linear range 200 times greater than that 
of X-ray film.
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CHAPTER 3: THE IGF AXIS IN CELLS OF THE SHEEP 
IMMUNE SYSTEM 
3.1 Introduction
A role for GH and IGF-1 in the immune response has been demonstrated in several 
species but few studies have addressed the role of the IGFBPs. Little is known about 
the IGF axis within the sheep immune system therefore the production of IGF-1, 
type-1 IGF receptor, IGFBPs, and IGFBP-3 protease were examined in order to 
establish a role for the IGFs in the sheep immune response.
3.2 Materials and Methods
3.2.1 Isolation of cells
Blood and tissues were obtained from Finn-Dorset cross sheep by venepuncture or 
at slaughter. Thymus, peripheral lymph node and mesenteric lymph node 
mononuclear cells (MNCs) were prepared by density gradient centrifugation (Boyum 
1968), using Lymphopaque (1.086 g/L, Nycomed UK, Birmingham, UK). Minced 
tissue was pushed through a wire mesh into RPMI, the cell suspension was pelleted, 
washed in RPMI at 300 x g for 10 min, before resuspending in RPMI, layering on 
a lymphopaque gradient and centrifuging for 30 min at 800 x g. The interface layer 
of cells was diluted 1/10 in RPMI, pelleted at 400 x g for 10 min, and then washed 
repeatedly at 200 x g for 10 min to minimise platelet contamination. Centrifugation 
at 200 x g pelleted white cells and left a platelet rich supernatant. Platelets were 
prepared from heparinised blood either from the interface layer of lymphopaque 
density gradients as above or directly from diluted blood (in EDTA containing
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buffer) by centrifuging at 250 x g for 20 min to obtain a platelet rich supernatant, 
which was then centrifuged at 900 x g for 10 min to pellet platelets. For some 
platelet preparations Hepes buffer (100 mM Hepes, 120 mM NaCl, 5 mM KC1, 1.2 
mM MgS04, 10 mM dextrose, 15 mM acetate, 2 mM EDTA pH 7.4) was used 
instead of RPMI.
Platelet-depleted defibrinated blood was centrifuged at 1600 x g for 20 min, 
and the buffy coat diluted 1/2 in RPMI before loading on a lymphopaque gradient. 
Peripheral blood MNC were obtained from the interface, washed and the red cells 
lysed by resuspending in prewarmed Tris-NH4C1 (144 mM ammonium chloride, 17 
mM Tris pH 7.2) for 15 sec, diluting in RPMI and washing cells twice at 300 x g 
for 10 min. Granulocytes were then isolated from the lymphopaque gradient by 
removing the ficoll layer, resuspending the pellet in RPMI, centifuging at 600 x g, 
then lysing RBC as above. Wrights stained cytocentrifuge preparations of the cell 
fractions were assessed by differential white blood cell counts.
3.2.2 Cell culture
Cells were cultured in Iscoves medium (Iscove’s modification of Dulbeccos medium 
with bovine albumin, human transferrin and soy bean lecithin, ICN Biomedicals, 
High Wycombe, Bucks. UK) supplemented with 100 U/ml penicillin, 100 jug/ml 
streptomycin, 2 mM glutamine (ICN Biomedicals) at 2 x 106/ml with Con A (Sigma 
C2575), PHA (Sigma L-9132), and IGF-1 where appropriate, at 37 °C in 95% 
air: 5 % C02. For some cultures Iscoves medium consisted of Iscoves modified Eagles 
medium (Northumbria Biologicals, Cramlington, Northumberland) supplemented
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with 400 /xg/ml soyabean lecithin, 400 /xg/ml BSA, 1 /xg/ml bovine transferrin (Sigma 
T5761), 100 u/ml penicillin, 100 /xg/ml streptomycin and 2 mM glutamine.
Conditioned medium was prepared by harvesting medium from 24 well-plate 
cultures after 24, 48 and 72 h, which was then centrifuged at 300 x g for 10 min (to 
pellet cells) then 14,000 x g (to pellet cell debris), snap frozen and stored at -20 °C. 
Cell stimulation was measured in corresponding 96-well cultures by adding 1 /xCi 
[3H]thymidine for the last 4 h of culture, then harvesting on an automatic cell 
harvester onto filter paper discs. Discs were tranferred to vials and Emulsifier Safe 
scintillation fluid added, then counted on a 1600 TR Liquid Scintillation Analyser 
(Canberra Packard). [3H]thymidine uptake assay in 96-well cultures was used to 
determine the appropriate concentration of mitogen to stimulate cells.
3.2.3 Solution phase assay for IGFBP activity
Conditioned media from thymus cell cultures (200 /xl) were assayed as in Chapter 2. 
Unconditioned medium was assayed in parallel and binding to it was subtracted from 
the total bound radioactivity in conditioned medium to determine specific binding 
activity.
3.2.4 IGFBP protease activity
Conditioned media from unstimulated, PHA-stimulated, and Con A-stimulated thymus 
cell cultures were assessed for protease activity as described in Chapter 2. Samples 
(15 /xl) were used and where appropriate incubation was in the presence of the 
protease inhibitors 10 mM EDTA, 2 mM (saturated) phenylmethylsulphonyl fluoride
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(PMSF), 10 mM N-a-p-tosyl-l-lysine chloromethyl ketone (TLCK), 1 mg/ml 
leupeptin (Peptide Institute, Osaka, Japan) or 0.4 mg/ml Aprotinin.
3.2.5 Western ligand blotting
WLB was performed as described in Chapter 2. Conditioned medium from 
peripheral lymph node and thymus cultures were used neat on gels (20 pi), or 
lyophilised and the equivalent of 50 pi loaded on a track. IGFBP activity was 
diminished on storage (-20 °C) or after dialysis against TBS, possibly because of 
proteolysis although dialysis was carried out at 4 °C.
3.2.6 Western immunoblotting
Western blotting was performed as decribed in Chapter 2, and the blots were then 
immunostained with antisera to bovine IGFBP-2 (UBI) at a 1/1000 dilution.
3.2.7 [125I]IGF-1 cell binding assay
Most assays were performed in RPMI 1640 containing 1% BSA 25 mM Hepes pH 
7.4. Some assays of platelet binding used Hepes buffer (as above) containing 1% 
BSA and 1 mM EDTA. 400 pi of cell suspension and 50 pi of [125I]IGF-1 (20- 
30,000 cpm) with 50 pi of unlabelled peptide where appropriate were incubated 
overnight at 4°C. Cells were then centrifuged at 400 x g for 10 min (1000 x g for 
platelets) twice and the pellets counted. Specific binding was calculated by 
subtracting non specifically bound radioactivity from the total bound. Nonspecific 
binding was determined as radioactivity bound in the presence of excess (1 pg/ml) 
unlabelled IGF-1 (Zhao et al. 1992).
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3.2.8 Northern analysis
IGF-1 mRNA was measured in RNA isolated from lymph node, thymus, spleen, and 
liver as described in Chapter 2.
3.2.9 IGF-1 Radioimmunoassay (RIA)
This was carried out as described in Chapter 2. Conditioned medium (5 /xl) from 
peripheral lymph node cultures were assayed after acid ethanol extraction against a 
standard curve ranging from 0.5-16 ng/ml which was diluted in Iscove’s medium. 
WLB of conditioned medium from these cultures showed no evidence of IGFBPs, 
therefore conditioned medium was subsequently assayed again without extraction, 
allowing a greater volume (100 /xl) to be used in the RIA.
3.3 Results
3.3.1 IGFBP production by cultured thymus cells
Conditioned media from thymus cells cultured with or without PHA or Con A were 
assayed for IGFBPs using a solution phase assay of [125I]IGF-1 binding. IGFBP 
activity increased with time in unstimulated, PHA-stimulated and Con A-stimulated 
cultures. Both PHA- and Con A-stimulation significantly increased the IGFBP 
activity compared with unstimulated cultures (Fig 3.1 A). Cell stimulation by PHA 
and Con A was verified by [3H]thymidine uptake (Fig 3. IB). WLB of conditioned 
medium from stimulated cultures detected a single band of about 24 kDa, binding 
to which could be competed by unlabelled IGF-1 (not shown).
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Fig 3.1 Production of IGFBP and [3H]thymidine incorporation by thymus cell
cultures. (A) Conditioned medium was collected at 24, 48 and 72h 
and IGFBP concentrations assayed by solution phase [125I]IGF-1 
binding. Results are expressed as the mean ±  SEM (n = 6 for 
unstimulated and PHA; n = 5 for Con A). Data was analysed using 
Genstat REML (Residual Maximum Likelihood); *P<0.01 compared 
with unstimulated cells. (B) [3H]thymidine incorporation was 
measured by culturing cells for 24, 48 or 72h and adding 0.5 pCi 
[3H]thymidine for the last 4h before harvest. Results are the mean ±  
SEM (n = 5). Data was analysed using Genstat ANOVA (Analysis 
of variance), *p<0.01 compared with unstimulated cells.
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3.3.2 IGFBP-3 Protease activity
IGFBP-3 protease activity in conditioned media from thymus cells cultured for 72 
h with or without PHA or Con A was assessed using iodinated recombinant hlGFBP- 
3 as a substrate. Conditioned media from PHA-stimulated cultures degraded 
[125I]hIGFBP-3 to lower molecular weight products; degradation could be inhibited 
markedly by PMSF, and to a lesser extent by Aprotinin and TLCK (Fig 3.2). 
Leupeptin and EDTA had little effect. Conditioned medium from unstimulated and 
Con A-stimulated cultures also degraded [125I]hIGFBP-3 to lower molecular weight 
products (not shown). In the presence of unconditioned medium some of the 
radioactivity remained at the top of the gel but this was not seen with any other 
samples, including conditioned medium from unstimulated cells and buffer control.
3.3.3 [125I]IGF-1 binding to cells
Specific binding was demonstrated on cells from the thymus and mesenteric lymph 
node, peripheral blood MNC, erythrocytes and platelets (Table 3.1). Binding to 
platelets was lower than to mesenteric lymph node or thymus cells, and binding to 
erythrocytes was very low. Specific binding was also demonstrated on granulocyte 
enriched preparations from defibrinated blood. Table 3.2 shows the proportion of 
granulocytes and MNC, and relative specific binding. Although granulocyte 
preparations were heavily contaminated with mononuclear cells (61%), specific 
binding was higher in the granulocyte preparations compared with the mononuclear 
cell preparation, which suggested that the granulocyte content was contributing to the 
specific binding.
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Proteolysis of [12T]IGFBP-3 by conditioned medium from thymus 
cells cultured for 72 hours with PHA. Samples (12 /xl) were incubated 
with 30,000 cpm recombinant non-glycosylated [125I]hIGFBP-3 for 5h 
at 37°C. Incubations were conducted in the presence of 10 mM 
TLCK, 10 mM EDTA, 1 mg/ml Leupeptin, 0.4 mg/ml Aprotinin or 
2 mM PMSF (saturated). The control sample is unconditioned 
medium. After incubation samples were separated by SDS-PAGE, the 
gel dried under vacuum and autoradiographed for 18 h.
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Mesenteric lymph node 
Thymus
Peripheral blood MNC 
Platelets 
Erythrocytes
“Data was normalised for the total radioactivity added.
Specific [ I]IGF-1 binding
(fmol per 1010 cells)8 
4.73 ±  0.13 (3)
4.64 ±  0.88 (5)
2.42 ±  0.72 (10)
0.80 ± 0 .11  (9)
0.02 ±  0.02 (8)
Table 3.1 Comparison of [125I]IGF-1 binding to cells from peripheral blood, 
mesenteric lymph node and thymus. Results are mean ±  SEM, the 
number of animals is shown in parentheses.
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Specific [125I]IGF-1 binding percentage cell type
(fmol per 1010 cells)8 mononuclear granulocyte
cell fraction
mononuclear 1.43 ± 0.57 99.8 ±  0.0 0.0 ±  0.0
granulocyte 3.21 ± 0.12 61.9 ±  11.2 38.1 ±  11.6
a Data was normalised for the total radioactivity added.
Table 3.2 Comparison of [125I]IGF-1 binding to cell preparations from 
defibrinated peripheral blood. Results are mean ±  SEM for three 
animals.
99
The relative potencies of IGF-1, IGF-2 and insulin as competitive inhibitors 
of [125I]IGF-1 binding to platelets were determined (Fig 3.3). Binding was inhibited 
50% by 1.8 ng/ml IGF-1, 2.3 ng/ml IGF-2 and 4.4 f i g / ml of insulin. Data from six 
IGF-1 dose response curves were analysed by the LIGAND program using a one site 
model (Fig 3.4) giving a Kd of 266 pM and about 40 binding sites per platelet.
3.3.4 IGF production
IGF-1 was undetectable (less than 0.5 ng/ml) in conditioned medium (24, 48, 72 h) 
from stimulated and unstimulated peripheral lymph node cells when either neat, or 
acid-ethanol extracted samples were analysed. Cell stimulation was verified by 
[3H]thymidine uptake and Fig 3.5 shows their response to dilutions of polyclonal 
activators. In corresponding cultures for conditioned medium production, cells at 2 
x 106/ml were stimulated with 0.5 f i g / ml Con A and 5 f i g / m l  PHA (Fig 3.5A), and 
where 4 x 106/ml cells were used Con A was at 0.2 f i g / ml and PHA at 1.56 f i g / ml 
(see Fig 3.5B).
3.3.5 Effects of IGF-1 on cell stimulation
Con A and PHA stimulated uptake of [3H]thymidine by peripheral blood MNC was 
enhanced by IGF-1 at 10 ng/ml (p< 0.02) (Fig 3.6A). The presence of IGF-1 did not 
affect [3H]thymidine uptake by mesenteric lymph node cells (Fig 3.6B).
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Fig 3.3 Inhibition of [125I]IGF-1 binding to platelets by unlabelled peptides. 
Binding was expressed as a percentage of maximal specific binding 
determined in the absence of any competing unlabelled peptide, which 
was 9.5% of input radioactivity. Nonspecific binding (binding in the 
presence of 1 ^ig/ml unlabelled peptide) representing 11.25% of the 
maximum [125I]IGF-1 bound was subtracted from the data. Results are 
mean values for six experiments.
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Fig 3.4 Scatchard analysis of [125I]IGF-1 binding to platelets. Analysis was 
performed with the LIGAND program, a one site model was fitted to 
the pooled results from six experiments. The calculated number of 
receptor sites per cell was about 40 and the Kd was 266 pM.
102
io
a>
<0
Q .3
■o
E>»
35 - |
ConA
25 -
PHA
15 -
10 -
unstimulated
1001 100.10.01
mitogen (jjg/ml)
B
E
Q .
€>
W
Q .
■o
E
>%
300 n
PHA
200  -
Con A
150 -
100  -
50 -
unstimulated
1001 100.10.01
mitogen (pg/ml)
Fig 3.5 [3H]thymidine incorporation into peripheral lymph node cell cultures.
Cells were cultured at 2 x 106/ml (A) or 4 x 106/ml (B) for 72h, 0.5 
fiCi [3H] thymidine was added for the last 4h before harvest. Results 
are the mean ±  SEM for replicate wells.
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Fig 3.6 [3H]thymidine incorporation into peripheral blood mononuclear cell
(A) or mesenteric lymph node cell cultures (B). Cells were cultured 
at 2 x 106/ml with 2 /*g/ml PHA or 0.5 ng/ml Con A for 72h, 0.5 
/xCi [3H]thymidine was added for the last 4h before harvest. Results 
are the mean ± SEM for replicate wells.
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3.3.6 Northern analysis
The major IGF-1 mRNA species detected in rat liver was at about 0.7-1.2 kb with 
minor bands 1.5 and 7.7 kb, whereas only the 7.7 kb species was detected in sheep 
liver. This probe hybridised to mRNA species of about 7.7 kb in sheep lymph node 
and thymus, and at 0.7-1.2 kb in sheep thymus (data not shown).
3.4 Discussion
Although there is increasing interest in the role of the IGFs in the immune system, 
few studies have investigated the role of the IGFBPs. This study provides evidence 
of IGFBP production by thymus cells. Furthermore PHA- and Con A-stimulation, 
verified by [3H]thymidine uptake, significantly increased the IGFBP activity 
suggesting that IGFBP production is by the lymphoid cells. Presence of an IGFBP 
was confirmed by WLB analysis which showed specific binding to a single band of 
about 24 kDa. This IGFBP could not be detected by an antiserum to bovine IGFBP-2 
(UBI), which crossreacts with sheep, though the low amount of IGFBP could explain 
this; the quantity of conditioned medium which can be run on a gel track is limited 
by the protein content, and Iscoves medium has 400 ^g/ml BSA. Solution phase 
assay or WLB could not detect IGFBP in conditioned medium from peripheral lymph 
node cultures.
Baxter et al. (1991) found that IGF-1 levels in conditioned medium from rat 
spleen cultures were equivalent in untreated and acid-extracted samples, suggesting 
that little or no IGFBP was present. Spleen tissue from adult rats expresses IGFBP- 
2, and -4, and in juvenile rats expresses IGFBP-2, though the particular cell types 
expressing mRNA was not identified (Domene et al. 1994, Yakar et al. 1994).
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Human peripheral blood cells express mRNA for several IGFBPs (Nyman & 
Pekonen 1993). Using PCR methods unstimulated cells were shown to express 
IGFBP-2 and -3, stimulated cells expressed in addition IGFBP-4 and -5, but IGFBP- 
1 mRNA was undetectable in either stimulated or unstimulated cells. However 
IGFBP protein in conditioned medium was difficult to detect by WLB in the 
presence of IGFBPs from the 10% FCS used in the culture medium. Cells cultured 
in the presence of 0.1 % BSA instead of FCS produced only one IGFBP at 34 kDa 
by WLB (Nyman & Pekonen 1993).
Recently IGFBP protein production has been demonstrated from human- 
leukaemic blasts lines (Neely et al. 1991). Both T- and B-lines produced IGFBP-2 
and -4, but none produced IGFBP-1, or -3. IGFBPs of 31 and 33 kDa were detected 
by anti Hec-IA antibody (raised against the products of Hec-IA endometrial 
carcinoma cells, which is known to detect IGFBP-3 and -2), but not by an antibody 
to IGFBP-3; the strong 31 kDa band was probably IGFBP-2, but the identity of the 
weaker 33 kDa band is unclear. Thus IGFBP protein can be detected in medium of 
lymphoid cells but levels are low. The thymus conditioned medium used in the 
present study is from a mixed culture of primary cells, and since only a portion of 
the cells will respond to stimulation, the cells producing IGFBP may be in small 
numbers.
Several IGF-1 mRNA species can be detected in rat liver, the proportions 
of which vary with the animals physiological state (Travers et al. 1993) and this 
cDNA probe detected IGF-1 mRNA expression in ovine thymus and lymph node. 
Expression of IGF-1 mRNA has previously been shown in rat spleen and thymus 
(Murphy et al. 1987). Using the highly sensitive PCR technique, PHA-stimulated 
human peripheral blood lymphocytes expressed both IGF-1 and IGF-2, though 
unstimulated cells expressed neither (Nyman & Pekonen 1993). Arkins et al. (1993)
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also detected IGF-1 cDNA transcripts in a variety of mouse lymphoid tissues and cell 
lines after PCR amplification. However using Northern blotting or ribonuclease 
protection assay, IGF-1 mRNA was negligible in lymphoid cell lines and lymphoid 
tissues. In contrast, abundant transcripts were found in differentiated macrophages 
(but not pre-myeloid cells), suggesting that in haemopoietic cells it is the myeloid 
rather than lymphoid cells which express IGF-1. If this is also the case with sheep 
cells, then Northern blotting would not be expected to detect IGF-1 mRNA in the 
ovine lymphoid cells.
IGF-1 protein could not be detected by RIA in conditioned medium from 
ovine lymph node i.e. less than 0.5 ng/ml, even though cell stimulation was verified 
by [3H]thymidine incorporation into corresponding cultures. Low levels of IGF 
production in lymphoid cells have previously been reported. IGF-1 was detected at 
less than 0.1 ng/ml and IGF-2 at less than 0.3 ng/ml, in conditioned medium from 
human leukaemic blast lines (Neely et al. 1991). Normal human B-lymphocytes 
produced no IGF, and although transformed cells produced no IGF-2, IGF-1 was 
detectable at 3 ng/ml and this was increased to 12 ng/ml when cells were GH 
stimulated (Merrimee et al. 1989). Baxter et al. (1991) detected IGF-1 production 
by rat spleen and thymus cells using immunocytochemistry, though on a per cell 
basis they produced 60 times less than cultured hepatocytes. Therefore since 
lymphocytic cells in other species seem to produce small amounts of IGFs, perhaps 
our methods were not sensitive enough. These small amounts may nevertheless have 
paracrine or autocrine effects in the local microenvironment of lymphoid tissue.
Conditioned medium from unstimulated and stimulated ovine thymus cultures 
contained an IGFBP-3 protease activity which was inhibited by protease inhibitors,
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strongly suggesting the presence of a Ca2+/Mg2+ independent IGFBP-3 serine 
protease. The presence of this protease may be responsible for the low level of 
IGFBP detected by WLB. Some of the radioactivity consistently remains at the top 
of the gel in the presence of unconditioned medium but not other samples, including 
the buffer control and conditioned medium from unstimulated cells. This suggests 
that Iscove’s medium aggregates radiolabel and that this is inhibited in media from 
stimulated cells. IGFBP-3 protease has been detected previously in a variety of tissue 
homogenates and cell conditioned media, it has not been investigated in the ruminant 
immune system. It is possible that this protease activity present in conditioned 
medium may have rendered IGFBP-3 in these cultures undetectable by WLB; 
perhaps proteases active against other IGFBPs are also present.
IGF-1 receptors have been shown previously on a range of myeloid and 
lymphocytic cells. Only one study has been reported in ruminants and this showed 
IGF-1 receptors on bovine peripheral blood mononuclear cells, neutrophils and to 
a lesser extent on erythrocytes (Zhao et al. 1992). Here we show that IGF-1 
receptors are present also on cells from normal ovine lymphoid tissue as we have 
demonstrated specific IGF-1 binding on cells from the thymus and mesenteric lymph 
node as well as peripheral blood MNC, platelets and erythrocytes, though binding 
to erythrocytes was very low. Preparations of granulocytes, while enriched for 
granulocytic cells, contained substantial numbers of MNC (Table 3.2). However 
since there is specific binding in both fractions, this would suggest that granulocytes 
are contributing to the specific binding seen, although this assumes that the MNC 
obtained from the interface layer (MNC fraction) are from the same population as 
the MNC in the granulocyte fraction.
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The platelet, derived from haemopoietic stem cells, possesses many features of the 
classical inflammatory cell, e.g. phagocytosis, cytotoxicity and the release of 
mediators augmenting inflammation. Wound IGF levels are important for healing and 
the IGF-1 and IGFBP-3 stored in human platelet a-granules (Spencer et al. 1993) 
when released on aggregation would contribute to wound levels. Human platelets 
show enhanced aggregation in response to stimulants in the presence of IGF-1. As 
the platelet is anucleate, this demonstrates a metabolic effect of IGF-1 in the absence 
of its mitogenic effect (Motani et al. 1992). Platelets have a lower binding per cell, 
but they are in much greater numbers than MNC in blood and since both cell types 
settle at the interface of a lymphopaque density gradient, MNC were prepared from 
platelet-depleted defibrinated blood. Cell preparations from tissues were repeatedly 
washed at low speed to minimise platelet contamination; preparations were used only 
if platelet contamination was too low to make a measurable contribution to [125I]IGF- 
1 binding. The IGF-1 binding was best characterised on platelets, which were 
therefore used for competitive binding studies. Competition by unlabelled 
polypeptides with potencies of IGF-1 > IGF-2 > > insulin suggests that [125I]IGF-1 
is binding to a type 1 IGF receptor since IGF-1 binding to a type 2 IGF receptor or 
to a cell surface associated IGFBP would not be competed by insulin (Massague & 
Czech 1982; Zapf et al. 1975). Platelet [125I]IGF-1 binding was competed by IGF-2 
at a concentration only slightly higher than IGF-1; this differs from the typical strong 
preference for IGF-1 (Massague & Czech 1982), but heterogeneity of IGF-1 
receptors has been described and the rat thymus and mouse thymoma IGF-1 
receptors bind IGF-1 and IGF-2 with equal affinity (Verland & Gammeltoft 1989). 
Scatchard analysis estimates of the Kd and the number of receptor sites are
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comparable to values obtained from human platelets (Hartmann et al. 1989). The 
high affinity IGF-1 binding shown here (Kd 266 pM) is also consistent with the 
presence of a type 1 IGF receptor since IGF-1 binds with much lower affinity (Kd 
0.4 /uM to the type 2 IGF receptor (Tong et al. 1988).
The IGFs have previously been shown to have effects on a variety of immune 
responses, including the enhancement of cell proliferation in response to polyclonal 
activators. Here a preliminary assay showed enhancement of [3H]thymidine uptake 
by ovine peripheral blood cells by IGF-1, but no significant effect on mesenteric 
lymph node cells. This discrepancy may reflect the differences in cell types from the 
two sources but in the absence of replication of these assays such conclusions cannot 
be drawn. There have been conflicting reports of IGF-1 effects on [3H]thymidine 
uptake into cells of the immune system. In some studies IGF-1 has no effect possibly 
because monocytes or other stromal cells provide sufficient endogenous IGF-1. Here 
the ovine cells cultures contained stromal cells, therefore future assays should utilise 
adherent cell-depleted preparations.
Blocking of the endogenous IGF activity by antibodies to the type 1 IGF 
receptor antibody could be considered, as previously used by Roldan et al. (1989). 
However the antibodies to type 1 IGF receptors available at the time of study, such 
as the widely used anti-IR3, do not crossreact with sheep type 1 IGF receptors. 
Likewise anti-sera to IGF-1 were not available in sufficient quantities to block 
endogenous IGF-1, therefore the effect of IGF-1 on cell proliferation was not 
pursued until a better design was possible. This study provides evidence for the 
involvement of the IGF axis in the sheep immune response, particularly in relation 
to the thymus. These preliminary findings warrant further evaluation of the IGF axis
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in the sheep immune response and in particular its assessment during the 
periparturient period when immunocompetence is compromised.
I l l
CHAPTER 4: PRODUCTION OF ANTIBODIES AGAINST 
SYNTHETIC PEPTIDE SEQUENCES OF IGFBP-2
4.1 Introduction
GH is well established as the major galactopoietic hormone in several species 
although its precise mode of action is still unknown. Systemic GH administration to 
lactating women (Milsom et a l 1992; Breier et al. 1993) and cows (Vicini et al. 
1991) increased milk volume and serum IGF-1 concentrations while decreasing 
serum IGFBP-2 concentrations. A negative relationship between serum GH and 
IGFBP-2 concentrations has been shown in other studies (Zapf et al. 1990), and it 
has been suggested that serum IGFBP-2 may mediate IGF transport and tissue 
distribution (Klempt et al. 1992), therefore it is feasible that GH may enhance 
galactopoiesis by similtaneously increasing IGF-1 and reducing the concentrations 
of inhibitory IGFBPs to enhance IGF effects; thus IGFBP-2 was of particular interest 
in the study of the IGFs during lactation.
Few studies have investigated IGFBP structure-function relationships and 
therefore the major aim was to use synthetic peptide technology to make site directed 
anti-sera which may be used to investigate IGFBP-2 action, for example by 
modulating IGFBP-2 action in cell culture. A further aim was to obtain an antiserum 
suitable for use in radioimmunoassay to allow quantitation of IGFBP-2. Since these 
studies require anti-sera which recognise the native whole IGFBP-2 molecule, anti­
sera must be directed against peptide sequences which are on the surface of the 
molecule. Although the 3-dimensional structure of the IGFBPs is unknown the choice 
of sequences was based on the likelihood of surface exposure; this approach is
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obviously limited to the identification of potential continuous epitopes, as 
identification of conformational epitopes would require knowledge of the 3- 
dimensional structure. In addition anti-IGFBP-2 antiserum could be used to identify 
denatured IGFBP-2 on western blots, although for this purpose the location of the 
epitopes in the whole molecule are not so important.
The peptide sequences were chosen from the deduced amino acid sequence 
of rat IGFBP-2 (Brown et a l 1989). The IGFBP-2 sequence of the rat was used to 
design peptides because a rat model was used to study the IGF axis in lactation, and 
because rat IGFBP-2 derived from Clone 9 hepatocyte cultures would be the likely 
source of IGFBP-2 to purify for use in culture systems. However antisera which 
crossreact with ruminant IGFBP-2 would enable this study to be extended to 
ruminants. Table 4.1 shows the rat peptide sequences chosen and the high amino 
acid sequence homology between the rat sequence and the corresponding bovine and 
ovine sequences, with amino acid differences shown in bold.
Peptides were chosen using the Jameson-Wolf index of antigenicity. Selection 
of suitable peptides depends on predictions of surface exposure, mobility, and 
antigenicity of the amino acid. Surface exposure correlates with hydrophilicity and 
mobility, polar and hydrophilic regions tend to be at the surface and are more 
mobile. IGFBP-2Ac[Tyr154](154-171)NH2 was chosen because it had previously been 
used successfully to raise an antiserum which recognised the whole molecule (Liu 
et al. 1993). This peptide also includes a putative short glycosaminoglycan (GAG) 
binding concensus sequence XXBBXBX (where B is a Lys or Arg group, and X is 
unidentified (underlined in Table 4.1)), which is likely to be of functional 
significance (Hodgkinson et al. 1994). The C-terminal peptide IGFBP-2(239-251)
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rat IGFBP-2 peptide species sequence
(61-75) rat
bovine
ovine
C Y P N P G S E K P L K A L V
C Y P N P G S E K P L H A L V
C Y P N P G S E K P L R A L V
[Cys112](97-112) rat
bovine
ovine
E D D H S  E G G L V E N H V D [ C ]
G E E H S E G G L V E N H V D
G E E H S E G G Q V E N H V D
Ac[Tyr154](154-171)NH2 rat
bovine
ovine
T Y 1 L S L E E P K K L R P P P A R T P  
L S L E E P K K L R P P P A R T P  
L G L E E P K K L R P P P A R T P
(72-185) rat
bovine
ovine
C Q Q E L D Q V L E R I S T  
C Q Q E L D Q V L E R I S T  
C Q Q E L D Q V L E R I S T
(239-251) rat
bovine
ovine
i q g a p t i & S D p e c
I Q G A P T l f c S & P E C
I Q G A P T l l ^ & P E C
Table 4.1 Rat IGFBP-2 peptide sequences synthesised: comparison with 
different species. Amino acid differences between species are shown 
in bold, glycosaminoglycan binding consensus sequence is shown 
double-underlined, and the Arg-Gly-Asp sequence which binds the 
fibronectin receptor is shown in shadow. Sequences were obtained 
from Brown et al. 1989 (rat), Upton et al. 1990 (bovine), and 
Delhanty & Han 1992 (ovine).
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was chosen to include the Arg-Gly-Asp (RGD) sequence which may bind to the 
fibronectin receptor (shadowed in Table 4.1). Most peptides were made with a 
cysteine at the N- or C-terminus to allow conjugation to the carrier protein using 
MBS (m-maleimidobenzoyl-N-hydroxy-succinimide ester).
4.2 Materials and Methods
4.2.1 Peptide synthesis
Peptides were synthesised by solid phase methods using small scale N-(9- 
fluorenylmethoxycarbonyl) (Fmoc) chemistry (Atherton et al. 1979) on an automatic 
431A synthesiser (Applied Biosystems, Warrington, Cheshire, UK). Amino acids 
were obtained as their Fmoc N-terminal protected derivatives containing side chain 
protecting groups as appropriate (ABI or Nova-Biochem). Protecting groups were: 
t-butyl for Asp, Glu, Ser, Thr, Tyr; trityl for Cys, Asn, Gin; Pmc (2,2,5,7,8- 
Pentamethylchroman-6-sulphonyl) for Arg; Boc (tert-butoxycarbonyl) for His, Lys. 
Most peptides were synthesised with a free C-terminus using HMP resin (0.11- 
0.12g), and after attachment of the first amino acid, free sites on the resin were 
blocked with Benzoic anhydride (Aldridge). Peptides with an amidated C-terminal 
end were synthesised using Rink amide AM resin.
TFA was used to cleave the peptide from the resin and to deprotect amino 
acid side chains, and ethanedithiol and thioanisole scavengers are added to minimise 
side reactions and protect certain amino acids. One peptide (IGFBP-2Ac[Tyr154](154- 
171)NH2) was initially cleaved in the presence of silane as a scavenger instead of 
ethanedithiol, but was subsequently subjected to the cleaving/deprotection step used 
ethanedithiol.
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After peptide synthesis the resin was placed in a flask on ice, to this was 
added 10 ml cooled (4 °C) cleavage mix consisting of 10 mis TFA, 0.5 ml distilled 
water, 0.5 ml thioanisole, 0.25 ml ethanedithiol. The flask was then removed from 
ice and allowed to warm room temperature, stoppered, and stirred for 90 min. The 
mixture was then filtered through glass wool (to retain resin) into about 100 ml of 
ice cold ether and allowed to stand for 5 min to precipitate the peptide. The ether 
peptide suspension was then centrifuged at about 700 x g for 5 min, the pellet was 
resuspended and washed 6 times in ether. The peptide was then dried in a vacuum 
dessicator, dissolved in a suitable solvent and freeze dried.
Peptides were analysed by reverse-phase HPLC on a C8 analytical column 
(Brownlee) using a model 151A HPLC system (Applied Biosystems). Peptides were 
dissolved at about 1 mg/ml in 0.1 % TFA and 100 /zl applied to the column. Elution 
was over 20 min in acetonitrile/water gradient consisting of 0.1% TFA in H20  
(buffer A) and 70% acetonitrile in H20  containing 0.035% TFA (buffer B) using 0- 
100% buffer B.
Peptide IGFBP-2[Tyr154](154-171)NH2 was obtained from Dr Nicholas Ling 
to use as a control for the IGFBP-2Ac[Tyr154](154-171)NH2 peptide we have 
synthesised here (identical except for an Ac at the N-terminus).
4.2.2 Amino acid analysis
This was performed on IGFBP-2Ac[Tyr154](154-171)NH2 by M-Scan, Ltd, Berks, 
UK, using a custom designed automatic amino-acid analyser. The sample was acid 
hydrolysed in constant boiling HC1 at 110 °C for 24 h. Separation was on an Aminex
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A8 Ion-exchange column followed by post-column derivatisation with Cadmium 
Ninhydrin.
4.2.3 Fast atom bombardment mass-spectroscopy (FAB-MS)
This was performed by M-Scan Ltd (for IGFBP-2Ac[Tyr154](154-171)NH2) or by Dr 
Su Chen, University of Warwick.
4.2.4 Conjugation methods
4.2.4.1 Conjugation o f peptides to haemocyanin using the heterobifunctional 
reagent MBS
Haemocyanin (Sigma HI757) dissolved in 50 mM KP04 pH 8.0 was added to MBS 
in DMSO in a molar ratio of 1:40, mixed and then stirred at room temperature for 
30 min. Unreacted MBS was then removed by immediately adding to a column pre­
equilibrated with 50 mM KP04 pH 6.7, 1 ml fractions were eluted and the OD280of 
the eluates measured. The MBS-activated haemocyanin was frozen at -20 °C until 
required. Peptides (5 mg) in PBS pH 7.5 were added to 5 mg MBS-activated 
haemocyanin in a carrier:peptide molar ratio of 1:2600, the pH was then adjusted 
to 7-7.5 with KOH, and mixed at room temperature for 3 h. Aliquots were stored 
at -20 °C.
4.2.4.2 Conjugation o f peptides to ovalbumin using the heterobifunctional reagent 
MBS
Ovalbumin (Sigma A5503) dissolved in 50 mM KP04 pH 8.0 was added to MBS in 
DMSO in a ratio of 1:10, and stirred for 30 min room temperature. MBS-activated
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ovalbumin was eluted from a Sephadex G25 column as above. 4.5 mg of MBS- 
activated ovabumin was added to 5 mg of peptide in PBS, and mixed for 3 h at room 
temperature (carrier:peptide molar ratio, 1:26), then aliquots were stored at -20 °C.
4.2.4.3 Glutaraldehyde conjugation o f peptides to ovalbumin
1 mg ovalbumin and 1 mg peptide (molar ratio 1:22) were dissolved in PBS and 
mixed with glutaraldehyde (final concentration 0.05%). After stirring for 30 min at 
room temperature the conjugate was then frozen in aliquots at -20 °C until use.
4.2.4.4 l-ethyl-3-(3 dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
conjugation o f peptide to ovalbumin
5 mg of peptide was added to a final concentration of lOmg/ml EDC in H20  and 
gently agitated at room temperature for 10 min. 4 mg of ovalbumin was then added 
(molar ratio 1:28), and the mixture stirred at room temperature (in foil) for 2h. The 
conjugate was then dialysed for 24 h against 5 L of distilled water containing 0.01 % 
2-mercaptoethanol.
4.2.5 Immunisation of rats
Three rats were immunised with each peptide. Peptide-haemocyanin (MBS) 
conjugates were emulsified in complete Freunds adjuvant (FCA, Sigma F-4258) (1 
part immunogen in PBS:1 part FCA:1 part incomplete Freunds adjuvant). 300 p\ of 
emulisified conjugate containing 100 pg peptide was injected subcutaneously over 3 
sites. Booster injections of conjugate containing 100 pg peptide were administered 
in incomplete Freunds (FIA) after 2 and 4 weeks, and a tail bleed was taken at 10
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days after the second boost. A third boost consisting of free peptide in FLA was 
given at 8 weeks, and a blood sample taken 10 days later. After a 6-week interval 
animals were boosted again using a peptide-ovalbumin (glutaraldehyde) conjugate in 
FIA as above, and a test bleed taken 10 days later.
4.2.6 Immunisation of rabbits
Peptide-ovalbumin (MBS) conjugate, or peptide-ovalbumin (carbodiimide) conjugate 
containing 500 pg of peptide was emusified in FCA (1 part conjugate in PBS: 1 part 
FCA), and 1 ml given subcutaneously over 4 sites to Dutch rabbits. Three booster 
injections of conjugate in FIA were given at approximately 3-week intervals, and 10 
days after boosting a test bleed was taken from the ear vein.
4.2.7 Antiserum to IGFBP-2 whole molecule
Antiserum raised to IGFBP-2 purified from MDBK cells (which crossreacts with 
sheep, rat, and human IGFBP-2) was purchased from TCS Biologicals Ltd, Bucks, 
UK. Antiserum to rat IGFBP-2 synthetic peptide fragment [Tyr137](l 18-137), amino 
acid sequence GGSSAGRKPPKSGMKELAVY, coupled to ovalbumin was a gift 
from Dr Nicholas Ling, the Whittier Institute, La Jolla, CA.
4.2.8 ELISA of anti-IGFBP-2 peptide responses
Immulon II plates (Dynatech) were coated by adding lpg peptide per well in 100 pi 
PBS pH 7.4, and incubating at 4 °C for 18 h. The plate was then washed 3 times in 
PBS/0.5 % Tween 20, flooded with buffer, and incubated at room temperature for 
30 min, then frozen at —20 °C until required.
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Sera were diluted in PBS/0.05 % Tween 20, and serial dilutions made using 
a multichannel pipette. 100 pi of primary antisera diluted in PBS/Tween was 
incubated for 90 min at room temperature, washed 4 times (brief soak between the 
last two washes). 100 pi of a 1/1000 dilution alkaline phosphatase conjugated anti­
rabbit or anti-rat IgG secondary antibody was added as appropriate, incubated for 90 
min, then washed 5 times (brief soak between the last 2 washes). 200 pi of 1 mg/ml 
nitrophenyl phosphate in alkaline phosphate buffer (100 mM glycine pH 10.3, 1 mM 
ZnCl2, 1 mM MgCl2) was added and incubated in the dark, and the OD405 measured 
at 20 min intervals on a Titertek twinreader (Flow Laboratories).
4.2.9 Western blotting
This was carried out as in Chapter 2. Bovine sera (15 pi) or Clone 9 conditioned 
media (150 pi) per gel was separated by SDS-PAGE and blotted onto nitrocellulose. 
Dilutions of anti-peptide sera (200 pi) were incubated for 60 min in a Biometra 
"miniblot'' apparatus. After washing, alkaline phosphatase conjugated secondary 
antibody was incubated with the blot in a plastic container.
4.2.10 Immunoprecipitation of peptides
Anti-IGFBP-2[Tyr157](l 18-137) positive control serum, rabbit anti-peptide serum or 
normal rabbit serum, were incubated overnight at room temperature with 17,000 cpm 
[125I]IGFBP-2AcTyrl54](154-171)NH2 or 25,000 cpm [125I]IGFBP-2[Tyr154](154- 
171)NH2 in a 300 pi volume. Anti-rabbit IgG precipitating antibody in 8% PEG/10
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mM EDTA/RIA buffer was added for 6 hours at room temperature. Tubes were then 
spun at 1700 x g for 30 min, the supernatant was tipped off and the pellet counted.
4.2.11 Immunoprecipitation of IGFBP-2 pre-bound to IGF-1
Clone 9 conditioned medium (5pi) was incubated with about 20,000 cpm [125I]IGF-1 
overnight, then dilutions of anti-peptide antibody were added and incubated 
overnight. Anti-rabbit IgG secondary antibody with 8% PEG/EDTA in RIA buffer 
was added for 6 hours at room temperature. Tubes were then spun at 1700 x g for 
30 min, the supernatant was tipped off and the pellet counted.
4.3 Results
4.3.1 FAB-MS Analysis and reverse phase HPLC
HPLC analysis of the peptides showed one major peak and some minor peaks as 
expected of unpurified peptides, however Mass Spectroscopy analysis was not 
currently available and therefore peptides IGFBP-2(61-75), IGFBP-2(172-185), 
IGFBP-2(239-251) and IGFBP-2[Cys112](97-112) were used for rat immunisations 
without further analysis. FAB-MS analysis of these peptides was subsequently 
performed by Dr Su Chen. Fig 4.1 A, C and D shows IGFBP-2(61-75), IGFBP- 
2(172-185), and IGFBP-2(239-251) have signals corresponding to the appropriate 
molecular ion, though there are many other signals present; when such a complicated 
mixture is analysed it is impossible to assign molecular ions to all the signals 
detected. IGFBP-2[Cys112](97-112) showed no appropriate signal at the molecular 
ion, but there was a peak at 2010 Da which could represent incompletely deprotected 
peptide, therefore this peptide was "recleaved", but the losses during the
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recleaving/deprotection were too great for the peptide to be used therefore it was not 
further analysed (Fig 4. IB).
Amino acid analysis of IGFBP-2Ac[Tyr154](154-171)NH2 peptide showed the 
experimentally determined ratio of amino acids correlated well with the expected 
ratio (Table 4.2). FAB-MS analysis of IGFBP-2Ac[Tyr154](154-171)NH2 peptide 
showed a molecular ion [M+H]+ at 2133.6 m/z corresponding to a protonated 
molecule of the expected peptide sequence (Fig 4. IE). Other sequence ions were also 
present including the doubly charged molecular ion [M+H]++ at m/z 1067.2. FAB- 
MS analysis using glycerol/thioglycerol and meta-NitroBenzylAlcohol matrices 
produced similar profiles. Several other potential molecular ions were present, at 
about 266 Da higher than expected and at 2173.6, signals at about 163 Da lower 
than these possibly reflect loss of tyrosines. Signals in the 2000-2600 Da range may 
arise from incomplete deprotection of various amino acid protecting groups, 
therefore this peptide was taken through the cleavage/deprotection step again, and 
subsequently analysed by FAB-MS. Fig 4. IF shows the signals in the 2000-2600 Da 
range in the original preparation have decreased and the 2134.5 m/z [M +H]+ signal 
has increased in amplitude. Reverse phase HPLC profiles of IGFBP-2 Ac[Tyr154](154- 
171)NH2 show the increased homogeneity after the second cleavage/deprotection 
step; the profile is similar to that of IGFBP-2[Tyr154](154-171)NH2.
On the basis of the FAB-MS profiles peptides IGFBP-2(61-75), IGFBP- 
2(172-185), IGFBP-2(239-251), and a mixture of recleaved IGFBP-2Ac[Tyr154](154- 
171)NH2/IGFBP-2[Tyr154](154-171)NH2 were conjugated to ovalbumin for rabbit 
immunisations.
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Fig 4.1A FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2(61-75) peptide.
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F ig  4 .1 B FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2[Cys112](97-l 12) peptide.
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F ig  4 .1 C FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2(172-185) peptide.
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Fig 4. ID FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2(239-251) peptide.
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Fig 4 .IE FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2Ac[Tyr154](154-171)NH2 peptide after one cleavage step.
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Fig 4.IF FAB-MS (A) and reverse-phase (C8) HPLC (B) analysis of synthesised
IGFBP-2Ac[Tyr154](154-171)NH2 peptide after a second cleavage step.
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Amino acid found theoretical 
ratio ratio
Lys 1.85 2
Thr 0.95 1
Ser 0.90 1
Glu 1.80 2
Pro 4.90 5
Arg 1.87 2
Ala 1.00 1
Leu 2.65 3
Tyr 0.73 1
Table 4.2 Amino acid analysis of IGFBP-2 Ac[Tyr154](154-171)NH2.
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4.3.2 ELISA of rat antisera raised against IGFBP-2 peptides
Fig 4.2 shows the antisera responses to homologous peptide after immunisation with 
peptide-haemocyanin conjugates, initial boosting twice with peptide-haemocyanin 
conjugate, then boosting once with either free peptide (closed symbols) or peptide- 
ovalbumin conjugate (open symbols). Non-immune rat serum (NRS) showed a low 
background response against all the peptides demonstrating the specificity of the anti­
peptide response. Fig 4.2 demonstrates the variation in response between rats given 
the same immunogen. In addition, boosting affected the response of the individual 
animals differently; the titre increased in some animals and was decreased in others.
4.3.3 Western Blots of rat antisera against rat IGFBP-2
None of the antisera bound either reduced or non-reduced rat IGFBP-2 (Clone 9) 
(results not shown). Anti-IGFBP-2[Tyr137](l 18-137) serum was used as a positive 
control which reacted strongly. No binding was detected against reduced bovine 
serum (dry cow) either using anti-bIGFBP-2 sera as a positive control.
4.3.4 ELISA of rabbit antisera raised against IGFBP-2 peptides
All anti-peptide sera bound homologous peptide but did not cross react with non- 
homologous peptides, except for a slight crossreaction of anti-IGFBP-2(61-75) serum 
with IGFBP-2(239-251) peptide (Fig 4.3).
4.3.5 Western blots of rabbit sera against rat IGFBP-2 peptides
Antisera were tested against both reduced and non-reduced rat IGFBP-2 (Clone 9). 
There was no binding to IGFBP-2 except with the positive control anti-IGFBP-
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Fig 4.2 ELISA of rat anti-IGFBP-2 peptide antiserum responses against the 
homologous peptide. Individual responses of three rats are shown 
after boosting with free peptide (filled symbols) and peptide- 
ovalbumin conjugate (open symbols). The non-immune rat serum 
response is shown for each peptide (★). Results are absorbances after 
20 min incubation with substrate.
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Fig 4.3 ELISA of rabbit anti-IGFBP-2 peptide antiserum responses against 
homologous and non-homologous peptides. Anti-IGFBP-2(61-75) (• ) ;  
anti-IGFBP-2(172-185) (A); anti-IGFBP-2[Tyr154](154-171)NH2 
mixture (T); anti-IGFBP-2(239-251) (■). Results are absorbances after 
40 min incubation with substrate.
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Fig 4.4 ELISA of rabbit IGFBP-2[Tyr154](154-171)NH2 mixture antiserum 
responses against the individual peptides. (A) IGFBP-2[Tyr154](154- 
171)NH2 and (B) IGFBP-2Ac[Tyr154](154-171)NH2 was coated on the 
plates. Control antiserum is anti-IGFBP-2[Tyr137](118-137). Results 
are absorbances after 20 min incubation with substrate.
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Fig 4.5 Immunoprecipitation of [125I]IGFBP-2 peptides by rabbit IGFBP- 
2[Tyr154](154-171)NH2 mixture antiserum. (A) IGFBP-2[Tyr154](154- 
171)NH2 and (B) IGFBP-2Ac[Tyr154](154-171)NH2 were incubated 
with anti-peptide antiserum and precipitated with anti-Ig secondary 
antibody. Control antiserum is anti-IGFBP-2[Tyr137](118-137).
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Fig 4.6 Immunoprecipitation of IGFBP-2 prebound to [125I]IGF-1. Rat IGFBP-
2 (Clone 9) was preincubated with [125I]IGF-1 followed by incubation 
with rabbit anti-IGFBP-2 peptide serum, non-immune serum or 
control antiserum (anti-IGFBP-2[Tyr137](l 18-137)) and precipitated 
with anti-Ig secondary antibody.
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2[Tyr137](118-137) serum. A faint band was detected with anti-IGFBP-2(172-185) at 
a higher molecular weight than that of IGFBPs (results not shown).
43.6 ELISA response of an antiserum raised to IGFBP-2AcfTyr154] (154-171)NH2/IGFBP- 
2[Tyr154](154-171)NH2 mixture against the individual peptides
Antiserum to the mixture recognised both peptides by ELISA equally well (Fig 4.4).
4 3 .7  Immunoprecipitation of [125I]IGFBP-2 peptide with anti-peptide antisera
Fig 4.5 shows the immunoprecipitation of both radiolabelled IGFBP-2Ac[Tyr154](154- 
171)NH2 peptide and IGFBP-2[ryr154](154-171)NH2 by antisera raised against a 
mixture of these peptides, but normal rabbit serum and control anti-IGFBP- 
2[Tyr137](l 18-137) did not precipitate either peptide.
4.3.8 Immunoprecipitation of IGFBP-2 (Clone 9) prebound to [12SI]IGF-1
Control anti-IGFBP-2[TyrI37](l 18-137) serum precipitated whole molecule IGFBP-2, 
whereas anti-IGFBP-2[Tyr154](154-171)NH2 mixture and non-immune rabbit serum 
were ineffective (Fig 4.6).
4.4 Discussion
Several antisera were raised which specifically bind homologous peptides by ELISA 
and in at least one case can precipitate peptide in solution. However none of these 
anti-sera showed detectable binding to the whole IGFBP-2 molecule either native in 
solution or denatured on western blots. Rats were initially chosen because they were 
available in greater numbers than rabbits thus allowing several animals to be
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immunised with each peptide, since individual variation in response between animals 
was expected. Immunised rats were boosted with free peptide or peptide attached to 
a different carrier to avoid the strong carrier response from detracting from the anti­
peptide response, but titres by ELISA were not improved nor did the antisera bind 
in western blotting.
Rabbit anti-IGFBP-2 peptide sera which bound IGFBPs in western blots were 
subsequently reported, and this approach was adopted along with the IGFBP-2 
peptide sequence used in that study (Liu et al. 1993). The limited number of rabbits 
available could have been utilised in two ways, either one animal per peptide for 
several peptides or several animals for fewer peptides. The former was chosen firstly 
because antisera to different regions of the molecule were desired, and secondly in 
the absence of the 3-D structure of IGFBP-2 the surface epitopes were unknown but 
based only on predictions.
There are several reasons why anti-peptide antisera may not bind the protein. 
Peptide IGFBP-2[Cysm](97-112) was used for rat immunisations but subsequently 
shown not to contain the appropriate peptide, therefore it is not surprising that the 
serum does not react with the protein, but peptides IGFBP-2(61-75), IGFBP-2(172- 
185), and IGFBP-2(239-251) used for immunisation of rats and rabbits were shown 
by mass spectroscopy to contain the appropriate peptide. However the peptide 
preparations were not purified and would contain other peptides. It is feasible that 
some of the antibody response to immunisation with crude peptides may be directed 
against these contaminants, thus detracting from the desired response.
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It is possible that the antisera bind to the peptide sequences chosen but these 
sequences, in spite of the predictions of surface exposure, may not be on the surface 
of the molecule or are otherwise inaccessible to the antisera. However anti-peptide 
sera tend to react well with the denatured form of the protein. Therefore the failure 
of anti-peptide sera to bind either reduced and non-reduced IGFBP-2 on a western 
blot was disappointing, although partial renaturation of blotted proteins on 
nitrocellulose has been described and the orientation of protein on the nitrocellulose 
may mask some peptide sequences.
Most peptides were conjugated to carrier protein using MBS. A cysteine 
residue was included at one end of the peptide sequence to foster conjugation through 
this end residue thus avoiding altering the required sequence. However most 
conjugation methods can involve more than one residue in the coupling and the 
peptides antigenicity may be altered by conjugation.
Some of the above considerations concerning the failure of anti-peptide sera 
to bind protein do not apply to IGFBP-2[Tyr154](154-171)NH2: it has been 
successfully used to raise an antiserum which binds peptide in solution and IGFBP-2 
on western blots, though unfortunately it was unknown if this antiserum binds the 
native molecule (Liu et al. 1993). A mixture of IGFBP-2 Ac[Tyr154](154-171) and 
peptide IGFBP-2[Tyr154](154-171) obtained from Dr N. Ling was used for 
immunisations, and the resulting antiserum bound both peptides equally well by 
ELISA. Difficulty in obtaining Bis-benzidine prevented the use of diazotised 
benzidine for carrier conjugation as used by Liu et al. (1993) and therefore 
carbodiimide was used. Therefore although mass spectroscopy and amino acid 
analysis confirmed the identity of IGFBP-2Ac[Tyr154](154-171)NH2, the difference
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in the conjugation methods used here and in Liu et al. (1993) may have resulted in 
different configurations of the peptide in the two conjugates and hence different 
antibody responses. Also, as mentioned above, even if identical peptide-carrier 
conjugates were prepared inter-animal variation in responses is expected.
In the absence of purified IGFBP-2 to iodinate for immunoprecipitation 
studies, an indirect assay was used in which IGFBP-2 was precomplexed to 
[125I]IGF-1 before adding antisera to IGFBP-2 peptides. This indirect method has the 
advantage of avoiding denaturation of IGFBP-2 by radiolabelling; the antiserum must 
bind the native molecule to modulate the biological function of the IGFBP, although 
such antisera are difficult to produce.
The positive control antiserum to rat IGFBP-2 synthetic peptide fragment 
[Tyr137](l 18-137) used here is of a higher titre than the anti-IGFBP-2[Tyr154](154- 
171)NH2 used in Liu et al. (1993). The anti-IGFBP-2[Tyr154](154-171)NH2 used in 
Liu et al. (1993) can detect 50 ng of IGFBP-2 by WLB, but in the absence of this 
antiserum or purified IGFBP (the IGFBP-2 content of the Clone 9 conditioned 
medium used is unknown), it is impossible to compare the reactivity of our anti- 
IGFBP-2[Tyr154](154-171)NH2 with that in Liu et al. (1993)
Blum et al. (1993) used rhIGFBP-2(176-190) (LEEPKKRPPP ART) to produce 
an anti-peptide antiserum which bound the protein. The surface exposure of this 
peptide was confirmed by the ability of the antiserum to bind native rhIGFBP-2 in 
solution. Interestingly, IGFBP-2 from rat or sheep did not cross react even though 
this sequence is homologous in all three species. This sequence is incidentally very 
similar to the peptide IGFBP-2[Tyr154](154-171)NH2) ([YJLSLEEPKKLPPPARTP). 
Thus a sequence which on the basis of secondary structure calculations is believed
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to be on the surface of the molecule failed to bind rat IGFBP-2. Although there is 
extensive IGFBP-2 amino acid homology between species, their secondary structure 
may differ: if the conformation of a peptide and its surrounding residues differs 
between species, its antigenicity and access to an antibody may be altered. In 
addition, post-translational modifications of proteins may affect antiserum binding, 
and although no potential O- or N-linked glycosylation sites have been described for 
human or rat IGFBP-2, the phosphorylation state of IGFBP-2 from different sources 
has not been studied.
In conclusion, although antisera to several IGFBP-2 peptides were 
successfully raised, antisera which bind the protein were as expected more difficult 
to obtain. Given the inter-animal variation in response and difficulty in precisely 
controlling conjugation, future immunisation strategy would require the use of more 
than one animal per peptide and more than one conjugation method for each peptide.
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CHAPTER 5: THE ROLE OF IGFBPS IN THE RAT 
MAMMARY GLAND
5.1 Introduction
Although PRL is the major galactopoietic hormone in the rat, GH plays an important 
role especially when serum PRL concentrations are low (Madon et al. 1986). The 
existence of functional GH receptors on mammary epithelial cells has not been 
demonstrated although there is evidence of GH receptor protein in rat mammary 
epithelial cells (Lincoln et al. 1990). The effects of GH have therefore been 
considered to be indirect, via either nutrient partitioning or IGF-1 since the 
mammary gland does possess IGF-1 receptors and IGFs are potent mitogens for 
mammary cells in vitro. A rat model has previously been established using a specific 
anti-GH serum, in conjunction with bromocriptine to ablate PRL, to study the role 
of GH and PRL in lactation. This model was used to investigate the ability of 
hormones to reinitiate milk production in animals where GH and PRL have been 
ablated (Flint et al. 1992), and test the ability of IGFs to mimic GH action in 
reinitiating milk production (Flint et al. 1994); the present study forms part of this 
investigation. There is little known about the role of IGFs and the IGFBPs in the 
involuting mammary gland, and the aim of the present study was to assess the 
IGFBP profiles and their hormonal control in serum, mammary gland and milk of 
rats in which involution had been initiated either by litter removal or by ablation of 
lactogenic hormones.
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5.2 Materials and methods
5.2.1 Endocrine manipulation of rats
5.2.1.1 Effects o f  bromocriptine and anti-GH treatment in combination with GH, 
IGF-1 and IGF-2 on serum IGFs and IGFBPS
Lactating rats were treated on day 14 of lactation by administration of bromocriptine 
(500 /Ag/injection) or sheep anti-rGH 7 -globulin (llOmg/injection) or a combination 
of both. In addition they received the following treatments: recombinant bovine GH 
(Monsanto, St Louis, MO, USA; 0.5 mg/injection), recombinant IGF-1 (Ciba-Geigy, 
Friebourg, Switzerland; 0.2 mg in 500 (jl 1 25% polyvinylpyrrolidone (PVP)) or 
recombinant bovine IGF-2 (Monsanto: 0.15 mg in 500 \x 1 25% PVP). Control rats 
received carrier solutions and non-immune 7 -globulin. All treatments were 
administered twice daily for 2 days.
5.2.1.2 Effects o f PRL, GH ora combination IGF-1 and IGFS bound to hIGFBP- 
3, after pretreatment with bromocriptine and anti-rGH, on serum IGF-1 and 
IGFBPS
Lactating rats were treated on day 14 of lactation by administration of bromocriptine 
(500 /Lig/injection) or sheep anti-rGH 7 -globulin (150 mg/injection) to inhibit 
lactation. Hormonal ablation treatment was administered subcutaneously (s.c.) twice 
daily for 3 days. Hormone replacement treatment was administered on the third day 
and comprised 1 mg bGH s.c. in 0.5 ml NaHC03 (0.1 mol/1), lmg oPRL, 0.25 mg 
IGF-1 precomplexed to 0.8 mg hIGFBP-3 in 1 ml PBS containing 0.1 % BSA or 0.25 
mg IGF-1 plus 0.2 mg IGF-2 precomplexed to 0.8 mg hIGFBP-3; control rats 
received PBS injections. Doses were administered s.c. as 0.2, 0.2 and 0.1 ml at
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1400 and 2200 h on day 3 and 1000 h on day 4. At 1200 h on day 4 all dams were 
killed by cervical dislocation, a blood sample obtained and mammary tissue removed 
and frozen in liquid nitrogen.
5.2.1.3 Effects o f bromocriptine and anti-GH treatment or litter removal on the 
concentration o f IGFBPs in milk and serum
Lactating rats were treated at day 12-14 of lactation by administration of 
bromocriptine, anti-GH or a combination of both as described above. Control rats 
received non-immune sheep 7 -globulin (150 mg/injection). Treatments were given 
twice daily for 2 or 4 days and after 48 or 96h treatment all dams had their litters 
removed for a further 4 h to allow milk to accumulate. Additional animals had their 
litters removed at time 0 and milk was allowed to accumulate over 48 h. Dams were 
anaesthetised with 0.3 ml sodium pentobarbitol (60 mg/ml Sagatal, RMB Animal 
Health, Dagenham, UK) after which the dam received 1 U oxytocin (Intervet UK, 
Cambridge, UK) to induce milk ejection and allow milk to be removed by gentle 
pressure. The dam was then killed by cervical dislocation and a blood sample 
obtained. Milk samples were frozen in liquid nitrogen and stored at -20 °C until use.
5.2.1.4 Effects o f  oestradiol treatment, teat-sealing, or litter removal in 
combination with PRL, GH, progesterone, corticosteroid, or anti-IGF-1 treatment, 
on serum IGF-1 and IGFBPs in milk
Lactating rats were treated on day 14 of lactation by daily administration of 17-/3- 
oestradiol (100 /xg in safflower oil/injection). Another group of animals had teats on 
one side sealed with tissue glue and the pup number reduced to 6 (one per unsealed
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gland). After treatment for 2 days litters were removed from these groups for 4 h 
to allow milk to accumulate before milking and blood sampling as described above.
Further groups of animals had litters removed and received one of the 
following treatments for two days: rbGH (1 mg in 20% PVP/injection) twice daily; 
PRL (1 mg in 20% PVP/injection) twice daily; hydrocortisone (1 mg in safflower 
oil/injection) once daily; progesterone (5 mg in safflower oil/injection) once daily; 
anti-IGF-1 serum (3 ml concentrated in a 1 ml volume/injection) twice daily. After 
treatment the animals were milked and blood samples taken as described above.
5.2.2 Collection of mouse milk
A lactating mouse was treated at day 11 of lactation by removal of its litter for 48 
h, and a second mouse had its litter removed for 4 h to allow milk to accumulate. 
The dams were then anaesthetised with a mixture of hypnorm and hypnovel after 
which the dam received 100 mU oxytocin to induce milk ejection and allow milk to 
be removed by gentle pressure.
5.2.3 IGF RIA
Serum IGF-1 concentrations were measured as described in Chapter 2. Serum IGF-2 
concentrations were measured by Dr F. Buonomo as descibed in Buonomo et al. 
(1988).
5.2.4 Solution phase assay for IGFBPs
This was performed as described in Chapter 2. The non-linearity of this assay did 
not seem to be caused by tracer limitation as increasing the counts 10-fold did not
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affect the percentage binding of tracer, therefore a pool of milk from animals whose 
litters had been removed for 48 h was used in a standard curve to compare the 
IGFBP content in different milk samples. Competitive binding assays were carried 
out in the presence of unlabelled IGF-1, IGF-2, or IGF-1 analogues as described in 
the results.
5.2.5 Western ligand blotting
This was carried out as in Chapter 2. For most assays 1 p\ of serum was used per 
gel track. Milk was diluted 1/10 in PBS or TBS and in some assays centrifuged at
100,000 x g for 20  min in a compressed air-driven high speed centrifuge, the 
supernatant was then removed and the pellet resuspended in buffer to the original 
volume. Casein micelles were disrupted by mixing equal volumes of milk with 200 
mM EDTA pH 7.0 before centrifugation as above, then all fractions were adjusted 
to the initial volume. Some conditioned medium samples from mammary epithelial 
cell cultures (see 5.2.12) were dialysed against distilled water overnight at 4 °C, 
freeze dried, and dissolved in a sixth of the original volume with distilled water.
5.2.6 Size exclusion chromatography of milk
Protection of the size exclusion column required defatting of milk and removal of 
particulate matter by centrifugation. Centrifugation also precipitated micelles 
containing casein in association with calcium phosphate and thus greatly reduced the 
protein content. Milk was diluted 1/4 in PBS or 50 mM Tris HC1 pH 7.5, 
centrifuged at 20 min at 13,500 x g, and the infranatant was filtered through a 0.22 
pm  filter. Filtrate (10 /xl) was incubated overnight at 4 °C with 5 x 105 cpm
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[125I]IGF-1 in a final volume of 500 p 1PBS/0.1 % tween. 100 pi of this was injected 
into a Superose 12 high performance size exclusion column. The column was run at 
a flow rate of 0.5 ml/min in PBS/0.1 % tween, and fractions were collected at 1 min 
intervals and counted in a gammacounter. Calibration markers were, /3-amylase (200 
kDa, Vo), BSA (66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.3 kDa), 
IGF-1 (7.5 kDa), tyrosine (180 Da).
5.2.7 Deglycosylation of IGFBP
To assess the N-glycosylation of the IGFBP in a pool of milk from dams whose 
litters had been removed for 48 h, normal rat serum was used as a source of 
glycosylated IGFBP-3 (positive control), and Clone 9 conditioned medium as a 
source of non-glycosylated IGFBP-2 (negative control). Milk (0.1-0.4 pi), serum (1 
pi), or Clone 9 conditioned medium (10 pi) was incubated with 0.5 U of N- 
glycanase for 20 h at 37 °C in a final volume of I0pl containing 50 mM EDTA, 2 
mM PMSF, 1% Triton, 0.05% SDS and 12.5 % glycerol. Control samples without 
N-glycanase were incubated in the same buffer at 37 °C or 4 ° C for 20 h. After 
incubation 5 pi of 5-times concentrated SDS sample buffer added and the samples 
analysed by WLB.
5.2.8 Western frmminoblotting
This was carried out as in Chapter 2 using antisera to IGFBP-5 and IGFBP-2 (UBI). 
Dilutions of Clone 9 conditioned medium (positive control for IGFBP-2) and milk 
were analysed by WLB and quantities which yielded bands of equal intensity were 
used for immunoblotting.
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5.2.9 Northern Analysis
Northern blot analysis of mammary RNA for IGFBP mRNA was carried out as 
described in Chapter 2.
5.2.10 In Situ Hybridisation
Frozen sections of rat mammary gland obtained from control lactating animals or 
after litter removal for 48 h were probed for IGFBP mRNA. Sections were 
dehydrated in 100% ethanol twice for 5 min then fixed in 2% formaldehyde in 100 
mM Tris HC1, 50 mM EDTA pH 8.0 for 5 min. The sections were rinsed in 
distilled water for 5 min and the tissue permeabilised in 10 pglml proteinase K, 50 
mM EDTA, 100 mM Tris HC1 pH 8.0 for 30 min at 37 °C. After fixation in 2 % 
formaldehyde solution, sections were rinsed in water, then in 100 mM 
triethanolamine pH 8.0 for 2.5 min and acetylated for 10 min at room temperature 
in 100 mM triethanolamine pH 8.0, 0.0025% (v/v) acetic anhydride. The sections 
were rinsed briefly in 2x SSC and dehyrated in a graded ethanol series (50%, 70%, 
95%, 100%, 100%) for 3 min each, dried under vacuum and stored dessicated at -20 
°C.
Anti-sense and sense RNA probes were prepared by incubating 1 ng of 
template DNA, 200 p d  35S UTP, 50 mM GTP/CTP/ATP, 20 U RNA polymerase, 
20 U ribonuclease inhibitor, 5 mM dithiothreitol (DTT), 2 mM spermidine, 10 mM 
NaCl, 6 mM MgCl2, 40 mM Tris HC1 pH 7.5 in a final volume of 20 pi at 37 °C 
for 2 h. DNase I (1 U) was then added at 37 °C for 15 min, then the reaction was 
stopped by adding 100 mM EDTA pH 8.0 and the labelled probe was separated from 
incorporated label using a Sephadex G-50 column.
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Sections were prehybridised overnight at 55 °C in a humidified chamber in 
100 pi hybridisation buffer consisting of 0.5 mg/ml tRNA, 0.5 mg/ml Torula yeast 
tRNA, 10 mM DTT, 50% formamide, 10% dextran sulphate, 0.2 mg/ml Ficoll 400, 
0.2 mg/ml PVP, 0.2 mg/ml BSA, 1 mM EDTA, 300 mM Na Cl, 10 mM Tris HC1 
pH 8.0. Sections were then hybridised with 1 x 107 cpm 35S RNA probe in 70 pi 
hybridisation buffer under a coverslip overnight at 55 °C in a humidified chamber.
After hybridisation the coverslips were soaked off in 4 x SSC then treated 
with 20 pg/ml RNase A in 500 mM Na Cl, 1 mM EDTA, 10 mM Tris HC1 pH 8.0 
for 30 min at 37 °C. The sections were then washed as follows: twice in 2 x SSC, 
1 mM DTT for 10 min at room temperature; once in 0.5 x SSC for 20 min; once 
in 0.1 x SSC/1 mM DTT at 65 °C for 60 min; rinsed once in 0.1 x SSC/1 mM 
DTT. Sections were dehydrated for 3 min in each of: 50% ethanol in 0.1 x SSC/1 
mM DTT; 70% ethanol in 0.1 x SSC/1 mM DTT; 95% ethanol; 100% ethanol. 
After vacuum drying for 30 min at room temperature the sections were exposed to 
/3-max Hyperfilm for 3 weeks to estimate the extent of hybridisation. The sections 
were subsequently coated in Kodak NTB-2 emulsion diluted 1/2 with water and 
exposed at 4 °C and developed (Kodak), counterstained, dehydrated and mounted 
then examined under dark and light field microscopy.
5.2.11 Preparation of mammary gland acini
Lactating rats at day 12-14 of lactation were treated with anti-rGH 7 -globulin and 
bromocriptine, or litter removal as described above. Mammary gland tissue was 
removed and rinsed in medium 199 and weighed. Tissue was minced with scissors 
and incubated at 2.5 g/20 ml digestion mixture (1 mg/ml collagenase (Worthingtons
CL3), 0.15 mg/ml hyaluronidase (Boehringer), 2 mg/ml BSA in Medium 199 with 
an additional 1 mg/ml glucose) at 37 °C for 95 min in a water bath with vigorous 
pipetting at 15 min intervals. The mixture was then sieved through a tea strainer, 
centrifuged for 10 min at 400 x g, and washed at 100 x g for 6 min three times in 
medium 199 containing 20 ^g/ml DNase. The pellet was then suspended in 10 ml 
of medium 199 (containing 100 U/ml penicillin, 100 /xg/ml streptomycin) and plated 
at 1 ml per well in a 12 well plate. An aliquot was retained for DNA measurement 
as described in Chapter 2. After culture the acini and conditioned medium were 
harvested by centrifuging at 600 x g for 10 min.
5.2.12 Preparation and culture of mammary epithelial cells
Mammary epithelial cells were prepared from mice on day 15-16 of pregnancy 
(Wilde et al. 1991) and plated at 3-5 x 105 cells/cm2 in 3.5 cm culture wells coated 
with Engelbreth-Holm-Swarm (EHS) matrix. Cells were cultured in Medium 
199/Ham’s F12 (50:50, v/v) containing insulin (5 ^tg/ml), hydrocortisone (1 jug/ml), 
triiodothyronine (0.65 ng/ml), epidermal growth factor (10 ng/ml) and PRL (1 
jug/ml). Foetal calf serum (10% v/v) was present for the first day of culture to 
promote attachment, thereafter medium was changed daily with medium without 
FCS. In some samples cultures were treated on day 5 with 2.5 mM EGTA for 20 
min, washed with culture medium and returned to culture for 24 h before the next 
harvesting.
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5.3 Results
5.3.1 Effects of bromocriptine and anti-GH treatment in combination with GH, 
IGF-1 and IGF-2 on serum IGFs and IGFBP-3 in lactating rats
Bromocriptine treatment did not produce any changes in serum IGF-1, IGF-2, or 
IGFBP-3. However Anti-GH treatment decreased serum IGF-1, and IGF-2 levels 
below control lactating values although IGFBP-3 levels were unaffected. Combined 
treatment led to significant reductions in IGF-1, IGF-2, and IGFBP-3 levels, and GH 
therapy prevented all of these effects (Table 5.1).
5.3.2 Effects of PRL, GH or a combination of IGF-1 and IGF-2 bound to 
hIGFBP-3, after pretreatment with bromocriptine and anti-rGH, on serum IGF- 
1 and IGFBP-3
Both GH and IGF-1 increased serum IGF-1 levels compared with those of animals 
given bromocriptine and anti-rGH treatment, but only GH treatment increased rat 
IGFBP-3 levels. In contrast PRL treatment did not affect serum IGF-1 or IGFBP-3 
levels (Table 5.2). There are discrepancies in the absolute IGF-1 concentrations in 
Table 5.1 and Table 5.2 for the treatments common to both studies (combined anti- 
rGH and bromocriptine treatment with or without GH replacement), although the 
relative differences are similar. These differences may be because the two assays 
were carried out 18 months apart using different primary antibody batches or 
alternatively they may reflect real differences in the serum IGF-1 levels between the 
groups of rats used.
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5.3.3 Effects of bromocriptine and anti-rGH treatment or litter removal on 
serum IGFBPs detected by western ligand blotting
The levels of all serum IGFBP bands were increased by litter removal compared 
with lactating rats. Combined treatment with bromocriptine and anti-rGH decreased 
both the IGFBP-3 and 28-31 kDa bands but the 24 kDa band (IGFBP-4) was 
unaffected by hormonal ablation; the length of treatment had no effect (Table 5.3).
5.3.4 Effects of bromocriptine and anti-rGH treatment or litter removal on 
IGFBP levels in milk measured by solution phase [125I]IGF-1 binding
Solution phase [125I]IGF-1 binding to milk was substantially greater after litter 
removal than after hormone ablation treatment for 48 or 96 h (Fig 5.1).
5.3.5 Competitive inhibition of [125I]IGF binding to milk from animals whose 
litters have been removed
Competitive inhibition of radiolabeled IGF-1 and -2 binding to 0.5 n 1 milk (50-100 
fxg protein) demonstrated a preferential binding of IGF-2 (Fig 5.2). Insulin and 
Long-R3-IGF-l did not compete even at high concentrations suggesting that binding 
was to an IGFBP rather than to a type 1 IGF receptor. Comparison of the ability of 
high concentrations of three IGF-1 analogues to compete for [125I]IGF-1 binding 
showed Long-IGF-1 competed better than R3-IGF-1, and Long-R3-IGF failed to 
compete (Fig 5.3).
5.3.6 Size exclusion chromatography of milk
IGFBPs in milk obtained after litter removal formed principally a small molecular 
weight complex with IGF-1 at about 40 kDa and there was some evidence of a larger 
molecular weight complex at about 100 kDa; complexes were essentially absent in 
control milk (Fig 5.4).
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Fig 5.1 Effects of bromocriptine (Br) and anti-rGH treatment or litter removal 
on IGFBPs in milk. IGFBPs were measured by solution phase 
[125I]IGF-1 binding to milk from hormonally manipulated lactating 
rats. (A) Comparison of treatment by hormonal ablation and litter 
removal for 48 h. (B) Comparison of hormonal ablation treatment for 
24 and 48 h. Values are means ±  SEM for 3-8 animals (A) or 5 
animals (B), *p< 0.001 compared with control (analysis of variance).
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whose litters had been removed for 48 h. Pooled milk was incubated 
with radiolabelled IGF in the presence of competitors, and bound and 
free hormone were separated by charcoal adsorbtion.
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Fig 5.3 Comparison of the ability of IGF analogues to inhibit solution phase 
[125I]IGF-1 binding to milk from lactating rats whose litters had been 
removed for 48 h. Pooled milk was incubated with [125I]IGF-1 in the 
presence of competitors, and bound and free hormone were separated 
by charcoal adsorbtion. Values are means ±  SEM for 3 replicate 
assays.
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Fig 5.4 Size exclusion chromatography of milk. Diluted and filtered milk (10 
ix\) was incubated overnight at 4 °C with 5 x 105 cpm [125I]IGF-1 in 
a final volume of 500 /xl PBS/0.1 % tween. 100 fxl of this was injected 
into a Superose 12 high performance size exclusion column. The 
column was run at a flow rate of 0.5 ml/min in PBS/0.1 % tween, and 
fractions were collected at 1 min intervals and counted in a 
gammacounter. Calibration markers were as indicated, /2-amylase 
(200 kDa, Vo), BSA (66 kDa), carbonic anhydrase (29 kDa), 
cytochrome C (12.3 kDa), IGF-1 (7.5 kDa).
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5.3.7 Western ligand blot analysis of fractionated milk from rats whose litters 
have been removed for 48 h
WLB analysis of milk obtained after litter removal confirmed the presence of a 
major IGFBP band of about 30 kDa band. In some samples additional less intense 
bands of about 39-43 kDa and >200 kDa were detected all of which could be 
competed by unlabelled IGF-1. In contrast IGFBPs were poorly detectable in milk 
from control or hormonal ablated lactating rats (results not shown). WLB analysis 
of high speed centrifugation fractions of diluted milk from animals whose litters had 
been removed showed that the IGFBP was partitioned to the pellet fraction (Fig 
5.5A). However disruption of casein micelles by HDTA treatment partitioned the 
IGFBP to the supernatant fraction (Fig 5.5B). A pool of milk which had been stored 
at -20 °C for several months was used for EDTA assays which may account for the 
less striking partitioning of IGFBP to the pellet fraction compared with the use of 
fresh milk samples in Fig 5.5A.
5.3.8 Deglycosylation and immimoblotting of milk from rats after litter removal
The molecular weight of the IGFBP in milk was unaffected by N-glycanase treatment 
(Fig 5.6). In addition IGFBPs were unaffected by the incubation temperature since 
there was no difference in control samples at 4°C and 37 °C (not shown). The IGFBP 
in milk migrates slightly in front of IGFBP-2 and was not recognised by an 
antiserum to bovine IGFBP-2 which crossreacts with rat IGFBP-2, however it was 
recognised by an antiserum to IGFBP-5 (Fig 5.7).
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Western ligand blot analysis of fractionated milk from lactating rats 
whose litters had been removed for 48 h. A full length example of 
one of the blots (pool (1)) used in Fig 5.5.
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Fig 5.5 Western ligand blot analysis of fractionated milk from lactating rats 
whose litters had been removed for 48 h. (A) Quantitation of 
centrifuged milk fractions (0.1 /jl\ equivalent). Values are means ±  
SEM for n = 5  observations, *p<0.05 compared with the supernatant 
fraction. (B) Effect of EDTA on the partitioning of milk IGFBP. Milk 
samples from two separate pools (1) and (2), were diluted in 100 mM 
EDTA before fractionation. Samples in (A) were from freshly 
collected milk but samples in (B) were from milk pools stored for 
several months; this difference may account for the discrepency in 
partitioning of IGFBP between pellet and supernatant fractions.
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Fig 5.6 Deglycosylation of milk, serum and IGFBP-2 by N-glycanase.
Western ligand blot of milk from lactating rats whose litters were 
removed 48 h (0.1-0.4 ^1), pooled normal rat serum (1 ^1), or 10 \x1 
clone 9 conditioned medium incubated with (+ ) or without ( —) 0.5 
unit of N-glycanase for 20 h at 37 °C in a final volume of 10 ^1 
containing 50 mM EDTA, 2 mM PMSF, 1 % Triton, 0.05% SDS and
12.5 % glycerol. Representative result of 3 separate assays.
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[l25I]IGF-l ligand blot IGFBP-5 Immunoblot
Mr( KDa)
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Fig 5.7 Immunoblotting of milk from lactating rats whose litters had been 
removed for 48 h.Milk (0.1 /xl) was Western ligand blotted with 
[125I]IGF-1 or immunoblotted with an antiserum to IGFBP-5. 
C =  control, R = litter removed.
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5.3.9 Effects of oestradiol treatment, teat-sealing, or litter removal in 
combination with PRL, GH, progesterone, corticosteroid, or anti-IGF-1 
treatment, on serum IGF-1 and IGFBPs in milk
Oestradiol treatment had no effect on IGFBP concentrations in lactating rats. 
Likewise lactating animals with half their glands sealed had IGFBP levels from the 
suckled glands similar to those of controls animals, but milk obtained from sealed 
glands had significantly increased IGFBP levels (5-10 fold), whereas litter removal 
increased IGFBP levels even further (100 fold). Concurrent PRL treatment reduced 
the level of the 29-30 kDa IGFBP in milk, whilst in contrast anti-IGF-1, GH, or 
hydrocortisone treatment in conjunction with litter removal did not affect milk 
IGFBP levels (Table 5.4).
Serum IGF-1 levels increased after litter removal compared with lactating 
controls, whereas lactating animals with half their glands sealed had serum IGF-1 
levels similar to those of lactating controls. PRL treatment in conjunction with litter 
removal increased serum IGF-1 levels even further when compared with litter 
removal alone. IGF-1 levels in anti-IGF-1 treated animals could not be determined 
because anti-IGF-1 antibody in the serum samples interfered in the IGF-1 RIA (Table 
5.4).
5.3.10 Northern analysis of IGFBP mRNA in mammary glands of lactating rats 
after combined bromocriptine and anti-rGH treatment or litter removal
Preliminary Northern analysis detected IGFBP-4 and -5 mRNA in mammary gland 
after litter removal at day 10 of lactation for 24 or 48 h (Fig 5.8); IGFBP-2 was also 
detectable, IGFBP-1 and -3 mRNA was undetectable but IGFBP-6 mRNA levels
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Fig 5.8 Northern analysis of IGFBP mRNAs in mammary gland from 
lactating rats whose litters were removed for 24 or 48 h. 20 /xg 
samples of total RNA were separated on agarose gels, blotted and
hybridised with RNA probes for IGFBP-4 and -5. The RNA was
stained with ethidium bromide before blotting and the 28s rRNA
species shown beneath the northern blot.
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Fig 5.9a Northern analysis of IGFBP mRNAs in mammary gland from hormonally 
manipulated rats. Full length examples of the Northern blots used in Fig 
5.9.
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Fig 5.9 Northern analysis of IGFBP mRNAs in mammary gland from 
hormonally manipulated lactating rats, (a) control (b) litter removal 
for 48 h (c) Bromocriptine (Br) plus anti-GH for 48 h (d) Br plus 
anti-GH for 48 h with PRL for 22 h (e) Br plus anti-GH for 48 h with 
GH for 22 h (f) Br plus anti-GH for 96 h. 20 /ig samples of total 
RNA were separated on agarose gels, blotted and hybridised with 
RNA probes for IGFBP-2, -4, and -5. The RNA was stained with 
ethidium bromide before blotting and the 28s rRNA species shown 
beneath the northern blot.
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5.10 Detection of IGFBP-1 to -6 mRNA in rat mammary gland using in 
situ  hybridisation. Frozen sections of mammary gland probed with 
antisense [35S]IGFBP cRNA and exposed to /5-max Hyperfilm to 
estimate the extent of hybridisation.
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Fig 5.11 Detection of IGFBP-4 and -5 mRNA in rat mammary gland using in 
situ hybridisation. Frozen sections of mammary gland were probed 
with sense or antisense [35S]IGFBP cRNA, then exposed to 
photographic emulsion to detect hybridisation. Sections were 
developed, counterstained, dehydrated and mounted then examined 
under dark and bright field microscopy.
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could not be assessed because there was no positive control used. In contrast IGFBP 
mRNA was undetectable in control lactating gland.
Mammary glands from dams whose litters had been removed for 48 h at day 
14 of lactation expressed IGFBP-2, -4 and -5 mRNA but mRNA was barely 
detectable or absent in glands from other treatments (Table 5.5). mRNA species 
detected were of about 1.8 kb for IGFBP-2, 1.3 kb for IGFBP-4, and 5.5 kb for 
IGFBP-5 (Fig 5.9).
5.3.11 In situ hybridisation analysis of rat mammary gland in lactation and after 
litter removal
Preliminary autoradiographic detection showed specific labelling with antisense probe 
to IGFBP-2, -4, and -5, but not IGFBP-1, -3, or -6 in mammary gland after litter 
removal. IGFBP-2 mRNA was also detectable in the control lactating gland. 
Subsequent detection of signals (x 200 magnification) using emulsion showed that 
gland obtained after litter removal expressed IGFBP-4, and -5 mRNA but these 
mRNAs were undetectable in glands from control lactating animals. In contrast 
IGFBP-2 was detectable in both control and involuting gland.
5.3.12 IGFBPs in mouse milk and mammary epithelial cell culture conditioned 
medium
WLB analysis of milk from a mouse whose litter had been removed for 48 h detected 
an IGFBP of the same mobility as that detected in rat milk from involuting glands. 
This IGFBP was undetectable in milk from control lactating mouse milk (Fig 
5.12A). Unconditioned culture medium containing 10% FCS contained several
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Fig 5.12 Western ligand blot analysis of mouse mammary epithelial cell culture 
conditioned medium and mouse milk. Mammary cells from pregnant 
mice were cultured on EHS matrix with lactogenic hormones. (A) 
Mouse milk (0.9 /xl) from lactating (C) or involuting (R) gland or rat 
milk from involuting gland (0.1 /xl). (B) Conditioned medium from 
two separate experiments: 1) 20 /xl conditioned medium from days 1-5 
2) dialysed concentrated conditioned medium (300 /xl equivalent) from 
days 5-8, treated with EGTA on day 5. U is 10 /xl unconditioned 
medium containing 10% FCS, M is rat milk (0.1 /xl) from involuting 
glands.
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[125I]rhIG FBP-3  
dye front
T R  C U M B  
Acini CM
Fig 5.13 Proteolysis of [l25I]IGFBP-3 by conditioned medium from mammary 
cells. Mammary acini from treated lactating rats were incubated for 
4 h at 37 °C, pregnant mouse mammary epithelial cells were cultured 
on EHS matrix with lactogenic hormones. Conditioned medium 
samples (20 fi\) were incubated with 30,000 cpm recombinant non­
glycosylated [125I]hIGFBP-3 for 5 h at 37°C. Acini samples: T is 
treatment with anti-rGH and bromocriptine for 48 h, R is litter 
removal for 48 h, C is control, U is unconditioned medium. M is 
mammary epithelial cells culture, B is buffer control. After incubation 
samples were separated by SDS-PAGE, the gel dried under vacuum 
and autoradiographed for 18 h.
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IGFBPs thus confounding the detection of mammary cell-derived IGFBPs at day 1-5. 
However the major IGFBP at day 1-5 has the same mobility as the IGFBP detected 
in rat milk from involuting glands. A similar IGFBP was detected at day 5-8 of 
culture when exogenous IGFBPs from FCS are absent from the medium.
5.3.13 IGFBPs in mammary acini conditioned medium
Conditioned medium from acini degraded [125I]rhIGFBP-3 to lower molecular weight 
products which migrated with the dye front suggesting the presence of a protease 
(Fig 5.13). WLB detected the presence of a faint IGFBP band of about 31 kDa (the 
same mobility as rat IGFBP-2) in all samples and an additional band of 29/30 kDa 
in samples after litter removal (data not shown).
5.4 Discussion
This study was undertaken as part of an investigation into the role of IGFs as 
mediators of the galactopoietic effects of GH. Systemically administered IGF failed 
to mimic the ability of GH to reinitiate milk production in PRL and GH deficient 
rats even when administered complexed with IGFBP-3 (Flint et al. 1992; Flint et al.
1994). The IGFBPs are major modulators of IGF action therefore the elucidation of 
the role of the IGFs in lactation requires investigation of the IGFBPs involved. In 
this study we provide information on systemic and mammary gland IGFBP 
production and their hormonal control during lactation and involution.
The decrease in serum IGF-1 levels induced by anti-GH treatment of lactating 
rats was not as dramatic as that previously seen in treated young male rats (Madon 
et al. 1986), suggesting IGF-1 levels during lactation are not under such stringent
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GH control as demonstrated in other states. Likewise, despite a 50% reduction in 
serum IGF-1 anti-GH treatment did not alter IGFBP-3 levels contrasting with the 
markedly reduced serum IGFBP-3 in young rats induced by anti-GH treatment 
(Palmer et al. 1993). Serum IGF-1 levels correlate with IGFBP-3 levels in a range 
of conditions and Gargosky et al. (1994) demonstrated that GH directly regulates 
serum IGF-1 in rats but serum IGFBP-3 is primarily regulated by IGF-1. The 
dissociation of serum IGF-1 and IGFBP-3 levels has been reported in another 
catabolic state: in endotoxin-treated fasted rats, serum GH and IGF-1 decreased but 
serum IGFBP-3 remained similar to control levels (Fan et al. 1993).
During lactation serum IGF-1 concentrations (Travers et al. 1993), serum 
IGFBPs (Donovan et al. 1991) and hepatic IGFBP-3 mRNA (Marcotty et al. 1994) 
are reduced. Although neither anti-GH or bromocriptine treatment alone affected 
serum IGFBP-3 levels, combined treatment decreased serum IGFBP-3. Furthermore, 
administration of GH, but not PRL, to PRL and GH deficient rats could restore 
serum IGFBP-3 levels. These data suggest that serum IGFBP-3 is under the dual 
control of GH and PRL during lactation. Dual control by GH and PRL has been 
shown for other parameters of galactopoiesis such as Acetyl Co-A Carboxylase 
activity and glucose transporter activity (Barber et al. 1992; Fawcett et al. 1991).
IGFBPs were poorly detectable in milk from lactating and hormone deficient 
rats although in some samples (data not shown) IGFBPs were detected of about 38- 
42 kDa, 29-30 kDa, and 24 kDa. Donovan et al. (1991) described IGFBPs in rat 
milk at 38-42 kDa (IGFBP-3), 29 kDa (IGFBP-2), 28 kDa (IGFBP-1), 24 kDa 
(IGFBP-4) and in some samples a 27 kDa proteolytic fragment of IGFBP-3. These 
IGFBPs were detected in the whey fraction of milk, in contrast with the IGFBP 
found in milk after litter removal which segregates with the casein pellet fraction.
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Size exclusion chromatography of milk from control lactating rats showed no IGFBP 
complexes although Donovan et al. (1995) demonstrated IGFBPs in association with 
ternary complexes. However the failure .to detect IGFBPs in control milk probably 
reflects the quantities of milk used.
Whereas serum IGF-1 and IGFBP-3 are low when involution is initiated by 
hormonal ablation, litter removal induced an increase in serum IGF-1 and IGFBP 
levels reflecting a return to maternal anabolism. The difference in physiological state 
induced by the two models of involution are also reflected in IGFBPs in milk.
The substantial solution phase [125I]IGF binding to milk after litter removal 
is a measure of IGFBP concentration. Competition of [125I]IGF-1 binding by IGF-1 
and IGF-2 with roughly equal affinities is consistent with binding to IGFBPs or type 
1 receptors. However since insulin did not compete for radioligand binding even at 
high concentrations IGF-1 binding was not to the Type 1 IGF receptor. Likewise 
IGF-1 analogues which have low affinity for IGFBPs but reasonable affinities for the 
Type 1 IGF receptor, failed to compete for ligand binding even at concentrations 
which would bind to the receptor. The ability of analogues to compete was in the 
order Long-IGF-1 > R3-IGF-1 >Long-R3-IGF-l, which correlates with their ability 
to bind IGFBPs from L6 myoblasts previously shown by Francis et al. (1992). Size 
exclusion chromatography showed [125I]IGF-1 binding was mainly in small molecular 
weight complexes suggesting binding to IGFBPs rather than to IGF receptors. There 
is evidence of [125I]IGF-1 binding to a high molecular weight band in WLB, although 
this was not as prominant in size exclusion chromatography. This binding may 
correspond to soluble (or membrane bound?) type 2 IGF receptor which has
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previously been detected in bovine colostrum (Skaar et al. 1991). Since the majority 
of IGFBP in milk after litter removal is associated with the particulate fraction there 
is the possibility that the IGFBP in supernatant fraction used in HPLC analysis is not 
representative of that found in whole milk although the major IGFBP in milk after 
litter removal is detectable in both fractions by WLB.
Samples for deglycosylation were SDS-denatured but reduction was not 
compatible with subsequent detection by WLB, therefore N-glycanase treatment 
partially deglycosylated serum IGFBP-3 to about 37 kDa as described by Donovan 
et al. (1991); reduction is necessary for complete deglycosylation of glycosylated 
rhIGFBP-3 (Sommer et al. 1991). Immunoblotting identified the IGFBP in milk after 
litter removal as IGFBP-5 although immunoidentification had proved difficult; 
several commercially available antisera raised against recombinant human proteins 
failed to detect the IGFBP and although some of these antisera have known 
crossreactivity with rat proteins, we did not have positive controls for rat IGFBP-5 
and -6  proteins.
IGFBP-5 in bone is bound tightly to mineralised calcium phosphate in bone 
(hydroxapatite, 3Ca3(P0 4)2.Ca(0 H)2) (Mohan 1993). IGFBP-5 in milk associates with 
the particulate fraction containing micelles composed of casein polypeptides in 
association with calcium phosphate nanoclusters. However it is unknown if these two 
interactions are analogous, and whether the association in milk is an artefact or has 
some physiological significance.
Preliminary WLB data from the mouse showed an IGFBP in milk obtained 
after litter removal for 48 h which had a similar mobility to that detected in rat milk 
from involuting glands. An IGFBP of this mobility was also detected in conditioned
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medium from mouse mammary epithelial cell cultures although IGFBPs in FCS- 
containing medium confound the detection of mammary-derived IGFBPs during the 
first few days of culture. Apoptosis has been described in mammary cell cultures 
around day 2 when mammospheres are forming and around day 8 when 
mammospheres degenerate (Quarrie 1996). This IGFBP in conditioned medium may 
be IGFBP-5 associated with apoptosis, but this correlation has not yet been 
established and would require a parallel study of IGFBPs and apoptosis in the same 
cultures.
The IGFs and IGFBPs in milk may be produced in the gland or enter via the 
paracellular route. Likewise IGFBPs produced in the gland may not be secreted into 
the milk. However, after litter removal tight junctions are leaky allowing IGFs and 
IGFBPs to enter milk from serum by a paracellular route, in addition to the normal 
secretory route via the epithelial cells. IGFBP-2, -4 and -5 mRNA expression was 
detected in glands after litter removal but was undetectable in glands from lactating 
or hormone-deficient rats. Thus milk IGFBP-5 is probably produced in the gland. 
High background binding of the [32P]cRNA probes used may have masked all but 
strong signals, thus accounting for the discrepancy with Donovan et al. (1995) who 
demonstrated IGFBP-2 and IGFBP-4 mRNA expression by lactating rat mammary 
gland. However in situ hybridisation analysis showed IGFBP-2 mRNA expression 
in lactating glands and confirmed the expression of IGFBP-2, -4 and -5 mRNA, but 
not IGFBP-1, -3, and -6 , after litter removal.
IGF-1 has been suggested as an anti-apoptotic factor in several studies (Raff 
1992; Rodriguez-Tarduchy et al. 1992; Drago et al. 1991; Sell et al. 1995) and if 
it had such a role in maintaining mammary epithelial cells during lactation it would
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be necessary to abrogate this effect during involution particularly since serum IGF-1 
concentrations increase after litter removal. The function of mammary gland IGFBP- 
5 thus may be to sequester IGF-1 from its receptor thereby attenuating the IGF-1- 
mediated survival signal.
Recently Guenette & Tenniswood (1995) also showed induction of IGFBP-5 
expression during involution of mammary glands after litter removal and their in situ 
hybridisation studies showed expression was localised to the epithelial cells. 
Similarly IGFBP-5 expression was induced during involution of the prostate after 
hormonal withdrawal. However in contrast with our Northern blot analysis IGFBP-2 
mRNA was unchanged in either tissue during involution (Guenette & Tenniswood
1995). Possibly the sensitivity of the different techniques account for this 
discrepancy.
A role for IGFBPs in apoptosis has been postulated within the intraovarian 
IGF system. Most follicles never ovulate and become atretic at different stages of 
development by an apoptotic mechanism. Healthy follicles have high IGF-1, high 
FSH, and low IGFBP-4 and -5 levels and the opposite is true of atretic follicles. Liu 
et al. (1993) showed in vitro that IGFBP-4 and -5 could block the ability of FSH to 
stimulate oestradiol and progesterone production. IGF-1 is synergistic with FSH in 
stimulating granulosa cells and is stimulatory to IGFBP-5 expression (Adashi et al. 
1994). In contrast FSH is not only inhibitory to the expression of IGFBP-4 and -5 
but induces a protease which degrades these IGFBPs (Liu et al. 1993). These data 
suggest IGF-1 availability may be an important determining factor in follicular 
development. The complex balance of inhibitory and stimulatory influences on 
IGFBPs may determine IGF-1 availability and thus regulate apoptosis.
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The development and function of the mammary gland is a well-studied 
example of the bidirectional exchange of information between cells and the ECM. 
Maintenance of the differentiated state is dependent on the basement membrane 
which induces, under hormonal control, the production of milk proteins. During 
mammary involution the withdrawal of endocrine stimuli induces degradation of 
basement membrane by proteases causing the loss of cells by an apoptotic 
mechanism; extensive remodelling occurs and the gland returns to a resting state.
Talhouk et a l (1992) demonstrated the coordinated expression of matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
regulate epithelial function during involution although the signals involved in 
regulating basement membrane integrity are not elucidated. Although IGFBP-5 is 
abundant after litter removal there is little evidence of IGFBP-4 by WLB despite 
increased IGFBP-4 mRNA expression in the gland. This may be explained by 
proteolysis of IGFBP-4 since proteolysed IGFBPs are poorly detectable by WLB (Liu 
et al. 1993). Involuting mammary glands express several MMPs such as stromelysin 
(Lefebrve et al. 1992), tissue plasminogen activator (tPA), and uPA (Strange et al.
1992). Foulkes et al. (1994) showed degradation of IGFBPs by MMP-1 (intestinal 
collagenase) and MMP-3 (stromelysin). TIMP-1 or antisera to MMP-1 and -3 could 
prevent the degradation of rhIGFBP-3 by pregnant rat serum, although TIMP-1 was 
previously found to be inactive against human pregnancy serum IGFBP-3 (Frost et 
al. 1993). In addition enzymes other than MMPs such as plasmin can proteolyse 
IGFBP-3 and this also is increased during involution.
IGFBP-5 is however easily detected by WLB suggesting the proteases in the 
involuting gland are inactive against this IGFBP or it is protected from proteolysis.
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Kanzaki et al. (1994) demonstrated that IGF-2 protected IGFBP-5 from proteolysis, 
but enhanced IGFBP-4 proteolysis. In addition the association of IGFBP-5 with 
extracellular matrix protects it from proteolysis (Arai et al. 1994): association with 
the particulate fraction of milk, or cell surfaces within the gland may thus protect it 
from proteolysis in the mammary gland.
The increase in IGFBP-5 levels after litter removal correlated with decreased 
total mammary DNA and the increase in DNA laddering indicative of apoptosis 
(Quarrie et al. 1995). PRL and GH ablation increased DNA laddering although to 
a lesser extent than litter removal whilst concurrent PRL treatment maintained DNA 
in anti-GH and bromocriptine treated rats. Travers et al. (1996) established that PRL 
is responsible for maintenance of the integrity of mammary cells. The maintenance 
of DNA levels by PRL is in agreement with previous studies demonstrating the anti- 
apoptotic effect of PRL during involution (Sheffield & Kotolski 1992). However 
neither GH nor IGF treatment of GH- and PRL-deficient rats inhibited DNA 
laddering, although GH did alter the pattern of fragmentation resulting in much 
higher molecular weight fragments (Quarrie et al. 1995). Feng et al. (1995) 
demonstrated local inhibition of mammary apoptosis by implants of corticosteroid 
and progesterone but not by PRL. This agrees with the earlier study of Ossowksi et 
al. (1979) who postulated that PRL inhibited involution indirectly by sensitising the 
dam to other factors. PRL levels during lactation maintain the corpus luteum thus 
maintaining high progesterone concentrations and the effects of the manipulation of 
PRL is therefore confounded to some extent by altered progesterone levels. The use 
of ovariectomised rats could help differentiate PRL and progesterone effects. 
Hormone ablation and litter removal induce different physiological states: litter
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withdrawal induces milk stasis whereas after hormone ablation the gland is empty 
of milk. Sealing of half the dams teats has shown that milk stasis can also induce 
apoptosis in the sealed gland in the absence of endocrine changes (Quarrie et al.
1996). Consistent with our hypothesis IGFBP-5 levels increased in sealed mammary 
glands compared with their unsealed contralateral counterparts.
Because high systemic IGF-1 concentrations after litter removal correlated 
with increased IGFBP-5 production after litter removal, it was possible that systemic 
IGF-1 was the stimulus for mammary IGFBP-5 expression since IGF-1 stimulates 
IGFBP-5 production in bone cells (Dong & Canalis 1995) and in the ovary (Adashi 
et al. 1994). However in our study GH treatment of hormonally-ablated animals did 
not increase the levels of IGFBP in milk or expression of IGFBPs within the gland 
despite raised systemic IGF-1 concentrations. Similarly PRL treatment in 
combination with litter removal decreased milk IGFBP-5 but raised serum IGF-1 
further still, suggesting systemic IGF-1 is not the stimulus for mammary gland 
IGFBP-5 expression during involution. Dams with half their teats sealed had serum 
IGF-1 concentrations similar to that of control lactating dams, but sealed glands had 
increased milk IGFBP-5 levels. In contrast oestrogen, corticosteroid, or progesterone 
treatment did not affect milk IGFBP-5 levels. However alterations in milk volume 
induced by PRL thus diluting milk IGFBP-5 concentrations cannot be ruled out, 
therefore IGFBP-5 mRNA analysis is necessary to investigate this possibility. Thus 
systemic PRL and milk accumulation are correlated with both IGFBP-5 expression 
and apoptosis in the mammary gland.
Strong evidence that IGF-1 contributes to the maintenance of lactation is 
provided by the inhibition of mammary involution in transgenic animals expressing
human des(l-3)IGF-l under the control of rat WAP promotor (Hadsell et al. 1996). 
A conclusion of the study of Hadsell et al. (1996) is that a WAP-based transgene can 
have effects on the tissue despite their secretion into milk. A 32 kDa IGFBP was 
produced in the glands of transgenic animals; although this IGFBP was unidentified 
it may be an IGFBP produced in response to IGF-1 stimulus, but which is ineffective 
in abrogating the IGF-1 stimulus because it binds poorly to des(l-3)IGF-l. In 
contrast overexpression of IGF-1 in lactating rabbit mammary gland under the 
control of the a sl-casein promotor had no effect on mammary development or 
lactation; possibly overexpressed IGF-1 is bound to IGFBPs limiting its availability 
to receptors (Brem et al. 1994). However Neuenschwander et al. (1996) also 
described the inhibition of mammary involution in transgenic mice overexpressing 
IGF-1 and IGFBP-3; presumably IGFBP-3 might enhance IGF-1 action in this 
situation although direct effects of IGFBP-3 cannot be ruled out.
The ability of locally overexpressed IGF-1 to inhibit involution contrasts with 
the failure of systemic IGF to do so. Systemic IGF-1 administration also failed to 
mimic GH action in the maintenance of lactation which implies that the exogenous 
IGF-1 cannot reach the mammary gland and mimic local production, even when 
administered as IGF-1 analogues which would not bind to any inhibitory IGFBPs 
which may be present (Flint et al. 1994). This suggests that GH has effects other 
than raising serum IGF-1 levels. Acid labile subunit (ALS) is reported to be in 
excess thus enabling IGF-1 administered to rats to form ternary complexes (Lewitt 
et al. 1993), GH regulates ALS production (Gargosky et al. 1994) therefore ALS in 
the hormone deficient rats may be limiting to ternary complex formation. 
Alternatively, Rutishauser et al. (1993) showed treatment with GH but not IGF-1
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induced serum IGFBP-3 proteolytic activity in hypophysectomised rats, thus systemic 
administration of GH and IGF-1 may have different effects on IGF availability. In 
addition since insulin alters IGFBP-1 transport (Bar et al. 1990) other hormones such 
as GH may also affect IGF and IGFBP transport.
However Flint & Gardner (1994) subsequently demonstrated the ability of GH 
to stimulate milk production when implanted directly in the mammary gland. GH 
may thus have direct effects on mammary cells (although functional receptors have 
not been demonstrated) or indirectly via stromal cells. GH may stimulate local 
production of IGFs by stromal cells such as adipocytes which do possess GH 
receptors. Adipocytes also produce IGFBPs (Beattie & Vernon 1995; Peter et al. 
1993) some of which are GH regulated and which might thus alter local IGF 
availability.
Evidence against a role for local IGF-1 in galactopoiesis comes from 
Marchotty et al. (1994) who showed low IGF-1 mRNA expression in the rat 
lactating mammary gland compared with pregnancy. Interestingly GH replacement 
treatment of PRL and GH deficient rats raised the serum IGF-2 concentration 
although IGF-2 is considered to be GH-independent. Local IGF-2 levels may be the 
important IGF-stimulus and although systemic IGF-2 levels in rats are low GH 
administration may regulate local IGF-2. In addition GH administration may 
modulate type 1 or 2 IGF receptors. In the ewe, there are high levels of IGFBP-5 
and type 2 IGF receptors in atretic ovarian follicles but low levels in healthy 
follicles. Serum withdrawal from ewe granulosa cell cultures induced apoptosis and 
increased levels of type 2 IGF receptors and membrane-associated IGFBPs (Monget 
et al. 1995). IGF-1 treatment of serum-free cultures increased cell viability and
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density, and decreased type 2 IGF receptors whilst increasing IGFBP-5 in the 
medium (Monget et al. 1995). In the mammary gland, GH could thus modulate 
apoptosis not only by increasing local IGF production, but by decreasing type 2 IGF 
receptor expression. The study of involuting mammary gland using in situ 
hybridisation and immunocytochemistry is required to identify the local expression 
of IGFs, their receptors and their regulation.
The mechanism of action of IGFs and their IGFBPs at the cellular level is not 
fully elucidated however the evidence for IGF-1 as a survival factor in other cell 
types, and the analogy with IGFBP-5 production in the prostate and ovarian IGF 
system, support the hypothesis that IGF-1 maintains lactation and IGFBP-5 is a 
primary regulator of mammary gland involution; a causal role of IGFBP-5 in 
mammary gland involution remains to be established.
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CHAPTER 6: FINAL GENERAL DISCUSSION
The aim of this study was the investigation of the IGF axis in two areas important 
to* animal health and hence lactational performance. There had been few studies of 
IGFBPs in either lactation or in animal health and disease. Here we have shown 
evidence supporting a role for IGFBPs in both lactation and the immune system.
During pregnancy and lactation the maternal metabolism adapts under 
hormonal control to meet the increased energy requirements and in some species the 
mother enters a catabolic state. In some species systemic IGF-1 decreases and 
IGFBP-3 proteolysis increases thus altering IGF availability. Serum IGF-1 
concentrations in goats fall dramatically at parturition and remain low in early 
lactation. Similarly in critical illness, cancer, and septicaemia, GH and IGFBP-1 
levels rise but IGF-1 and IGFBP-3 are low and IGFBP-3 protease activity is 
increased (Bentham et al. 1993). Immunosuppression is a characteristic of 
hypercatabolic states and since the IGFs have immunomodulatory effects on the 
immune system it is conceivable that the IGF system could contribute to this 
immunosuppression.
The contribution of systemic and local IGF and IGFBPs are unclear and 
systemic IGF levels may not reflect local levels. For example endotoxin treatment 
of rats reduces IGFBP-3 in the liver but not in peripheral tissues. Under the 
influence of the circulating hormonal milieu of lactation the mammary gland fully 
differentiates whereas the thymus involutes: at weaning the mammary gland regresses 
and the thymus regenerates. The IGFs have stimulatory effects on both mammary 
and immune cells therefore differential cellular reactivity and the complex mixture 
of systemic and local factors must control local IGF effects. If IGFBP-5 abrogation
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of the anti-apoptotic effect of IGF-1 were hypothesised as a common mechanism 
during involution then local control mechanisms would be required to regulate this 
effect.
To define the role of the IGFs the analysis of systemic and local IGF-IGFBP 
production is required at both the mRNA and protein levels. In situ hybridisation and 
immunocytochemistry studies would determine the sites of synthesis and cellular 
localisation of IGF and IGFBP expression. Post translational modifications of 
IGFBPs, their proteolysis and location could clearly alter their biological function.
The immune system of the sheep has all the elements of the IGF axis, type 
1 IGF receptors, IGF-1, IGFBP, and IGFBP protease production; unfortunately 
IGFBP nucleic acid probes were unavailable when these studies were undertaken 
therefore IGFBP mRNA levels were not determined. Recently Li et al. (1996) 
showed the production of a 25 kDa IGFBP-4 by murine thymus, spleen and mature 
myeloid cells but not by lymphoid cells. This implies that the IGFBP detected in 
sheep thymus cultures may be produced by stimulated macrophages in the cultures. 
Although these are clearly only preliminary and descriptive observations, they 
support a role for IGFs in the sheep immune response and form a basis to study the 
interactions of the immune and endocrine systems in ruminants.
Thymus regression during pregnancy is maintained into lactation. The rate 
of thymic regeneration during lactation is inversely correlated with the number of 
young and the number of functional nipples (Gregoire 1947a; Gregoire 1947b). 
Oestrogen induces thymic regression, but sex steroids decline in lactation and thymic 
involution is maintained in spayed animals thus multiple factors are involved; 
involution is induced by a complex interaction of neural, endocrine and immune
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factors. Lymphoid and myeloid cells possess PRL and GH receptors and both 
hormones have immunomodulatory effects on haemopoietic tissues (Hooghe et al. 
1993). For example PRL administration antagonises the suppression of mitogen- 
induced lymphocyte proliferation caused by corticosteroids (Bemton et al. 1992). 
However PRL administration failed to maintain thymic involution in rats after litter 
removal (Gregoire 1947b). GH enhances thymulin production by thymic epithelial 
cells via IGF-1 (Timsit et al. 1992) and therefore it is feasible that alterations in 
IGFs or IGFBPs in the microenvironment during lactation may contribute to thymic 
regression.
A similar decline in B-lymphopoiesis in pregnancy was recently identified and 
pregnancy hormones were shown to influence lymphopoiesis. Oestrogen is a negative 
regulator of B-lymphopoiesis and progesterone dramatically reduces the amount of 
oestrogen required to deplete B-lineage precursors in non-pregnant mice (Kincade 
et al. 1994). Lactation prolongs the regeneration of B-cell precursors (Medina et al. 
1993) however the effect of post partum hormones on B-lymphopoiesis has not been 
well studied. IGF-1 enhances B-lymphopoiesis in vivo (Jardieu et al. 1994) and in 
vitro (Landreth et al. 1992). Bone marrow stromal cells produce IGF-1 and IGFBPs 
in culture (Abboud et al. 1991), and osteoblasts produce IGFs, IGFBPs and IGFBP- 
proteases (Kanzaki et al. 1994). Recently Arkins et al. 1995 showed that colony- 
stimulating factors induced expression of IGF-1 mRNA during differentiation of 
cultured murine bone marrow myeloid cells. In addition IGFBP-3 could inhibit cell 
proliferation implying that locally produced IGF-1 is a haemopoietic growth factor. 
Within this microenvironment the IGF axis may be shared between the cells 
maintaining bone cell and blood cell production.
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It is unclear however how thymic involution and compromised B-cell 
lymphopoiesis in pregnancy and lactation contributes to the apparent 
immunosuppression. During pregnancy there is a suppression of cell-mediated 
responses but humoral immunity is spared. In mid pregnancy the cortex shrinks and 
many cortical thymocytes die, but the medulla expands and forms structures called 
medullary epithelial cell rings (MERs) around thymocytes, and although these shrink 
in late pregnancy the thymulin-producing epithelial cells remain. Glucocorticoids are 
powerful immunosuppressants and are potent inducers of apoptosis in lymphoid cells; 
this contrasts with their ability to inhibit apoptosis locally in the mammary gland 
(Feng et al. 1995). Hormones and growth factors can have different effects on 
haemopoiesis and on mature cell function, for example corticosteroids deplete pre-B 
cells but do not affect mature B-cells. In addition low-dose corticosteroid can 
stimulate cells in vitro rather than induce apoptosis. Thus the effects of 
glucocorticoids could depend on its concentration and the state of differentiation of 
cells.
The immunosuppression of late pregnancy and lactation has implications for 
the welfare of the mother and is likely to have deleterious effects on milk production 
and consequently on the young dependent on the milk. There have been many studies 
of the immunosuppression of pregnancy in rodents but fewer have studied ruminants 
that may have adopted different strategies to allow the mother to host an allogeneic 
foetus. The interactions of the lactogenic and galactopoietic hormones with IGFs in 
ruminant immune cells thus require further study.
Studies of hormonally manipulated lactating rats provide evidence of 
hormonal control of IGFBPs in lactation and suggested a role for IGFBP-5 in the
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involution process. Both PRL and GH regulate circulating IGFBP-3, and IGFBP-5 
expression in the involuting mammary gland is regulated by PRL and local factors 
induced by milk accumulation. To examine in detail the role of IGFBPs in the 
mammary gland an in vitro system is required. Preliminary assay of IGFBPs in 
conditioned medium from short term rat acini cultures suggested these were not 
suitable because of proteolytic activity against rhIGFBP-3; this protease may have 
been derived from the digestion mixture and could have rendered other IGFBPs 
undetectable by WLB. IGFBPs have however been previously detected by WLB in 
conditioned media from cultured bovine lactating and non lactating mammary gland 
explant and acini (Campbell et al. 1991). Explant and acini culture may therefore be 
useful to assess IGFBP production in hormonally manipulated animals. Primary 
cultures of mammary epithelial cells attached to reconstituted basement membrane 
form multicellular (mammosphere) structures that differentiate, become polarised and 
secrete milk components vectorially (Aggeler et al. 1991). Both rodent and ruminant 
mammosphere culture systems exist thus enabling the study of IGFs, IGFBPs, and 
IGFBP-proteases in differentiated mammary cells. Preliminary data suggests that 
mouse mammary epithelial cell cultures produce IGFBPs, including a 29-30 kDa 
IGFBP that was also in milk from involuting glands.
IGFBP-5 has been associated with apoptosis of mammary, prostate and 
ovarian follicles suggesting it may have a central role in regulating apoptosis in a 
variety of tissues. Several approaches could be used to establish a causal role for 
IGFBP-5 in mammary involution, such as the ability of recombinant IGFBP-5 
administration to initiate involution in lactating animals. Recombinant IGFBPs may 
also be used in in vitro culture systems to investigate their mechanism of action
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during lactation and involution. Recombinant IGFBP-5 and mammary-derived 
IGFBP-5 may differ in their posttranslational modifications (with possible 
consequences for their biological effects) therefore this would require 
characterisation in vitro. An alternative strategy would be the use of antisense 
oligonucleotides to block endogenous IGFBP-5 production. In addition, antisera to 
IGFBPs used with IGFs and IGFBPs could help elucidate the role of the IGFBPs.
Evidence for IGFBP-5 involvement in involution in commercially important 
species must be established. There are clearly great species differences in the 
reproductive strategy of different animals and extrapolation between species must be 
exercised with caution. In addition, mammary gland structure differs between 
species: unlike the rat, in ruminant mammary glands the milk collects in the cisternal 
space therefore proteins newly synthesised during early involution may be diluted. 
Assessment of mammary gland IGFBP mRNA is therefore particularly important in 
ruminants to determine IGFBP expression. Preliminary WLB analysis of milk from 
pigs detected a 29-30 kDa IGFBP in milk obtained after litter removal for 48 h but 
not in control milk.
Proteases are important in the remodelling process and some proteases in 
remodelling tissue proteolyse IGFBPs. The increase in IGFBP-4 mRNA expression 
in involuting mammary gland requires further investigation and suggests further 
complexity to the situation. This may be similar to the intraovarian IGF-IGFBP 
system where there are coordinate rises in IGFBP-5 and IGFBP-4 and their proteases 
(Adashi et al. 1994). Currently several studies shown the complexity of the IGF- 
IGFBP mediated regulation of IGFBP-4 proteases (Kanzaki et al. 1994; Donnelly & 
Holly 1996). Proteolysis of IGFBPs may render them enhancing or inhibitory to IGF
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action: a 23 kDa proteolysed IGFBP-5 in bone potentiated IGF action (Andress & 
Birnbaum 1992), but fibroblast IGFBP-5 potentiated IGF action only when intact and 
a 21 kDa proteolysed form had no potentiating activity (Jones et al. 1993a). Although 
the IGFBP-5 detected in milk from involuting gland is largely intact its association with 
casein micelles may protect it from proteolysis. However if IGFBP-5 is secreted within 
the tissue it may not be thus protected; this is difficult to ascertain because of 
contamination of tissue by milk, but could be assessed using conditioned medium from 
the apical surfaces of mammosphere cultures.
Commercial bovine herds are normally concurrently pregnant and lactating and 
are dried off late in lactation; in contrast the rats in this study were non-pregnant and 
weaned in peak lactation. Optimal milk production in ruminants is achieved if there is 
a short dry period between lactation and parturition (Dias & Allaire 1982). Tissue 
remodelling is a complex process particularly during concomitant pregnancy where 
growth of ductal cells overlaps with apoptosis of differentiated epithelium. There is the 
possibility that the involution process induced by abrupt litter removal in peak lactation 
may be an emergency measure and therefore involution may not result in optimum 
remodelling for subsequent lactation cycles.
Although there is major cell loss during involution in rodents the process is not 
well elucidated and there may be carry-over of cells to subsequent cycles similar to that 
described in ruminants (Holst et al. 1987; Hurley 1989). The contribution of IGFs in 
the remodelling process is unclear. We have postulated an inhibitory role for IGFBP-5 
on IGF action in apoptosis, which contrasts with its enhancing roles in fibroblasts 
(Andress & Birmbaum 1992) and bone (Jones et al. 1992). IGFs are mitogenic and 
differentiation factors for a wide range of cell types and are anti-apoptotic for several
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cell types. IGFs are also motogenic for several cell types, and IGFBPs attached to 
the ECM could sequester IGFs in the microenvironment and provide a haptotactic 
stimulus. IGFs may be required for the survival of epithelial cells for subsequent 
lactation cycles, or for the motility and growth of stromal cells during remodelling; 
thus an alternative role for IGFBPs in involuting mammary gland may be the 
protection and delivery of IGF. In addition IGFBP-5 can have IGF-independent 
actions on cell proliferation (Andress et al. 1993).
The gland is most susceptible to infection during the early dry period and 
least susceptible in the mid-dry period. There is considerable interest for animal 
welfare in prolonging lactation and therefore further elucidation of the process of 
involution could be very important economically. To help define the involvement of 
the IGF axis in pregnancy and lactation, mammary gland IGFBP expression could 
be compared in the different species during pregnancy, lactation, concomitant 
pregnancy and lactation, and after multiple cycles of lactation.
IGFBP-5 is the most highly conserved IGFBP between species (James et al.
1993) and is widely expressed in adult rat (Shimasaki et al. 1991) and mouse tissues 
(Kou et al. 1994). The mouse IGFBP-5 gene is tightly linked to the IGFBP-2 gene 
and the gene and promoter has been characterised (Kou et al. 1995). Green et al.
(1994) described tissue and stage specific expression of IGFBP-2 and -5 in the 
embryo and proposed a role for these IGFBPs in development. Richers & Wood
(1995) recently described IGFBP-5 as the most highly expressed IGFBP in mammary 
tissue during pregnancy. IGFBP-5 expression was located exclusively in the 
epithelium of the mammary ducts, while IGFBP-2 was expressed in both epithelium 
and myoepithelium but levels were highest in the ductal epithelium.
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It is thus likely that tissue-limited and developmentally regulated transcription 
factors control IGFBP-5 expression. The expression pattern of IGFBP-5 is similar 
to that of AP-2 in rat embryogenesis (Green et al. 1994). Duan & Clemmons (1995) 
showed that the high expression of transcription factor AP-2 in fibroblasts is partly 
responsible for their constitutively high expression of IGFBP-5.
IGFs are both differentiation and mitogenic factors for myoblasts and it is 
unclear how the switch between these responses occurs. IGF-1 induces myogenin 
expression (Florini et al. 1991) and during myoblast differentiation the expression 
of IGF-2, type 2 IGF receptor and IGFBP-5 increases (James et al. 1993). Similarly 
IGF-1 (Canalis & Gabbitas 1995) and bone morphogenic protein-2 (BMP-2) induces 
IGFBP-5 in differentiating osteoblasts. Although IGF-1 and IGF-2 act through the 
type 1 IGF receptor, overexpression of this receptor inhibits differentiation in L6 
myoblasts (Quinn et al. 1993). IGFBP-5 binds to the cell surface and has a higher 
affinity for IGF-1 than the type 1 IGF receptor thus sequestering IGF-1; therefore 
IGFBP-5 may play a pivotal role for in determining IGF action.
The IGFs are important in mammary gland development and therefore a 
model such as undifferentiated cells from non pregnant animals in matrix culture 
could be used to study the influence of IGFBPs in differentiation and induction of 
milk protein synthesis.
In conclusion, the main findings of these studies support a role for the IGF 
axis in two areas important to animal performance, lactation and the immune system. 
The immune system of the sheep has all the elements of the IGF axis: type 1 IGF 
receptors, IGF-1, IGFBP, and IGFBP protease. Further study of the role of these 
factors in regulation of the immune system in sheep is clearly worthwhile.
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The rat mammary gland, in which involution has been induced by litter 
removal, expresses IGFBP-2, -4 and -5 mRNA, and high levels of IGFBP-5 are 
detected in milk. Milk accumulation in sealed glands increased IGFBP-5 levels in 
milk, while PRL treatment of animals whose litters had been removed decreased the 
levels of IGFBP-5 despite milk accumulation. Serum IGF-1 concentrations did not 
correlate with increased IGFBP expression. Both PRL and GH have important roles 
in maintaining mammary cell function during lactation. PRL and GH may exert their 
effects by modulating the IGF-1 survival signal for mammary epithelial cells: in this 
model, GH induces IGF-1 production (possibly produced locally within the 
mammary gland stroma) while PRL suppresses the expression of IGFBP-5. During 
involution the withdrawal of PRL permits the production of IGFBP-5 which then 
abrogates the anti-apoptotic effects of IGF-1. We thus postulate that IGFBP-5 is an 
initiator of cell death in the involuting mammary gland and the direct demonstration 
of the survival effects of IGF-1, and a causal role for IGFBP-5 in involution are 
required to support this hypothesis.
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